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A. HArvey W. CusHing
Harvey Williams Cushing (1869-1939) was born as the 10th child of a well-educated, 
puritanical medical family in Cleveland (figure 1). He attended Yale University, graduated 
cum laude from Harvard Medical School and was trained as a general surgeon at Johns 
Hopkins under the famous but drug-addicted William Halsted. He proceeded to special-
ize in surgery of the brain and nervous system. In this way, he personally invented the 
field of neurosurgery and in the process of doing so, named a dozen of pathophysiologi-
cal conditions after himself. Moreover, he introduced a number of ideas to the field of 
general clinical medicine, which are still of great value today: he was the first physician 
to use diagnostic X-rays on his own patients, he proposed the use of anaesthesia (Ether’s) 
charts within the operating theatre after the avoidable death of one of his patients and 
also was the first doctor to use electrocoagulation during surgery (1). 
Apart from his medical achievements, he was regarded as a World War I hero and 
furthermore a more than talented baseball and tennis player, a Pullitzer-Prize winning 
author, medical historian and artistic drawer. Personally, he was good friends with Sir 
William Osler and the Russian physiologist Pavlov and was a great fan of the 16th century 
Italian anatomist Andreas Vesalius. Unfortunately, Harvey Cushing was also a victim of 
the notorious 1918 Spanish flu, which left him with some chronic disability, not being 
Fig 1
Figure 1: Harvey Cushing at work in the operating theatre 
Source: www.dodd.cmcvellore.ac.in
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able to walk more than a few steps at a time. Despite this disability, he proceeded to 
perform more than 2000 brain surgeries and wrote over 330 books and articles. 
He was a hard-working, stern man who was both respected and feared by his residents 
and nursing staff for his sarcastic remarks and stormy outbursts. Not much of a family 
man to his wife and 5 children, he consistently placed his medical work ahead of anything 
else in life and could mourn for days after the death of a patient, blaming only himself. At 
the age of 70 he died in a way, which is both ironic as well as symbolic for the life he has 
lived. When working on a manuscript about Vesalius, he died of a myocardial infarction, 
presumably induced by the lifting of one of the heavy folio volumes of Vesalius’ work. At 
autopsy, he had a posterior coronary artery occlusion, as well as a 1 cm colloid cyst of the 
third ventricle, in line with the common belief that doctors tend to develop the disease 
in which they have specialized.
B. CusHing’s DiseAse: PAtHoPHysiology AnD Current treAtment
As early as 1932, Harvey Cushing reported the remarkable constellation of symptoms 
in a group of patients he had seen over the years, who showed pronounced abdominal 
and facial obesity, but also had remarkable wasting of the arm and leg musculature 
(2). In addition, they often had high blood pressure and could be severely depressed. 
Harvey Cushing was the first physician to discover that this full-blown clinical picture 
could be caused by a small basophilic adenoma in the human pituitary gland, secreting 
excessive amounts of ACTH. According to the common practice of that era, he named 
this new clinical entity after himself. In Cushing’s disease (CD), the ACTH-producing pi-
tuitary adenoma stimulates the adrenal glands to produce excessive amounts of cortisol 
(figure 2). Chronic exposure to these high levels of endogenous cortisol has detrimental 
effects on a variety of organ systems including the cardiovascular, musculoskeletal and 
metabolic system (figure 3). Patients with CD are at substantial risk to suffer from any of 
the well-known sequelae of CD such as myocardial infarction, stroke, osteoporosis and 
depression (3). Age-adjusted mortality rates are significantly higher than those in the 
normal population (4).
 
As originally proposed by Harvey Cushing himself, the first line of treatment for this 
disease is the surgical removal of the ACTH-producing adenoma via a transsphenoidal 
approach. The introduction of transsphenoidal surgery instead of a classical craniotomy, 
which was customary at Harvey Cushing’s time, single-handedly reduced intra-operative 
mortality during neurosurgery from 90% to below 10%. Since that time, many factors 
within and outside the operating theatre have improved, thereby gradually increasing 
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the success rates for this type of surgery. Despite these great technical advances and 
further refinements of this surgical technique, selective transsphenoidal adenomectomy 
in patients with CD remains a highly challenging type of surgery to master. At present, 
even in most experienced hands, surgical cure rates decline to below 70% when patients 
are followed-up for at least 5 years after their initial surgery (5). A second transsphe-
noidal surgery in patients with a recurrence of CD is known to have significantly lower 
success rates than the primary surgery (6, 7). Other treatment options for patients with 
persistent or recurrent CD include conventional radiotherapy or gamma knife surgery. 
Fig 2
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Figure 2: Normal physiology of the hypothalamus-pituitary-adrenal axis (left) and the pathophysiology 
of Cushing’s disease (right). In the normal situation (left), hypothalamic CRH (corticotrophin releasing 
hormone) stimulates the anterior pituitary to secrete ACTH, which stimulates the adrenal glands to 
increase cortisol production. By a negative feedback system, increased levels of circulating cortisol 
decrease pituitary ACTH and hypothalamic CRH secretion. In Cushing’s disease (right), a monoclonal 
expansion of ACTH-producing adenoma cells (grey circle) autonomously secretes excessive amounts 
of ACTH into the circulation. The excess ACTH stimulates the adrenal glands to produce high levels of 
endogenous cortisol. The pituitary corticotroph adenoma cells are partially resistant to negative feedback 
by circulating cortisol (black cross), leading to a state of sustained hypercortisolism.
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Both are effective at reducing ACTH hypersecretion in the majority of patients, but have 
a slow onset of action, with an average time until remission of 9-24 months (8). In addi-
tion, radiotherapy is accompanied by a significant risk of inducing secondary pituitary 
dysfunction, cranial nerve damage or secondary brain tumours (8-10). As a definitive 
cure, patients with persistent CD can undergo bilateral adrenalectomy, but this does 
have important implications in terms of lifelong dependence on hormone replacement 
therapy and the risk of future Addisonian crises, as well as Nelson’s syndrome. 
Fig 3
Figure 3: Clinical characteristics of patients with Cushing’s disease. Source: Emanuel Rubin, john L. Farber, 
Pathology, 3rd edition, Lippincott-Raven Publishers (1999)
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therapy for CD. A great number of drugs that act at the level of the pituitary, the adrenals 
or the glucocorticoid receptor itself, have been evaluated in the past decades with gen-
erally modest and variable results (11). Most compounds either show limited efficacy or 
are associated with serious toxicity and adverse events. For instance, the steroidogenic 
inhibitor ketoconazole has been shown to effectively decrease cortisol levels in about 
50% of patients when used at high doses (12), but often causes considerable gastro-
intestinal side effects and carries a serious risk of medication-induced hepatitis, which 
limits its use as a long-term monotherapy in CD patients (13). Similarly, metyrapone can 
be effective in reducing cortisol levels in patients with CD, but can cause hypertension 
and hypokalemia. Blockade of the glucocorticoid receptor with mifepristone (RU-486) 
can improve symptoms of hypercortisolism, but the absence of a suitable biochemical 
parameter to monitor treatment efficacy makes dose titration difficult and this can result 
in severe adrenal insufficiency in some patients (14). In recent years, however, important 
new insights in corticotroph cell physiology and the receptors, which govern the regula-
tion of ACTH release from these cells, have opened up the way for some potentially new 
medical therapies for CD. 
C. reseArCH on novel meDiCAl tHerAPies For CD
As the underlying pathophysiology of CD is located at the level of the pituitary corti-
cotroph cell, it is plausible to direct any medical interventions primarily at this specific 
cell type. Different receptors have been identified within the human anterior pituitary, 
which may all be involved in the regulation of ACTH release and may therefore all rep-
resent potential targets for the development of new medical therapies. These include 
somatostatin and dopamine receptors, which will be the subject of this research thesis, 
but also the retinoic acid receptor, interferon gamma receptor and the peroxisome-
proliferator activating receptor gamma. The potential of the latter receptors as novel 
therapeutic targets for the medical treatment of Cushing’s disease are discussed in detail 
elsewhere (15) 
One issue that negatively affects overall progress in the evaluation of all of these po-
tential targets is the low incidence of human CD, approximately 1.2-2.4 cases/million/
year (4, 16). This means that not only clinical studies are difficult to carry out because 
of low patient numbers, but also that in vitro research on primary corticotroph tissue 
from patients with CD is largely dependent on the scarce availability of these tissues 
after transsphenoidal surgery. It needs to be emphasized, that studies using these pri-
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mary corticotroph adenomatous tissues, are crucial in the evaluation of the biological 
relevance of any novel therapeutic target receptor.
Interestingly, CD is a very frequent disorder in dogs with an estimated incidence of 1-2 
cases/thousand/year (17, 18). In a few centers worldwide, including the Faculty of Veteri-
nary Sciences of Utrecht University, the Netherlands, it is technically possible to perform 
transsphenoidal hypophysectomy in dogs with CD, resulting in favourable long-term 
outcome rates compared to medical therapy (19, 20). It also means that canine CD may 
provide a novel source of corticotroph adenoma tissue, which could facilitate in vitro re-
search on the pathophysiology and treatment of CD in general. However, for a thorough 
evaluation of the feasibility of canine CD as a direct model for human CD, it is important 
to investigate the molecular make-up of these canine corticotroph adenomas, compared 
to their human counterparts. 
AIM OF THESIS: To characterize canine corticotroph adenomas for the expression and func-
tional role of two receptor families that are currently of interest as potential targets for the 
treatment of human CD, i.e. somatostatin and dopamine receptors, and to compare these 
results with the current knowledge on their expression in human corticotroph adenomas. In 
this way we aim to evaluate canine Cushing as a potential spontaneous animal model for 
human CD. The results of these studies are described in Chapter 2. 
D. somAtostAtin AnD DoPAmine reCePtors: generAl PHysiology
Somatostatin and dopamine receptors
Somatostatin (SS) is a 14-or 28 amino acid-long cyclic peptide that is widely distributed 
throughout the human body. Its functions vary from increasing gastro-intestinal motility 
to neurotransmission within the central nervous system, mediating immune responses 
and inhibition of hormone release (21, 22). SS exerts its functions by binding to all five 
somatostatin receptor subtypes (sst1-5), which belong to the family of G-protein coupled 
receptors (GPCRs) (23). Dopamine (DA) is a catecholamine with an equally wide range 
of functions including neurotransmission, control of vascular tone, renal function and 
hormone secretion (24). Also for DA receptors, five subtypes are known (D1-5) that be-
long to the GPCR family, which are further classified into D1-like (D1, D5) and D2-like (D2, 
D3, D4). D1-like receptors generally mediate stimulatory functions, whereas most D2-like 
receptors are associated with inhibition. Upon binding of SS or DA to their respective 
receptors expressed on the plasma membrane of target cells, multiple cellular effector 
systems can be activated, which include inhibition of Ca2+-influx, inhibition of adenylyl 
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cyclase activity or stimulation of phosphotyrosine phosphatases, resulting in a variety of 
biological effects (figure 4) (23, 24). Both sst and DA receptors are abundantly expressed 
in the human neuro-endocrine system and in the tumours that are derived from it (25, 
26). Most of the in vivo functions of SS and DA (D2-like) receptors are inhibitory and, 
therefore, targeting these receptors with their natural agonists or synthetically derived 
analogs has provided opportunities for medical therapy of various neuro-endocrine 
disorders. 
SS analogs and DA agonists
Soon after its discovery in 1972, SS was known to be a major regulator of GH release from 
the pituitary and was therefore of potential interest for the treatment of acromegaly 
(27). One of the characteristics of native SS, however, is its very short half-life in the 
circulation, which is approximately 3 minutes (28). For that reason, the production of 
synthetic SS analogs with a significantly longer half-life, was a major step forward in 
the treatment of this disorder. The first stable SS-analog produced was Octreotide (SMS 
201-995), which has a half life of approximately 120 minutes after subcutaneous admin-
Somatostatin receptor
Fig 4
Dopamine receptor
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Phosphotyrosine phosphatases
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Figure 4: Schematic representation of somatostatin and dopamine receptors and their main second 
messengers. Both receptors are members of the family of 7-transmembrane spanning G-protein 
coupled receptors. Upon ligand binding, the activated Gi subunit of the receptors can result among 
others in activation of phosphotyrosine phosphatases and inhibition of Ca2+-channels and the enzyme 
adenylylcyclase. The subsequent decreases in cAMP and intracellular Ca2+  can result in a variety of 
downstream cellular effects.
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istration and was shown to reduce GH and IGF-1 levels in approximately two thirds of 
acromegalic patients (29, 30). 
An important further step in the development of SS analogs was the discovery of the 5 
somatostatin receptor subtypes in the 1990s. These findings clarified indirectly that the 
two available SS-analogs, Octreotide and its long-acting form Lanreotide, bind preferen-
tially to the sst2, but only modestly to sst5 or any of the other subtypes. Native SS, on the 
other hand, binds with high affinity to all of its receptors (sst1-5). In the subsequent years, 
evidence grew that not all neuro-endocrine tumours expressed receptor subtypes in 
a similar manner. Whereas growth-hormone producing adenomas generally expressed 
high levels of sst2, other adenomas, such as corticotroph adenomas expressed consider-
ably lower levels of sst2 (figure 5). The concept that different neuro-endocrine tumours 
with important differences in sst expression profiles would require specific sst-targeting 
analogs, sparked the interest for the development of new types of SS-analogs that dis-
played high affinity for one or more SS receptor subtypes (table 1). One example of such 
a compound is BIM-23244, which is a bispecific SS-analog with high affinity for both sst2 
and sst5. In GH-producing adenomas that were only partially responsive to Octreotide, 
this novel bispecific compound suppressed GH-production in vitro significantly more 
effective than Octreotide, probably through co-activation of sst2 and sst5 receptors (31). 
Another example is Pasireotide (SOM230), which is a multi-ligand SS-analog with high 
binding affinity for the sst1, sst2, sst3 and sst5 with IC50 values of 9.3, 1.0, 1.5 and 0.16 nM, 
respectively (table 1) (32). Its binding profile, which includes high sst5-affinity, makes 
it a promising new drug in the treatment of a number of neuro-endocrine tumours, 
including CD (see below).
Dopamine agonists are an important class of drugs with a broad range of therapeutic 
indications, including neurological disorders (Parkinson’s disease), cardiovascular dys-
function and neuro-endocrine disorders. They can be classified into either non-ergot 
(e.g. quinagolide) or ergot-derived (e.g. bromocriptine, cabergoline, pergolide). Bro-
mocriptine has been known for many years to effectively inhibit prolactin (PRL) release 
in the majority of prolactinomas (33). With increasing knowledge on DA receptors, it also 
became evident that selectivity of dopaminergic compounds for DA receptor subtypes 
was of great importance for their overall efficacy and safety profile. In comparison with 
bromocriptine, cabergoline has a longer plasma half-life, binds with a higher affinity to 
the D2 receptor, is better tolerated by patients and can induce normalization in patients 
with hyperprolactinemia that are proven to be resistant to bromocriptine therapy (34). 
The fulfilment of these criteria makes cabergoline a promising drug for the treatment of 
a number of neuro-endocrine disorders in which D2 expression plays an imminent role. 
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Figure 5
400400
Somatotroph adenomas Corticotroph adenomas 
sst1sst1
0
100
200
300
ss
t 1/
hp
rt
0
100
200
300
nd nd nd nd nd nd ndndnd nd
1 2 3 4 5 61 2 3 4 5 6 7
300
400
300
400 sst2 sst2
pr
t
1 2 3 4 5 6
0
100
200
1 2 3 4 5 6 7
0
100
200
ss
t 2/
hp
200
300
400
/hp
rt
200
300
400 sst3sst3
1 2 3 4 5 6
0
100s
st 3
/
1 2 3 4 5 6 7
0
100
ndndndnd nd ndnd nd
1000
15002000
3000 sst5
1000
15002000
3000
sst5
st 5
/hp
rt
1 2 3 4 5 6
0
500
1 2 3 4 5 6 7
0
500
ss
Adenoma no. Adenoma no.
Figure 5: Overview of sst expression in 7 GH-producing (somatotroph) and 6 ACTH-producing 
(corticotroph) human pituitary adenomas. Note the difference in scale of the y-axis between sst1-3 and 
sst5. Somatotroph adenomas have abundant expression of both sst2 and sst5 (left column), whereas 
corticotroph adenomas express sst5 at similar levels but have a significantly lower expression of sst2 (right 
column). Values are expressed as copy numbers relative to that of the reference gene hprt. N.d. = not 
detectable. Adapted from (57, 116).
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The binding affinities of dopamine (DA), bromocriptine and cabergoline to the D2 and D4 
receptors, are also shown in table 1.
Chimeric somatostatin-dopamine compounds
The fact that many neuro-endocrine cells co-express both sst and DA receptors, has 
driven the hypothesis that these receptors may work synergistically. In 2000, Rocheville 
et al. published an important paper on the functional heterodimerization of sst5 and 
D2 receptors in stably transfected CHO-K1 cells, which resulted in overall enhanced 
biological potency (35). Based on these observations, new chimeric molecules have 
been synthesized that contain structural elements of both SS and DA compounds and 
therefore bind with high affinity to both sst and DA receptor subtypes. By binding to 
the two different receptors, these hybrid molecules were proposed to draw the recep-
tors together in a spatial manner. This can lead to enhanced potency of the chimeric 
compound, compared to activation by two separate DA or SS analogs (36). At present it 
is not known, however, whether this enhanced potency is merely due to this proposed 
phenomenon of heterodimerization between the SS and DA receptors or whether other 
mechanisms may also be involved, such as superior activation at the level of individual 
receptors. 
table 1 Binding affinities (IC50) of SS-analogs and DA-agonists (in nM)
Compound sst1 sst2 sst3 sst4 sst5 D2Short D2Long D4
SS-analogs
Somatostatin (SS-14) 0.93 0.15 0.56 1.50 0.29
Octreotide 280 0.38 7.10 >1000 6.30
Pasireotide (SOM230) 9.3 1.0 1.5 >1000 0.16
BIM-23244 >1000 0.3 133 >1000 0.7
Dopamine agonists
Dopamine 350 320 100
Bromocriptine 4.5 3.9 >1000
Cabergoline 0.53 0.41 81
Dopastatin chimera 
BIM-23A760 622 0.03 160 >1000 42 15*
# References: SS-binding data (32, 117), DA-binding data (118), BIM-analog binding data (31, 119)
* IC50 for D2 receptor (both short and long isoform)
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AIM OF THESIS: We aimed to further characterize the functional aspects of one of these new 
dopamine-somatostatin chimeric compounds, BIM-23A760, in vitro. The results of these 
studies are described in Chapter 7. 
e. somatostatin and dopamine receptors in Cushing’s disease (CD)
1. Somatostatin analogs in Cushing’s Disease
Sst expression in normal corticotroph cells
Whereas the role of hypothalamic SS as a principal regulator of pituitary GH-release has 
been firmly established (37), the effect of SS on ACTH release by the anterior pituitary 
gland has been less clear. Rat pituitary corticotrophs are known to express multiple sst, 
including sst2 and sst5 (38-40), but treatment of cultured rat corticotrophs with SS-14 does 
not result in inhibition of ACTH-release (41, 42). On the other hand, when rat pituitary 
cells are cultured in glucocorticoid-free media, SS-14 is able to decrease ACTH-release 
(43). In agreement with these findings, infusion of SS-14 or Octreotide does not alter 
ACTH-release in normal subjects (44-47), whereas both of these compounds can acutely 
decrease plasma ACTH levels in conditions of hypocortisolemia such as untreated Addison 
disease (48). These observations suggest that the presence of glucocorticoids reduces the 
inhibitory effects of native somatostatin and traditional SS analogs on ACTH release.
In vitro studies with SS-analogs in corticotroph cell lines and adenomas
The only available ACTH producing cell line from corticotroph origin is the murine 
AtT-20 cell line. A number of studies have indicated that in these cells sst2 and sst5 are 
principally involved in regulation of ACTH release and that selective agonists that target 
these subtypes effectively inhibit ACTH secretion (49-53). More recently it was found that 
especially sst5 played a crucial role in regulating ACTH release in these cells and that sst5-
targeting agonists were more effective than sst2-agonists in inhibiting ACTH release (54). 
Interestingly, pre-incubation with dexamethasone decreased the expression of sst2 in 
these cells, but not of sst5, and in line with these findings Octreotide, but not Pasireotide, 
lost most of its ACTH inhibiting potential after glucocorticoid pre-treatment (54). These 
data are in line with the original observations that glucocorticoids downregulate the 
total number of SS binding sites in cultured pituitary cells (55). Evidence for abrogation 
of sst2-mediated effects by glucocorticoids has also been provided by Stalla et al (56). 
They found that Octreotide decreased ACTH levels in corticotroph adenomas in vitro, 
but not in CD patients in vivo. However, when these corticotroph adenoma cells in vitro 
were pre-treated with the glucocorticoid hydrocortisone, the ACTH inhibiting effects of 
Octreotide were abolished in one of the cultures. Given the generalized state of hyper-
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cortisolism in CD patients and the relative resistance of sst5 to glucocorticoid-induced 
down-regulation compared to sst2, SS-analogs with high sst5 affinity are of great interest 
in the development of new medical therapies for CD. 
AIM OF THESIS: To investigate more in detail the effects of glucocorticoids on the expression 
levels of not only sst2 and sst5, but also D2 in three human neuro-endocrine cell lines. These 
data could provide important insights into the biological processes that are responsible for 
the observed sst/DA receptor expression patterns in both pituitary-dependent and ectopic 
forms of Cushing’s syndrome. In addition, these data may also provide further directions for 
the type and timing of future sst/DA directed therapies in these patients. The results of these 
studies are described in Chapter 3.
In 2005 and 2006, two studies were published that independently investigated sst 
expression in human corticotroph adenoma tissues, obtained at the time of transsphe-
noidal surgery. In the first study, Hofland et al. showed by quantitative PCR that sst5 was 
highly expressed in 6/6 adenomas, whereas sst1,2,3,4 were expressed at much lower levels 
(figure 5) (57). In concordance with this, functional studies in five additional adenomas 
demonstrated overall superior ACTH inhibition by Pasireotide (10nM) compared to 
Octreotide (10nM) after 72 hr. 
In the second study, Batista et al. reported on a series of 13 corticotroph adenomas de-
rived from both adult (n=7) and pediatric (n=6) CD patients (58). In this study, quantita-
tive PCR demonstrated the expression of subtypes 1, 2, 4 and 5 in these adenomas, while 
at immunohistochemistry expression of all subtypes was found. Both of these methods 
showed the highest expression of the sst5 subtype. Six of the adenomas were cultured in 
vitro and treated with Pasireotide. In 6/6 adenomas Pasireotide significantly decreased 
cellular proliferation rates (range 10-70%) as measured by uptake of fluorescent vital 
stain and in 5/6 a significant decrease in ACTH production was observed (range 23-56%) 
at doses of 1 to 10 nM after 48-96 hr. Furthermore, a dissociation was seen in some of the 
adenomas between the anti-secretory and anti-proliferative effects of Pasireotide, simi-
larly to what has been described previously for GH-producing adenomas in response to 
SS-analog treatment (59). 
AIM OF THESIS: Since the above data were derived from relatively small patient series, we 
aimed to investigate somatostatin receptor subtype expression in a larger set of human 
corticotroph adenomas. Furthermore, we concomitantly investigated dopamine receptor 
subtype expression in these adenomas to assess the degree of co-expression of both receptor 
subtypes. In this way, we aimed to get a better estimate of the percentage of patients with 
CD that could benefit from DA or SS receptor targeted therapy. The results of these studies 
are described in Chapter 4. 
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Clinical studies with SS-analogs in CD 
Early studies showed that in patients with CD, Octreotide is not able to effectively re-
duce ACTH secretion and hence cortisol levels (56, 60, 61). In contrast, several smaller 
studies and case reports found that patients with Nelson Syndrome, i.e. an expanding 
ACTH-producing pituitary adenoma after bilateral adrenalectomy, did respond to Oct-
reotide with reductions in ACTH (60, 62-64). This difference is readily explained by the 
differences in average circulating cortisol levels in both disease states and the effects of 
glucocorticoid-induced down-regulation of sst2 receptors, as mentioned earlier (65). 
Since then, few clinical studies have been reported that examined SS-analogue therapy 
in CD, until some important new insights developed. It was foremost the discovery that 
sst5 was highly expressed in the majority of human corticotroph adenomas, which made 
the novel multi-ligand SS-analog Pasireotide an interesting compound to evaluate in 
patients with CD, due to its subnanomolar sst5-affinity. A phase II multi-center clinical 
study has been performed in 29 patients with de novo or recurrent CD (66). Patients 
were treated with SOM230 600 μg twice daily over a 15-day period. Primary endpoint 
was normalization of 24-hour urinary free cortisol (UFC) levels. This study showed that 
out of 29 included patients, 5 (19%) obtained complete UFC normalization, while a total 
of 22 patients (76%) showed a decrease in UFC levels. Overall, Pasireotide was well toler-
ated in the 2 x 600 μg dose, except for some mild gastro-intestinal side effects such as 
nausea, abdominal pain and loose stools or diarrhoea. A major side effect of Pasireotide, 
however, which was already known from previous studies in acromegalic patients, was 
an overall increase in blood glucose levels. Overt deterioration of glucose tolerance was 
observed in approximately one third of the patients in this study. 
2. Dopamine agonists in Cushing’s Disease
DA receptor expression in normal corticotrophs
In humans, no firm data exist whether or not ACTH release is directly regulated by DA 
receptors in normal corticotroph cells. In rats it is known that the intermediate lobe in 
the pituitary is under tonic inhibitory control from dopaminergic neurons from the hy-
pothalamus (67-69). The predominant cell type in the intermediate lobe is the melano-
troph, which produces pro-opiomelanocortin (POMC). In the intermediate lobe POMC 
is processed into α-melanocyte stimulating hormone (α-MSH) and corticotropin-like 
intermediate lobe peptide (CLIP). This is different from the POMC-processing in anterior 
corticotroph cells, which mainly results in ACTH. The tonic inhibition by hypothalamic 
dopamine is thought to be exerted through D2 receptors. This is demonstrated by the 
fact that D2-deficient mice develop intermediate lobe hypertrophy with increased 
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POMC expression, elevated ACTH and corticosterone levels, resulting in adrenal gland 
hypertrophy (70). In humans, the intermediate lobe in the pituitary is a rudimentary 
structure, but is still thought to contain important biological functions. Human cortico-
troph adenomas arising from the intermediate lobe may have different characteristics 
than those arising from the anterior lobe, although some controversy exists around this 
subject (71, 72) . 
In vitro studies with DA agonists in corticotroph cell lines and adenomas
Two reports have been published on the use of dopamine agonists in the murine 
corticotroph cell line AtT-20, but these have produced conflicting results. Farrell et al. 
found that treatment with the dopamine agonist bromocriptine did not reduce POMC 
mRNA expression in these cells, whereas Yin et al. did show that bromocriptine inhibited 
proliferation of these cells with induction of apoptosis (73, 74). The observed difference 
may be due to the fact that in the second study treatment with bromocriptine was 
significantly longer than in the first study (72 hr vs. 24 hr, respectively). 
In 2004, Pivonello et al. investigated DA receptor expression in a series of 20 human 
corticotroph adenomas (75). They showed that the majority (80%) of these adenomas ex-
press the D2 receptor as demonstrated by immunohistochemistry (IHC), receptor-ligand 
binding and RT-PCR. Of these D2-positive adenomas, approximately 40% expressed the 
D2 long isoform, 20% D2 short and 40% expressed both isoforms. D4 was expressed in 
20% of cases, whereas D1, D3 and D5 expression was not observed. Functional studies in 
vitro correlated very well with the D2 expression data: adenomas high in D2 expression 
responded well to either bromocriptine or cabergoline therapy with inhibition of ACTH 
release by 43 to 60%, whereas D2-negative adenomas failed to respond. The D2- expres-
sion data reported in this study are similar to those described by an earlier paper, where 
11/16 (69%) of corticotroph adenomas, both functional and silent, expressed D2 recep-
tors as demonstrated by in situ hybridisation and immunohistochemistry (76). 
Clinical studies with DA agonists in CD
The DA agonist bromocriptine has been widely evaluated for its potential use in human 
corticotroph adenomas. Overall, results of these studies have been variable. Although 
initial reductions in ACTH levels are evident in almost half of CD patients in response to 
bromocriptine administration, these reductions are often minor and sustained responses 
to bromocriptine therapy occur only in a small percentage of patients (77). Some studies 
have suggested that corticotroph adenomas arising from the intermediate lobe may be 
more likely to respond to bromocriptine (78).
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Compared to bromocriptine, cabergoline binds with even higher specificity and affinity 
to D2-receptors and has a longer duration of action (table 1) (34). Over the past decade, 
various case reports have demonstrated that ACTH-producing adenomas can be highly 
responsive to cabergoline therapy, both in patients with CD as well as in Nelson’s Syn-
drome (table 2) (79-85). In some of these cases shrinkage of the corticotroph adenoma 
was observed on MRI (80-83). In the previously mentioned study by Pivonello et al., 20 
patients with CD were treated with cabergoline at a dose of 1-3 mg/week for 3 months 
(75). This resulted in a significant decrease in urinary free cortisol (UFC) in 60% of patients 
and even complete UFC normalization in 40% of them. Interestingly, there was a very good 
correlation between the in vitro findings on D2 receptor expression and the responses to 
cabergoline therapy in vivo. All D2-expressing adenomas showed decreased cortisol levels 
in vivo in response to cabergoline therapy, whereas D2-negative cases did not. Preliminary 
data from another research group showed similar in vivo response rates after cabergoline 
monotherapy (86). In this study, 10/29 CD patients (34%) had a complete normalization of 
24 hr UFC after 3-6 months of therapy, while another 5 patients (17%) had a partial response 
(UFC ≤ 1.25 x ULN). In both studies, cabergoline therapy was generally well tolerated. Both 
research groups, however, also report the occurrence of (late) relapses in patients who 
were initially complete responders to cabergoline monotherapy. These treatment escapes 
reduce the long-term efficacy rates of cabergoline to approximately 27-40% (86, 87).
table 2 Overview studies on cabergoline use in ACTH-producing pituitary adenomas (CD and Nelson)
Year First author (ref) No. of 
patients
Type Macro-
adenoma
Dose 
(mg/wk)
Duration 
(months)
Shrinkage
observed
Remarks
1999 Pivonello (81) 1 Nelson no 1-2 12 yes normalization ACTH
2001 Petrossians (80) 1 Silent 
CD
yes 1.75 24 yes restored cranial 
nerve function
2004 Miyoshi (82) 1 CD yes 0.25-0.5 6 yes decreased ACTH
2004 Casulari (83) 1 Nelson yes 1.0 48 yes normalization ACTH
2006 Shraga-Slutzky 
(85)
1 Nelson yes 1.5-2 72 no decreased ACTH 
(-90%)
2006 Illouz (79) 3 CD no 1-3 1-9 no normalization UFC 
in 2/3 patients 
2007 Garcia (84) 1 Nelson no 2 42 n.e. decreased ACTH
2004 Pivonello (75) 20 CD 5/20 1-3 3 n.e. 40% full + 20% 
partial UFC 
response
2008 Godbout (86) 29 CD n.m. 2 3-6 yes 34% full + 17% 
partial UFC 
response 
2009 Pivonello (87) 20 CD n.m. 1-7 3-24 n.e. 40% full remission 
after 2 yrs
n.e. = not evaluated
n.m. = not mentioned
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One important issue that recently has dominated the field of medical therapy with DA-
agonists has been the possible association between valvular heart disease and long-term 
therapy with the ergot-derived dopamine agonists (EDDA) pergolide and cabergoline. 
Two important papers were published in early 2007, which reported significantly in-
creased risks (RR: 4.6-7.3) of valvular regurgitation in patients with idiopathic Parkinson’s 
disease that had received chronic treatment with either one of these drugs (88, 89). 
Other studies have recently confirmed these data (90). The pathogenetic mechanism 
behind this deleterious side effect is thought to be the binding of EDDA to 5-HT2 recep-
tors expressed in the endocardial tissue of heart valves (89). 
These findings have led to a number of important actions, including the withdrawal 
of pergolide from the US market. The impact of these studies on the (future) use of 
cabergoline in patients with CD cannot be fully determined yet, as one important issue 
needs to be emphasized. The maximum dose of cabergoline prescribed in CD is around 
0.65 mg per day (4.5 mg/week), whereas the patients with Parkinson’s disease in the 
study by Zanettini et al. received an average daily dose of 3.6 mg/day (89). In the other 
study by Schade et al., an important risk difference was found between patients taking 
>3 mg cabergoline daily for more than 6 months (RR 50.3, 95% C.I: 6.6-381.4) compared 
to those who took less than 3 mg daily (RR 2.6; 95% C.I: 0.5-12.8) (88). Therefore, these 
observations in Parkinson’s disease patients can not be directly extrapolated towards 
lower-dose cabergoline therapy in CD. Recent studies have shown that patients who are 
on long-term cabergoline therapy for prolactinoma, do not have an increased incidence 
of heart valve abnormalities, as assessed by cardiac echocardiography (91-95). Most 
important, perhaps, is the notion that mild tricuspid regurgitation is a common finding, 
which can be present in up to 40% of the normal population (96). Therefore, the clinical 
relevance of finding mild, echocardiographic valve abnormalities in patients on long-
term cabergoline use remains unclear (96, 97). Nonetheless, until definitive conclusions 
can be drawn on this subject, most clinicians will agree that periodical evaluation of 
cardiac function in any patient on long-term cabergoline therapy, especially those who 
are on higher doses, should be performed during follow-up (98).
3. Combined treatment with SS analogues and DA agonists in CD
Due to the reported presence of both sst and DA receptors in human corticotroph ad-
enomas and the fact that both receptor types can inhibit ACTH production in vitro, the 
concept of a combination therapy with both SS-analogs and DA-agonists in CD seems 
to be a feasible approach (99). These studies could be performed by co-treatment with 
individual SS-analogs and DA-agonists (pasireotide + cabergoline) or perhaps, in the 
near future, by administration of SS-DA-chimeric compounds such as BIM-23A760, which 
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displays high affinity for sst2, D2 and to a lesser extent sst5 (see table 1). If functional het-
erodimerization of these receptor subtypes occurs in vivo, as has already been shown to 
occur in vitro by different groups, this type of treatment could result in greatly enhanced 
efficacy of these compounds (35). Also, as corticotroph adenomas can differ considerably 
in the total number of sst and D2 receptors they express (57, 58, 75), targeting of multiple 
receptors could increase the overall response rate in this group as a whole, compared to 
the use of individual SS or DA agonists. This has already been shown for GH-producing 
adenomas, where BIM-23A760 had overall superior efficacy compared to individual sst2, 
sst5 or D2-targeting agonists in terms of in vitro GH inhibition (100, 101). As it is known 
that also in CD only subsets of patients have responded to either cabergoline or pasir-
eotide monotherapy in vivo, it may well be that similar phenomena occur in corticotroph 
adenomas and that combination therapy can increase overall response rates. Until now, 
no studies have been published that have investigated this hypothesis.
AIM OF THESIS: To investigate whether combined therapy with SS-analogues with sst5 affin-
ity and D2 targeting agonists increases the percentage of CD patients that can be controlled 
biochemically during the standard pre-operative period of three months. We have investi-
gated this in a multi-center clinical trial in patients with de novo or recurrent CD. Preliminary 
results of this ongoing study are presented in Chapter 5. 
Theoretically, co-treatment with sst and DA agonists may have other advantages as well. 
As stated before, the inefficacy of sst2-preferring compounds in CD, is probably due to 
down-regulation of sst2-expression by high levels of circulating glucocorticoids (54, 56, 
57). Inversely, if combined treatment with these analogs is effective and thus lowers 
cortisol levels in these patients, this could result in re-expression of sst2. The latter would 
result in enhanced efficacy of SS-analogs with sst2-affinity and hence strongly increase 
pharmacotherapeutical options in these patients (65, 102). 
F. somAtostAtin AnD DoPAmine reCePtors in eCtoPiC ACtH-
ProDuCing synDrome (eAs)
Ectopic ACTH-producing Syndrome (EAS)
Some peripheral neuro-endocrine tumours can secrete excessive amounts of ACTH, 
which can lead to the clinical entity known as the Ectopic ACTH-producing Syndrome 
(= Ectopic Cushing’s Syndrome). Primary therapy is preferably the surgical removal of 
the neuro-endocrine tumour, but in some cases this is not technically possible. Bilateral 
adrenalectomy can offer a definitive cure, but has the same disadvantages as described 
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earlier for patients with persistent Cushing’s disease who undergo this procedure. For 
that reason, medical therapy could be an important secondary treatment option in 
selected cases of EAS. 
Somatostatin analogs in EAS
For some decades it has been known that neuro-endocrine tumours that cause Ectopic 
ACTH-producing Syndrome (EAS), such as bronchial carcinoids or small cell lung cancer 
(SCLC), often express functional SS receptors. A number of smaller studies and case 
reports have been published on the use of Octreotide in patients with EAS. Interest-
ingly, Octreotide was efficacious in lowering cortisol levels in a significant number of 
these patients, as opposed to the studies performed in patients with CD (103-106). This 
discrepancy is further confirmed by the fact that many patients with EAS have posi-
tive lesions on 111In-pentreotide scan (OctreoScan), whereas most patients with CD do 
not (107). The observation that many of the EAS producing neuro-endocrine tumours 
have functional sst2 receptors, despite the chronic hypercortisolism they are exposed 
to, could be explained by aberrant glucocorticoid receptor signalling in these tumour 
cells. This has been investigated extensively by a number of research groups over the 
past twenty years. It was found that many of the cell lines, derived from EAS producing 
small-cell lung carcinomas, carry gross mutations in the genetic sequence of the gluco-
corticoid receptor (GR) (108, 109). These can be located either in the DNA-binding or the 
ligand-binding domain, but can also involve a number of transcription factors. The loss 
of function of the GR has important impact on POMC production in these cells. Any form 
of negative feedback is generally lost in these cells, leading to excessive and uninhibited 
production of POMC and ultimately, the full clinical spectrum of Cushing’s Syndrome. 
Another result of aberrant GR functioning, may be that glucocorticoid-induced down-
regulation of somatostatin receptor subtype 2 (sst2) does not occur in these tumours, 
as opposed to pituitary-derived corticotroph adenomas. This could well explain the 
relatively high degree of positive OctreoScans and reported efficacy of Octreotide in 
this group of neuro-endocrine tumours (110, 111). One main concern with the use of 
SS analogs in EAS, however, appears to be the long-term control of hypercortisolism. 
Although initial responses to Octreotide are frequent, these are not always sustained 
and treatment escapes are commonly encountered, due to a number of possible mecha-
nisms of tachyphylaxis (112). 
AIM OF THESIS: To illustrate the clinical relevance of glucocorticoid-induced changes in 
somatostatin receptor subtype expression in EAS, we have described our in vitro and in vivo 
findings on sst and DA receptor expression patterns in a patient with EAS, before and after 
glucocorticoid-lowering therapy. The results of these studies are described in Chapter 6.
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Dopamine agonists in EAS
Farrell et al. showed in 1992 that the dopamine agonist bromocriptine could effectively 
inhibit POMC mRNA and ACTH precursor secretion in a small cell lung cancer cell line 
(CORL103), that is known to cause EAS (73). After these initial observations, to our 
knowledge no (clinical) studies have been performed that investigated the potential 
use of DA compounds in EAS, until a recent study by Pivonello et al. (113). In this study, 6 
patients with EAS-causing carcinoid tumours (4 lung, 1 thymic, 1 pancreatic) underwent 
surgery. Five out of these 6 resected EAS tumours expressed D2, as determined by IHC. 
Three patients had persistent EAS after surgery and were treated with cabergoline at 3.5 
mg/week for 6 months. All three patients had measurable D2 mRNA and 2 out of 3 had 
D4 mRNA expression on RT-PCR. Two patients had complete normalization of UFC after 3 
months of cabergoline treatment, although one of them had a treatment escape after-
wards. Of note, the long-term responder had the strongest overall D2 expression, includ-
ing the D2 short isoform, and was also D4-receptor positive. In other pituitary tumours 
this expression profile has been associated with a good response to cabergoline therapy 
(75, 114). Despite the small size of this study, it is probable that at least a subgroup of 
EAS patients could benefit from D2-targeted treatment, but obviously these results need 
to be confirmed in larger series.
Combined treatment with SS analogues and DA agonists in EAS
A recent case report suggests the potential synergism between sst and DA receptors 
in EAS. In this case, a man with EAS due to a lung carcinoid tumour was treated medi-
cally after incomplete surgical removal. Cortisol levels normalized only temporarily with 
either a SS-analogue (Lanreotide) or a dopamine agonist (Cabergoline) alone. However, 
when both drugs were given simultaneously, based on co-expression of sst5 and D2 that 
was demonstrated by RT-PCR on the resected tumour specimen, the patient came into 
complete and prolonged remission (115). 
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ABstrACt
Cushing’s disease (CD) is a severe disorder characterized by chronic hypercortisolism 
due to an ACTH-secreting pituitary adenoma. Transsphenoidal adenomectomy is the 
treatment of choice in humans with CD but recurrences occur frequently. Finding an 
effective and safe medical treatment for CD may improve long-term clinical outcome. 
The recent demonstration of expression of somatostatin receptor subtypes (mainly sst5) 
and dopamine D2 receptors in human corticotroph adenomas offers the possibility for 
medical treatment of CD with novel somatostatin analogues and dopamine agonists. 
Investigation of the effects of these drugs is hampered by the low incidence of CD in 
humans. Interestingly, CD is a frequent disorder in dogs with striking clinical similarities 
with CD in humans. Therefore, we investigated the expression and functional role of 
D2 and sst receptors in corticotroph adenoma cells from 13 dogs with active CD that 
underwent therapeutic hypophysectomy and normal anterior pituitary (NAP) cells from 
5 dogs. Quantitative RT-PCR and immunohistochemistry revealed that both in CD and 
NAP, sst2 was the predominant receptor subtype expressed, whereas D2 was modestly 
expressed and sst5 was expressed only at very low levels. In primary cultures of canine 
adenomas (n=7), the sst2-preferring agonist octreotide also showed the strongest ACTH-
suppressive effects. In conclusion, canine corticotroph adenomas provide an interesting 
model to study CD, but differences in sst and dopamine receptor expression between 
humans and dogs should be taken into account when using dogs with CD as a model 
to evaluate efficacy of novel somatostatin analogues and dopamine agonists for human 
CD.
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introDuCtion
Cushing’s disease (CD) is a severe endocrinological disorder due to an ACTH-producing 
pituitary adenoma. The resulting chronic hypercortisolism causes significant morbidity 
and, if left untreated, mortality in these patients (1). Primary treatment of CD is trans-
sphenoidal selective adenomectomy (2), but only results in long-term cure in 50-80% 
of patients (3). Secondary treatments such as radiotherapy or bilateral adrenalectomy 
are generally effective, but can cause permanent hypopituitarism or the necessity of 
life-long adrenal hormone replacement therapy, respectively.
For that reason, finding an effective and safe medical therapy for human CD can be 
of great importance for those CD patients that are not cured by neurosurgery alone. 
Various drugs have been used in patients with CD, but most of them have not been ef-
ficacious in long-term treatment or are associated with an unfavorable safety profile (4). 
Novel drug targets have been identified, however, as it was found that the somatostatin 
receptor subtype 5 (sst5) and the dopamine (DA) receptor subtype 2 (D2) are expressed 
in the majority of human corticotroph adenomas (5-7). Compounds that target these 
receptor subtypes, such as the multiligand somatostatin analogue with high sst5-affinity 
pasireotide (SOM230) and the D2-agonist cabergoline, have already shown in some in 
vitro and in vivo studies to decrease ACTH release by corticotroph adenoma cells and 
thus lower cortisol levels (5, 6, 8).
For the development of new medical therapies in human CD, research on primary 
corticotroph adenoma tissue is crucial. The efficacy of new compounds in CD can only 
be genuinely tested in the cell type they are primarily directed at, i.e., the human corti-
cotroph cell. This tissue can only be obtained at the time of transsphenoidal adenomec-
tomy in a CD patient. Due to the low incidence of CD of approximately 1.2 to 2.4 cases/
million/year (9, 10) and the fact that 80-90% of these cases are due to microadenomas 
with a diameter of less than 10 mm (11, 12), there is a severe shortage of human corti-
cotroph tissue, which limits research options in human CD. For that reason, finding ways 
to increase the availability of primary corticotroph adenoma tissue is a major challenge 
in this research field. 
In contrast to the situation in humans, CD is a frequent endocrinological disorder in 
dogs, with an estimated incidence of 1 to 2 cases/1000/yr (13-16). Canine CD, also re-
ferred to as pituitary-dependent hyperadrenocorticism (PDH), has a remarkably similar 
pathophysiology and clinical presentation as CD in humans and can hence be regarded 
as a spontaneous animal model for human CD (17). In dogs with CD true microadenomas 
are rare and pituitaries are frequently enlarged (18). Medical treatment of dogs with CD 
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involves the use of adrenolytic drugs such as mitotane or an inhibitor of steroidogenesis 
such as trilostane (19, 20). In the Netherlands, hypophysectomy has been performed in 
dogs with CD since 1993 and has proven to be a safe and effective treatment (18, 21, 22). 
The procedure consists of a complete hypophysectomy via a transsphenoidal approach 
as is described in detail elsewhere (22). 
Given the high incidence of CD in dogs, the high degree of similarity with human CD 
and the availability of corticotroph adenoma tissue obtained at hypophysectomy, we 
hypothesized that evaluation of the efficacy of new compounds for treatment of human 
CD may be tested first in canine corticotroph adenoma tissue. Therefore, our main study 
aim was to characterize these canine corticotroph adenomas for the expression and 
functional role of those receptor subtypes that are of primary interest in the research 
of human CD: somatostatin receptor subtype 2 (sst2), somatostatin receptor subtype 
5 (sst5) and dopamine receptor subtype 2 (D2), and to compare these results with the 
current knowledge on human corticotroph adenomas. 
mAteriAls AnD metHoDs
Study population
Thirteen dogs (5 females (4 spayed) and 8 males (3 castrated)) with Cushing’s disease 
(i.e. pituitary-dependent hypercortisolism, PDH) from various breeds were included in 
the study (Table 1). The median age was 8 years (range 5-14 years) and the median body 
weight was 23.2 kg (range 6.7-48.0 kg). Hypercortisolism was diagnosed by clinical signs, 
routine laboratory investigation and determination of the urinary corticoid-to-creatinine 
ratio (UCCR) in two consecutive morning urine samples as described previously (23-26). 
The mean UCCR was 116.7 x 10-6 (range 26.5-302.5 x 10-6; normal <10 x 10-6) (18). After 
collection of the second urine sample, three oral doses of 0.1 mg dexamethasone per 
kg body weight were administered at 8 h intervals and the next morning a third urine 
sample was collected (high dose dexamethasone suppression test). In 10 dogs the UCCR 
in the third sample was less than 50% of the mean in the first 2 samples and PDH was 
diagnosed (18). In 2 cases with less than 50% suppression, dexamethasone-resistant 
PDH was confirmed by measurements of plasma ACTH concentrations and further 
supported by visualization of the adrenals by ultrasonography and pituitary imaging 
(27-30). Computed tomography (CT) of the pituitary gland revealed pituitary enlarge-
ment in each case, except one (C8), with a mean pituitary height-to-brain area ratio (P/B) 
of 0.58 (range 0.30-1.00; pituitary enlarged when P/B > 0.31 x 10-2 mm-1) (31). Plasma 
cortisol, ACTH and α-MSH concentrations were determined with assays that have been 
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described previously (32). Pre-operative mean (+range) plasma values were: α-MSH 27.8 
(<5-224) pg/ml, cortisol 196.9 (61-414) nmol/l and ACTH 21.5 (9.3-41.8) pmol/l (see Table 
1 for reference values). Microsurgical transsphenoidal hypophysectomy was performed 
as published previously (22). 
Unaffected pituitary tissue was obtained from five Beagle dogs, which had been eutha-
nized for reasons unrelated to the present study and for which approval was obtained 
from the Ethical Committee of Utrecht University, the Netherlands. The pituitary gland 
was collected within 10 minutes after euthanasia. The anterior pituitary was separated 
from the neurointermediate lobe and the anterior pituitary was processed for analysis. 
Surgical tissue and cell isolation
During transsphenoidal hypophysectomy, pituitary adenomatous tissue was identified 
macroscopically by the veterinary surgeon and resected. A representative part of the 
adenoma was fixated in 4% buffered paraformaldehyde and sent for histopathology for 
haematoxylin and eosin (HE) staining and immunohistochemistry to evaluate ACTH, 
α-MSH and GH expression (33). The surplus adenomatous tissue was immediately 
placed in a pre-chilled (4 ˚C) solution of Minimal Essential Medium (MEM) with Earle’s 
salts, supplemented with 10% fetal calf serum (FCS), L-glutamine (2 mmol/l), penicillin 
(105 U/l) and fungizone (0.25 mg/l). Media and supplements were obtained from Invit-
rogen (Breda, the Netherlands). Upon arrival in the laboratory, the adenoma tissue was 
further divided into two parts: one part was snap-frozen on dry ice and stored at –80˚C 
for qPCR studies; the other part was kept overnight at 4˚C in MEM. Next day, the latter 
adenoma part was washed in HBSS/HSA, dispersed with dispase 103 U/l (Roche, Almere, 
the Netherlands) + collagenase 2 mg/ml (Sigma Aldrich, Zwijndrecht, the Netherlands) 
at 37ºC for 1 h and resuspended in MEM complete culture medium. Viable pituitary cells 
were counted in a standard haematocytometer. 
Cell distribution and culture
The average yield per tumor in terms of viable canine pituitary cells was 2.4 x 106 cells 
(range: 0.5-11.0 x 106). Of these cells, 0.2 x 106 were used for qPCR studies and 0.1 x 
106 for the preparation of cytospins for immunohistochemistry (IHC, see below). The 
remainder of the cells was cultured in 48 well plates (Corning, Cambridge, USA) at a den-
sity of 10,000 cells/well for 4-6 days at 37 ˚C in a humidified incubator in 5% CO2. At that 
time, culture media were refreshed and incubations were started with the different DA 
agonists and SS analogues for 4-72 h. Both basal and corticotropin-releasing hormone 
(CRH)-induced ACTH-release were studied. At the end of the incubation period, media 
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were collected and stored at –80˚C for hormone analysis after addition of aprotinin (4 x 
105 IU/ml medium; Bayer, Mijdrecht, the Netherlands) to prevent ACTH degradation. All 
experimental conditions were performed in quadruplicates. 
Hormone analysis in vitro
ACTH production by the corticotroph cells in vitro was measured using a commercially 
available, non-isotopic, automatic, chemiluminescence immunoassay system (DPC Im-
mulite, Los Angeles, USA). Intra- and interassay coefficients of variation were 5.6 and 
7.8% respectively. 
Design of canine sst2, sst5 and D2 primers
The sequences of the canine housekeeping gene hypoxanthine phosphoribosyltrans-
ferase (hprt), sst2, sst5 and D2 genes are available at the NCBI website (www.ncbi.nlm.
nih.gov) with the following accession numbers: AY283372 (hprt); AY702068 (sst2); 
XM_547202 (sst5); NM_001003110 (D2). Primers and probes were designed with Primer 
Express® software (Applied Biosystems, Foster City, USA) and ordered from Sigma Aldrich 
(Zwijndrecht, the Netherlands). Their sequences are depicted in Table 2. 
Quantitative PCR
Expression analysis by quantitative PCR (qPCR) was performed both on the 2 x 105 cells 
obtained via the isolation procedure, as well as on a representative part of adenoma tissue 
that had been stored at –80˚C directly post-operatively. For qPCR we used a previously 
table 2. Primer-probe sequences 
Primer/probe sequence 5’-3’ Bases
sst2 forward GCCATACTATGACCTGACCAGCA 23
sst2 reverse TGTTGCCACACAATCCAATGA 21
sst2 probe FAM-TGCAGTCCTCACATTCATATATTTTGTGGTCTGC-TAMRA 34
sst5 forward TGCTGGTCATCTGCCTCTGTT 21
sst5 reverse GCCGGACGCCTTCACC 16
sst5 probe FAM-CCTGCTCATCGTGGTC-TAMRA 16
D2 forward TGGCCACGCTCGTCATG 17
D2 reverse TGAATTTCCACTCACCTACCACC 23
D2 probe FAM-CCTGGGTTGTCTACCTG-TAMRA 17
hprt forward GCTTGCTGGTGAAAAGGACC 20
hprt reverse GAATTTCAAATCCAACAAGTCAGGT 25
hprt probe FAM-CTCGAAGTGTTGGCTATA-TAMRA 18
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described method (34). In short, poly(A+) mRNA was isolated from the corticotroph cells 
with the use of Dynabeads Oligo (dT)25 (Dynal AS, Oslo, Norway). The poly (A
+) mRNA was 
eluted in H2O (65˚C) for 2 x 2 minutes and used for cDNA synthesis in a Tris buffer [50 mM 
Tris-HCl (pH 8.3), 100 mM KCl, 4 mM DTT and 10 mM MgCl2] with 10 units RNase inhibitor, 
2 units avian myeloblastosis virus Super Reverse Transcriptase and 1 mM of each deoxy-
nucleotide triphosphate in a final volume of 40 µL. This was incubated for 1 h at 42˚C and 
the resulting cDNA was diluted 5-fold in 160 µl sterile H20. One twentieth of the total cDNA 
library was used for quantification of hprt, sst2, sst5, and D2 mRNA levels. The total reaction 
volume (25 μl) consisted of 10 µl cDNA and 15 μl TaqMan Universal PCR Mastermix (Alphen 
a/d Rijn, the Netherlands). Primers and probes were used at final concentrations of 300nM 
(both primers) and 200 nM (probe). Real-time quantitative PCR was performed in 96-well 
optical plates with the TaqMan Gold nuclease assay (Applied Biosystems, Roche, USA) and 
the ABI Prism 7700 Sequence Detection System (Perkin Elmer, Foster City, USA). After two 
initial heating steps at 50˚C (2’) and 95˚C (10’), samples were subjected to 40 cycles of 
denaturation at 95˚C (15 sec) and annealing at 60˚C (60 sec). All samples were assayed 
in duplicate. Values were normalized against the expression of the housekeeping gene 
hprt. Dilution curves were constructed to calculate PCR efficiencies (E) for every primer-
probe set (35). Efficiencies were: sst2 2.01, sst5 1.77, D2 1.96 and hprt 1.84. Estimated copy 
numbers were calculated using the comparative threshold method with efficiency cor-
rection, as described previously (36). To exclude genomic DNA contamination in the RNA, 
the cDNA reactions were also performed without reverse transcriptase and amplified with 
each primer pair. To exclude contamination of the PCR reaction mixtures, the reactions 
were also performed in the absence of cDNA template, in parallel with cDNA samples. 
Assessing purity of corticotroph cell population 
Three steps were taken to secure the purity of the examined corticotroph adenoma 
tissue. First of all, the veterinary surgeon provided us only with pituitary tissue that was 
macroscopically adenomatous. When the surgeon assessed the pituitary tissue to be 
a mix of adenomatous and unaffected tissue, this was specifically noted. Secondly, a 
part of the isolated cells (1.0 x 105) was used to check for ACTH-immunopositivity on 
freshly prepared cytospins (see below for methods). Only isolated cell populations with 
significant ACTH-immunopositivity were eligible for analysis. As a third and final step, 
the expression of growth hormone (GH) and pro-opiomelanocortin (POMC) mRNA was 
analyzed in all samples with Bio-Rad My-IQ detection system (IQ SYBR green Supermix 
and My-IQ Bio-Rad, Veenendaal, the Netherlands) with final primer concentrations of 
400 nM according to previously published protocols (37). For GH and POMC, the ribo-
somal protein S19 (rps-19) was used as a reference gene (38). Ratios of GH/POMC mRNA 
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expression were established in normal anterior pituitary cells (N1-5) and compared to 
those in the corticotroph adenoma samples (C1-13). 
Neuro-D1 expression
In order to investigate the possible origin of the corticotroph adenoma (anterior vs. 
intermediate lobe), we also assessed Neurogenic Differentiation factor D1 (Neuro D1) 
mRNA expression in all samples, using the same qPCR protocol as for GH and POMC and 
with rps-19 as reference gene. Neuro-D1 is a transcription factor that promotes POMC 
expression and is a corticotroph marker in mice, dogs and humans (39, 40). It is highly 
expressed in the normal canine anterior lobe but not in the intermediate lobe (41).
Dexamethasone and sst2 mRNA expression
To study the effects of glucocorticoids on sst2 expression, isolated corticotroph cells 
were plated at a density of 100,000 cells/well and cultured for 72 h in the presence or 
absence of the glucocorticoid dexamethasone (DEX) 10 nM, the glucocorticoid receptor 
antagonist RU-486 100 nM or their combination. After 72 h, cells were lysed and mRNA 
expression levels of sst2 and hprt were determined. All experimental conditions were 
performed in quadruplicates. 
Immunohistochemistry (IHC): paraffin-embedded tissue and cytospins
The expression of ACTH and sst2 was assessed in representative adenoma tissue by means 
of IHC according to a previously published method (42). Formalin-fixed, paraffin-embed-
ded corticotroph adenoma tissues were cut (5μm), deparaffinized, rehydrated, heated 
in citrate buffer (pH 6.0) for 20’ at 100˚C for antigen retrieval and incubated with the fol-
lowing primary antibodies: anti-ACTH (Santa Cruz, mouse monoclonal, 1:100, 1 h RT) and 
anti-sst2 (Gramsch, rabbit polyclonal, 1:2000, o/n 4˚C). This was followed by 30’ incuba-
tion at RT with Poly-AP-Goat anti Mouse/Rabbit IgG from PowerVision+ (ImmunoVision 
Technologies Co, Brisbane, CA, USA) and 30’ incubation in New Fuchsin solution. Slides 
were counterstained with HE and cover slipped. Negative controls included omission of 
the primary antibody and preabsorption with an immunizing receptor peptide (100 nM) 
for the sst2 polyclonal antibody. Three different commercially available antibodies against 
the human D2 and two against the human sst5 receptor were tested on canine normal an-
terior pituitary tissues and on a number of canine corticotroph adenomas. Unfortunately, 
none of these antibodies resulted in specific immunohistochemical staining. 
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To check for corticotroph purity of the adenoma specimen obtained at surgery (see 
above), cytospins of freshly isolated adenoma cells were made using a Cytospin 4 ma-
chine (Thermo Shendon Limited, Astmoor, U.K.), in which 2 x 104 cells were spun onto 
adhesive microscopic slides (Starfrost, Braunschweig, Germany). Subsequently they were 
air-dried, fixed in acetone for 10’ and next, a similar IHC protocol as described above was 
used with an anti-ACTH antibody dilution of 1:600. In these cytospins, we counted the 
percentage of ACTH-positive cells as a measure of the percentage of corticotrophs in our 
isolated cell population. 
Test substances
Test substances were obtained from Novartis Pharma AG, Basel, Switzerland (octreotide, 
pasireotide), Sigma Aldrich (RU-486), Pharmacia, Milan, Italy (cabergoline) and the Eras-
mus MC pharmacy (dexamethasone, CRH).
Statistical analyses
All data were analyzed with GraphPad Prism software (San Diego, CA, USA). Data on hor-
mone release are expressed as mean ± SEM. All experiments were run in quadruplicate. 
Overall differences between treatment groups were determined by ANOVA. In case of 
significant differences found by ANOVA, a multiple comparison between groups was 
performed with a Newman-Keuls test. Correlation analyses were performed between 
the expression levels of NeuroD1, sst or D2 receptor subtypes and/or corresponding pre-
operative hormone levels by determining Spearman’s correlation coefficients. P-values 
less than 0.05 were considered statistically significant. 
results
Study population follow-up 
Remission of hypercortisolism occurred in 12 of the 13 dogs and was confirmed by reso-
lution of clinical signs and UCCR values < 5 x 10-6 within 8 weeks after hypophysectomy. 
In one dog (C11) hypercortisolism recurred 4 months post-operatively. One other dog 
was lost to follow-up (C7). Histopathology revealed pituitary adenoma in 11 of 13 cases, 
with an adenoma originating from the pars intermedia in one case (C9). Immunostain-
ing was positive for ACTH in 11 of 13 cases (Table 1). 
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Purity of obtained corticotroph tissue
Macroscopically pure adenoma tissue was identified by the surgeon in 9 of 13 cases. In 
the remaining cases the resected tissue was a mixture of adenoma and unaffected (pre-
existent) pituitary tissue. Cytospins that were prepared from the isolated corticotroph 
cells, showed variable but significant ACTH-immunoreactivity in all cases that were 
analyzed (Table 3). 
GH and POMC mRNA expression was determined in the 5 normal anterior pituitaries 
(NAP) and in the 13 adenomas (Table 3). The mean (± SEM) POMC/GH ratio in the 5 NAP 
cases was 0.36 ± 0.18. We defined pure corticotroph adenomas as having a POMC/GH 
table 3. mRNA expression data and immunohistochemistry cytospins
Case1 Tissue2 ACTH+3 POMC/GH4 Classification5 NeuroD16
N1 N n.a. 0.35 normal 0.22
N2 N n.a. 0.10 normal 0.16
N3 N n.a. 0.07 normal 0.08
N4 N n.a. 0.22 normal 0.21
N5 N n.a. 1.05 normal 0.23
C1 C n.a. 231495.07 pure adenoma 0.04
C2 C/N 3+ 3.58 non-pure 0.43
C3 C/N 1+ 0.02 non-pure 0.10
C4 C 4+ 5920.75 pure adenoma 2.27
C5 C 3+ 149.43 pure adenoma 0.93
C6 C 3+ 11.45 pure adenoma 0.29
C7 C/N 3+ 0.17 non-pure 0.63
C8 C/N n.a. 0.03 non-pure 0.09
C9 C 4+ 548.86 pure adenoma 0.06
C10 C n.a. 12.82 pure adenoma 0.17
C11 C 3+ 856.95 pure adenoma 9.67
C12 C 1+ 6230.95 pure adenoma 4.43
C13 C 3+ 1.82 non-pure 0.50
¹ = N1-N5: normal dogs; C1-C13: patients with Cushing’s disease 
2 = Macroscopic appearance of resected tissue as judged by veterinary surgeon. C: pure adenoma tissue; 
C/N: mixture of adenoma and unaffected tissue
3 = Percentage ACTH-positive cells on cytospin: 1+ (0-10%); 2+ (10-20%); 3+ (20-30%); 4+ (>30%); n.a. = 
not available
4 = POMC/GH mRNA ratio in normal anterior pituitary cells (N1-N5) and in corticotroph adenoma cells 
(C1-C13) 
5 = Classification of tissue: normal (= unaffected anterior pituitary tissue); pure adenoma tissue; non-pure 
(mixed adenoma-unaffected) tissue
6 = NeuroD1/rps-19 mRNA (x 10-2) expression 
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mRNA ratio of ≥10 x higher than the POMC/GH mRNA ratio observed in NAP. In this way, 
8/13 adenomas were classified as pure adenomas and 5/13 adenomas as a mixture of 
adenoma and unaffected (= non-pure) pituitary tissue. Four of the latter 5 adenomas 
had been classified macroscopically by the surgeon as being a mixture. One case (C13) 
was assessed by the surgeon as pure adenoma but the POMC/GH mRNA ratio in vitro 
was low, indicating non-pure pituitary tissue.
mRNA expression: sst, D2 and NeuroD1
In the corticotroph adenoma cells, which were obtained after cell dispersion in vitro, 
there was a strong but highly variable expression of the sst2 receptor subtype (median 
1.90; range 0.22-26.28) with two adenomas (C1, C6) showing very high sst2 expression 
levels (Figure 1). D2 was moderately expressed (median 0.75; range 0.00-8.07) and sst5 
was expressed at very low levels (median 0.02; range 0.00-0.49). These results were 
confirmed in similar but independent experiments with RNA that was extracted from 
the primary adenoma tissue that had been stored directly post-operatively at –80˚C. In 
these experiments a similar mRNA expression pattern was observed (data not shown). 
For comparison, expression levels in the normal anterior pituitaries were (median and 
range): sst2 (7.98; 3.81-18.7), sst5 (0.30; 0.08-0.66) and D2 (0.96; 0.45-2.98). The anterior 
pituitary marker NeuroD1 was variably expressed among the adenomas with a median 
value of 0.43 x 10-2 (range 0.04-9.67 x 10-2), which was higher than that of NAP (median 
0.21 x 10-2, range 0.08-0.23 x 10-2, Table 3). No significant correlations were found be-
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Figure 1: Overview of sst2, sst5 and D2 mRNA expression in canine corticotroph pituitary adenomas 
(C1-13) and in normal anterior pituitary tissue (NAP). All expression levels are normalized against the 
housekeeping gene hprt. Values for C1-C13 represent the mean of two duplicate measurements ± SEM. 
For comparison, the median expression level in NAP (n=5) is depicted.
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tween NeuroD1 and sst-D2 receptor subtype expression or with pre-operative hormone 
levels (Spearman’s correlation coefficients: p>0.05). 
In vitro culture data
For seven pure corticotroph adenomas, we were able to measure the effects of DA/SS 
analogues on ACTH inhibition in vitro. Mean basal ACTH production in these adenomas 
was 86 pmol/l at 4 h (range 33-188), 222 pmol/l at 24 h (range 56-471) and 591 pmol/l 
at 72 h (range 88-1240). Stimulation with CRH 10 nM induced a mean 2.0 fold increase 
(range 0.7-3.9) in ACTH production at 4 h compared to basal. In all adenomas combined, 
the sst2-preferring agent octreotide (OCT) was most effective at inhibiting 4 h CRH-
induced ACTH release (-27%, p<0.01 vs. control), whereas the multiligand SS-analogue 
pasireotide (PAS) (-18%, p<0.05) and the D2-agonist cabergoline (CAB) (-13%, p<0.05) 
were less effective (Figure 2A). All compounds were used at the 10 nM concentration. 
Combining CAB with either OCT or PAS did not increase ACTH inhibition compared 
to OCT or PAS alone (OCT+CAB -23%, p<0.05 vs. control; PAS+CAB –20%, p<0.05). Of 
note, the two adenomas with the highest sst2 mRNA expression (C1, C6) were also most 
responsive to OCT (10 nM) treatment in terms of 4 h CRH-induced ACTH inhibition: C1: 
OCT -67%, p<0.001 (Figure 2B); C6: OCT -74%, p<0.001 (Figure 2C). The other 5 adenomas 
(C4, C5, C9, C11, C12) showed minor to moderate (10-30%) ACTH inhibition in response 
to the different compounds. 
Parallel to this, we investigated ACTH inhibition in these adenomas without CRH stimula-
tion. At the 24 h time point a similar pattern of response to DA and SS analogues was ob-
served. Data for all adenomas combined were: OCT -20% (p<0.001 vs. control), PAS -13% 
(p<0.05) and CAB -9% (p>0.05). In these experiments without CRH stimulation, adding 
CAB to OCT or PAS increased the overall ACTH inhibition: OCT+CAB: -24% (p<0.001 vs. 
control) and PAS+CAB: -20% (p<0.001) (Figure 2D). Similar patterns of inhibition were 
observed after 72 h, although average levels of ACTH inhibition were lower at this time 
point (data not shown). 
Immunohistochemistry (IHC)
In normal canine pituitary tissue, sst2 was expressed in the anterior pituitary, but immu-
noreactivity for sst2 was especially strong in cells of the intermediate lobe (Figure 3). The 
staining pattern was primarily cytoplasmatic and absent with omission of the primary 
antibody or when co-incubated with an immunizing peptide. In a subset of patients 
(n=5), we were able to perform IHC for sst2 on the corticotroph adenoma tissue that was 
formalin-fixed and paraffin-embedded directly after surgery. For these adenomas, the 
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results of IHC for sst2 expression corresponded well with the previously described mRNA 
data. In one of the tumors with a very high sst2 mRNA expression (C1), a strong overall 
sst2 staining was observed with clear co-localization of sst2 and ACTH-immunoreactivity 
(Figure 4), whereas the other corticotroph adenomas showed staining of minor intensity 
(C4, C5) or only of isolated cells (C2, C3). Due to unavailability of canine-specific antibod-
ies, we were not able to test for sst5 or D2-immunopositivity in these tissues. 
Dexamethasone and sst2 mRNA expression
To explore potential regulation of receptor subtype expression by glucocorticoids, we 
investigated the effects of the synthetic glucocorticoid dexamethasone (DEX) on sst2 
mRNA expression in two primary corticotroph cultures (C4, C12) with a sufficiently high 
cell yield that allowed us to perform additional experiments. Treatment with DEX 10 
nM for 72 h caused increased sst2 mRNA expression in both adenomas with an average 
Fig 2A
150
))
100
nd
uc
ed
le
as
e 
(%
)
**
* * **nd
uc
ed
le
as
e 
(%
)
50C
R
H
-i
n
A
C
T
H
 r
el
*
C
R
H
-i
n
A
C
T
H
 r
el
0
A
CT PAS CAB PAS+ OCT+OCT
A
CAB CAB  
Fig 2B
150
))
100
nd
uc
ed
le
as
e 
(%
)
** **n
du
ce
d
le
as
e 
(%
)
50C
R
H
-i
n
A
C
T
H
 r
el
*** ***C
R
H
-i
n
A
C
T
H
 r
el
0
A
CT PAS CAB PAS OCTOCT
A
+
CAB
+
CAB
Fig 2C
150
)
100
nd
uc
ed
el
ea
se
 (%
*
50C
R
H
-i
A
C
T
H
 r
e
*** ******
0
A
n.d.
CT PAS CAB PAS+
CAB
OCT+
CAB
OCT
 
Fig 2D
150
))
100
as
al
el
ea
se
 (%
*** *******as
al
el
ea
se
 (%
50
B
a
A
C
T
H
 r
e
*B
a
A
C
T
H
 r
e
0
A
CT PAS CAB PAS OCTOCT
A
+
CAB
+
CAB
Figure 2A-D: ACTH inhibition in canine corticotroph adenomas. Fig 2A-C: Primary corticotroph cells 
were cultured and stimulated for 4 hours with CRH 10 nM in the presence or absence of pasireotide 
(PAS) 10 nM, octreotide (OCT) 10 nM, cabergoline (CAB) 10 nM or their combination. Data are shown 
for all adenomas combined (fig 2A), adenoma C1 (fig 2B) and adenoma C6 (fig 2C). Fig 2D: Basal ACTH 
production after 24 h in the presence or absence of the same compounds as above (data for all adenomas 
combined). After 4 h or 24 h, respectively, media were collected and ACTH levels were determined. All 
experimental conditions were performed in quadruplicates. Values represent percent change ± SEM 
relative to control (CT). Control was CRH alone (for CRH-data) or untreated cells (for basal data). * = 
p-value <0.05; ** = p<0.01; *** = p<0.001 vs. control; n.d. = not determined.
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increase of 61% (p<0.05 vs. control, Figure 5), with C4: +51%, p>0.05 and C12: +71%, 
p<0.05. Addition of the glucocorticoid antagonist RU-486 100 nM abolished these ef-
fects. The effects of DEX could not be investigated for sst5 and D2, as the expression 
levels of these subtypes were too low in these particular adenomas. 
DisCussion
Canine corticotroph adenomas resected during transsphenoidal surgery constitute a 
new and interesting source for retrieving considerable amounts of valuable primary 
corticotroph tissue. This primary tissue can be of great value for research regarding 
pituitary developmental processes, as well as etiology, diagnosis and therapy of pitu-
itary disorders (43). Due to the high incidence of CD in dogs, surgical specimens of fresh 
adenoma tissue become available at a routine basis and have a high average yield in 
terms of viable corticotroph adenoma cells. Furthermore, these cells remain viable in 
culture, produce ACTH in significant amounts, are CRH-responsive to a variable degree 
and can respond to commonly used agonists in vitro. The fulfilment of all of these criteria 
makes canine corticotroph adenomas a feasible and readily used model for the study of 
(human) Cushing’s disease. 
Fig 3
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Figure 3: Immunohistochemistry for sst2 expression in the normal canine anterior pituitary. Top panel left, 
magnification 40x: strong sst2 expression in the anterior lobe (AL) and the intermediate lobe (IL, arrow), 
but not in the posterior lobe (PL). Top panel right, 400x: cytoplasmatic staining for sst2 in individual cells 
of the intermediate lobe. Bottom panel left (40x) and right (400x): no staining in negative control with 
immunizing receptor peptide.
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The main objective of our present study was to evaluate the expression and functional 
significance of dopamine (D2) and somatostatin receptor subtypes (sst2 and sst5) within 
these canine corticotroph adenomas. These receptor subtypes are the main focus of 
much of the current research into human CD and agonists that target these receptor 
subtypes have already been used in clinical studies with promising results (6, 8). From 
this perspective, canine corticotroph adenoma tissue could constitute a useful tool to 
further explore efficacy and mechanism of action of novel SS or DA compounds for 
future use in human CD. 
Fig 4
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Figure 4: Immunohistochemistry for sst2 expression in canine corticotroph adenoma C1. Top panel: 
strong ACTH expression in the adenomatous tissue (arrow), magnification left 40x and right 400x. Middle 
panel: sst2 expression is evident in the areas of ACTH-positive adenoma tissue, 40x and 400x. Bottom 
panel: no staining in negative control with immunizing receptor peptide, 40x and 400x.
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Despite the many striking similarities in etiology and clinical presentation between 
human and canine CD, canine corticotroph adenomas differ clearly from their human 
counterparts in terms of SS and DA receptor expression patterns. Canine corticotroph 
adenomas mainly express sst2, whereas D2 and especially sst5 are expressed at much 
lower levels. The predominance of sst2 is observed at the mRNA level, as demonstrated 
by quantitative PCR, and confirmed at the protein level by immunohistochemical stud-
ies. In agreement with this, the sst2-preferring agonist octreotide is the most efficacious 
agent in inhibiting ACTH release in both basal and CRH-stimulated conditions, whereas 
the multiligand SS-analogue pasireotide is significantly less effective. The lower efficacy 
of pasireotide compared to octreotide is readily explained by its 2.5 fold lower binding 
affinity for the sst2 receptor (IC50 1.0 vs. 0.38 nM, respectively) (44) in combination with 
the low overall expression of sst5 in canine corticotroph adenomas. The D2 agonist cab-
ergoline shows some efficacy in the 7 cultured adenomas combined, albeit lower than 
octreotide and pasireotide. This finding is in line with the lower D2 mRNA expression 
compared to sst2 observed in this study. 
Nonetheless, this modest level of D2 receptor expression could still prove to be of func-
tional value. In a recent study by Castillo et al. dogs with CD were treated with cabergo-
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Figure 5 Glucocorticoid regulation of sst2 mRNA expression. Adenoma cells of C4 and C12 were cultured 
in the absence or presence of the glucocorticoid dexamethasone (DEX) 10 nM and/or the glucocorticoid 
receptor antagonist RU-486 100 nM. After 72 h, cells were lysed and mRNA expression levels of sst2 and 
housekeeping gene hprt were determined by qPCR. Hprt expression levels did not vary among treatment 
groups. All experimental conditions were performed in quadruplicates. Values represent percent change 
± SEM relative to control. * = p-value <0.05 vs. control (CT).
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line (0.07 mg/kg/wk) for 1 year, which resulted in an overall response rate of 42.5% (45). 
One factor that could explain this observed difference between the in vitro and clinical 
efficacy of cabergoline could be the duration of treatment. It is known from studies in 
human patients with CD that it can take up to 3 months before the maximal cortisol-
inhibiting effects of cabergoline are observed (6). In this respect, our in vitro data on 
ACTH inhibition after 4-72 h may not necessarily reflect the full potential of cabergoline 
as a drug in canine CD. On the other hand, the high levels of sst2 expression both on the 
mRNA and the protein level, in combination with the superior efficacy of octreotide in 
cultured canine corticotroph adenomas, suggest an even stronger role of this receptor 
subtype as a therapeutic target. Based on our findings, a clinical study to investigate the 
effects of an sst2-preferring compound such as octreotide on ACTH and cortisol levels in 
canine CD could be of great interest to see if superior response rates could be achieved 
with the use of such compounds, compared to those obtained with cabergoline. In ad-
dition to this, it would be very interesting to study whether combined targeting of sst2 
and D2 receptors, either by co-treatment with the individual SS/DA analogs or by the use 
of novel chimeric SS-DA molecules could result in even higher clinical efficacy. 
To return to our original research question, the receptor expression pattern observed 
in canine adenomas is remarkably different from the one observed in human corti-
cotroph adenomas, where sst5 and D2 are the predominant receptor subtypes and sst2 
expression is generally low. The reasons for this dissimilarity between canine and hu-
man corticotroph adenomas are yet unknown. One important factor, however, appears 
to be the difference in regulation by glucocorticoids of receptor subtype expression. 
Down-regulation of sst2 expression by glucocorticoids has been demonstrated in murine 
corticotroph AtT-20 tumor cells and is also thought to explain the low sst2 expression 
in human corticotroph adenomas (5, 46, 47). Striking, therefore, was the observation 
in our study that this glucocorticoid-induced down-regulation did not occur in canine 
corticotroph adenomas. In fact, treatment of the canine corticotroph cells in vitro with 
dexamethasone increased the expression of the sst2 receptor, as was observed in two 
different adenomas. From a future perspective, it would be interesting to see whether 
these differences can be ascribed to the 7% inhomology between the canine and the 
human sst2 genetic sequence, as it is possible that this genomic variation is also present 
in areas within the human sst2 gene that are known to contain glucocorticoid-responsive 
elements. 
It is important to emphasize that sst and D2 are not the only receptors that have been 
linked to regulation of ACTH secretion in corticotroph cells. Receptors such as the retinoic 
acid receptor (RAR) and peroxisome-proliferator-activated receptor-γ (PPARγ) have also 
been shown to decrease ACTH regulation in different in vitro and rodent models and have 
therefore been implicated as potential new targets for medical therapy of CD in humans 
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(48, 49). Most notably, retinoic acid was used in a recent clinical study in dogs with CD 
and showed significant clinical efficacy (50). In this respect, it would be very interesting 
to evaluate canine corticotroph adenomas for the presence and distribution of novel 
drug targets such as RAR and PPARγ, and to see whether correlation is higher between 
canine and human CD for these receptors than for SS and DA. These investigations could 
help to fully evaluate the potential of canine CD as a direct animal model for human CD. 
In conclusion, canine corticotroph adenomas obtained after transsphenoidal surgery, 
provide a model to study corticotroph cell (patho)physiology, due to the high yield of 
viable, primary tissue that retains most of its corticotroph features in vitro. Some distinct 
differences do exist, however, between human and canine corticotroph adenomas in 
terms of sst and D2 receptor expression patterns and their responses to SS and DA ago-
nists in vitro. These differences should be taken into account when using dogs with CD 
as a model to evaluate efficacy of novel somatostatin analogues and dopamine agonists 
for future use in human CD. 
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ABstrACt
Dopamine agonists and somatostatin analogues have been proposed in the treatment 
of ACTH-producing neuro-endocrine tumours that cause Cushing’s syndrome. Inversely, 
glucocorticoids (GC) can differentially influence dopamine receptor D2 or somatostatin 
receptor subtype (sst) expression in rodent models. If this also occurs in human neuro-
endocrine cells, then cortisol-lowering therapy could directly affect the expression of 
these target receptors. In this study we investigated the effects of the GC dexametha-
sone (DEX) on D2 and sst expression in three human neuro-endocrine cell lines: BON 
(carcinoid) and TT (medullary thyroid carcinoma) versus DMS (small cell lung cancer), 
which is severely GC-resistant. In BON and TT, sst2 mRNA was strongly down-regulated 
in a dose-dependent manner (IC50 0.84 nM and 0.16 nM), whereas sst5 and especially D2 
were much more resistant to DEX-treatment. Sst2 down-regulation was abrogated by a 
GC receptor antagonist and reversible in time upon GC withdrawal. At the protein level, 
DEX also induced a decrease in the total number of SS (-52%) and sst2-specific (-42%) 
binding sites. Pre-treatment with DEX abrogated calcitonin-inhibition by sst2-preferring 
analogue octreotide in TT. In DMS, DEX did not cause significant changes in expression of 
these receptor subtypes. In conclusion, we show that GCs selectively down-regulate sst2, 
but not D2 and only to a minor degree sst5 in human neuro-endocrine BON and TT cells. 
This mechanism may also be responsible for the low expression of sst2 in corticotroph 
adenomas and underwrite the current interest in sst5 and D2 as possible therapeutic 
targets for a medical treatment of Cushing’s disease.
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introDuCtion
Somatostatin (SS) and dopamine (DA) are small molecules with a variety of functions 
throughout the human body, including neurotransmission and inhibition of hormone 
release (1, 2). They bind to high-affinity receptors that belong to the family of G-protein 
coupled receptors. Both for SS and DA multiple receptor subtypes have been identified: 
sst1-5 and D1-5 (2, 3). The presence of these receptors has been demonstrated on a number 
of neuro-endocrine tumours and therefore, SS-analogues and DA-agonists could play 
an important role in the medical treatment of these tumours (4). Recent reports have 
shown significant efficacy of selective D2-receptor agonists, such as cabergoline, and 
of a multiligand SS-analogue with high sst5 affinity (pasireotide / SOM230) in the medi-
cal management of pituitary-dependent Cushing’s syndrome (5-7). The use of sst2-or 
D2-targeting agonists has also been advocated in cases of Cushing’s Syndrome due to 
ectopic ACTH-production by neuro-endocrine tumours (8, 9). 
The hallmark of Cushing’s syndrome, regardless of its cause, is a profound and sustained 
overproduction of glucocorticoids (GCs) by the adrenal glands. It is also known that GCs 
can have (in)direct effects on receptor expression patterns of different neurotransmit-
ters and hormones in the human body. Therefore, when considering the clinical use of 
DA-agonists and/or SS-analogues to lower cortisol levels in a patient, it is important 
to investigate how alterations in glucocorticoid levels (i.e. response to treatment) can 
secondarily affect the expression of the target SS and DA receptors in ACTH-producing 
neuro-endocrine tumours. If such a (in)direct relationship exists, then this could first of 
all explain our current knowledge on SS and DA receptor expression patterns in human 
corticotroph adenomas as it has been described before by different groups (5, 10, 11). 
Secondly, perhaps more importantly, it could help us to predict what happens to the 
expression of the target SS and DA receptors, when medical therapy lowers circulating 
GC levels. This may have implications for the type and timing of additional SS-or DA-
based medical treatment in these patients. 
A considerable number of studies have investigated the effects of GCs on dopamine recep-
tor expression, mainly within the central nervous system and associated neuro-psychiatric 
disorders, but not in human neuro-endocrine tumour cells (12-16). Most of these studies 
report no or only minor effects of GC exposure on D2 receptor expression. Several other 
studies have shown that GC’s can influence somatostatin receptor subtype expression in a 
differential manner in rat or murine pituitary cells and cell lines (17-19). No study thus far, 
however, has concomitantly evaluated D2 and SS receptor subtype expression and their 
regulation by GC’s within the same, human-derived neuro-endocrine cell system.
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For that reason we conducted the present study. We investigated the time- and dose-
dependent effects of the synthetic glucocorticoid dexamethasone (DEX) on sst2, sst5 and 
D2 receptor expression in vitro in three different human neuro-endocrine cell lines (BON, 
TT and DMS-79), for which evidence of direct transcriptional regulation by GC’s has been 
reported (20-22). BON (pancreatic carcinoid) and TT (medullary thyroid carcinoma) cells 
are not known to have any defects in their GC regulation and signalling pathway. By using 
these two different neuro-endocrine cell lines we aimed to find general patterns in GC-
mediated effects that are representative for the larger group of neuro-endocrine tumours 
as a whole. Since BON and TT cells do not necessarily reflect ectopic ACTH-producing 
tumours that display severe GC-resistance, we compared these results with a third and 
completely different neuro-endocrine cell line: the human ectopic ACTH-producing 
small cell lung carcinoma cell line DMS-79, which harbours distinct mutations in the 
glucocorticoid receptor gene and is known for its severe GC-resistant properties (22, 23).
mAteriAls AnD metHoDs 
Cell culture
BON cells were routinely grown in 75 cm2 flasks containing DMEM-F12 Glutamax® me-
dium supplemented with 10% Foetal Calf Serum, penicillin (1x105 U/l) and fungizone 
(0.25 mg/L). Cells were cultured in a 5% CO2 incubator at 37ºC and routinely passaged 
by trypsinization (trypsine 0.05% -EDTA 0.02%). Medium was refreshed twice a week and 
cell viability always exceeded > 95% as measured by trypan blue staining. TT cells were 
cultured following the same protocol with F-12K Nutrient Mixture (Kaighn’s Modifica-
tion). DMS cells were grown in suspension under the same conditions with 10% FCS, 
glutamine and penicillin in RPMI 1640 medium (ATCC 30-2001). All cell lines were con-
firmed to be mycoplasma-free. Media and supplements were obtained from Invitrogen 
(Breda, the Netherlands) unless otherwise stated. 
Cell treatment for mRNA expression studies
For the experiments, cells were trypsinized, counted in a standard haemocytometer and 
seeded at a density of 15,000 (BON) or 100,000 (TT, DMS) cells/well in 24 well plates 
(Corning, Cambridge, MA, U.S.A.) in 1 ml of medium. After 72 h media were refreshed 
and incubations started without or with different doses of DEX and/or the GC receptor 
antagonist RU-486. At the different time points, media were removed and cells were lysed 
on ice with a buffer containing 100 mM Tris-HCl (pH 8), 500 mM LiCl, 10 mM EDTA (pH 
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8), 5 mM DTT and 1% LiDS (HT Biotechnology Ltd, Cambridge, U.K.) and stored at –80˚C 
until further analysis. All experimental conditions were performed in quadruplicates. 
Quantitative PCR 
Quantitative PCR was performed according to a previously published method (24). In 
short, poly(A+) mRNA was isolated from the lysed cells with the use of Dynabeads Oligo 
(dT)25 (Dynal AS, Oslo, Norway). The poly (A
+) mRNA was eluted in H2O (65˚C) for 2 x 2 
minutes and used for cDNA synthesis in a Tris buffer [50 mM Tris-HCl (pH 8.3), 100 mM 
KCl, 4 mM DTT and 10 mM MgCl2] with 10 units RNase inhibitor, 2 units avian myeloblas-
tosis virus Super Reverse Transcriptase and 1 mM of each deoxynucleotide triphosphate 
in a final volume of 40 µL. This was incubated for 1 h at 42˚C and the resulting cDNA was 
diluted 5-fold in 160 µl sterile H20. 
One twentieth of the total cDNA library was used for quantification of hprt, sst2, sst5 and 
D2 mRNA levels. The total reaction volume (25 µl) consisted of 10 µl cDNA and 15 µl Taq-
Man Universal PCR Mastermix (Applied Biosystems, Branchburg, NJ, U.S.A.) with primers-
probes in the following concentrations: hprt, sst2 and sst5 500-500-100 nM and D2 300-
300-200 nM of forward primer, reverse primer and probe, respectively. The primer and 
probe sequences that were used for hprt, sst2, and sst5 have been published previously 
(24). D2 primer-and-probe sequences were: D2 forward 5’-GCCACTCAGATGCTCGCC-3’, D2 
reverse 5’-ATGTGTGTGATGAAGAAGGGCA-3’ and D2 probe 5’-FAM-TTGTTCTCGG CGTGT-
TCATCATCTGC-TAMRA-3’. This primer-probe set measures total D2 expression (D2 long + 
short isoform). All primers and probes were purchased from Sigma Aldrich (Zwijndrecht, 
the Netherlands). Real-time quantitative PCR was performed in 96-well optical plates 
with the TaqMan Gold nuclease assay (Applied Biosystems, Roche, NJ, U.S.A.) and the 
ABI Prism 7700 Sequence Detection System (PerkinElmer, Foster City, CA, U.S.A.). After 
two initial heating steps at 50˚C (2 min) and 95˚C (10 min), samples were subjected to 40 
cycles of denaturation at 95˚C (15 sec) and annealing at 60˚C (60 sec). All samples were 
assayed in duplicate. Values were normalized against the expression of the housekeeping 
gene hypoxanthine phosphoribosyltransferase (hprt). Dilution curves were constructed 
to calculate PCR efficiencies (E) for every primer-probe set (25). Efficiencies were: sst2 
1.92, sst5 1.92, D2 1.94 and hprt 1.93. Estimated copy numbers were calculated using 
the comparative threshold method with efficiency correction, as described previously 
(26). To exclude genomic DNA contamination in the RNA, the cDNA reactions were also 
performed without reverse transcriptase and amplified with each primer pair. To exclude 
contamination of the PCR reaction mixtures, the reactions were also performed in the 
absence of cDNA template, in parallel with cDNA samples. 
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Cell proliferation and DNA fragmentation assays 
After trypsinization, the cells were counted, seeded and treated with DEX in similar 
fashion as described above in the experiments for qPCR analysis. At the different time 
points media were aspirated and cells were collected for DNA measurement. Measure-
ment of total DNA contents, representative for the number of cells, was done using the 
bisbenzimide fluorescent dye (Hoechst 33258; Boehring Diagnostics, La Jolla, CA, U.S.A.) 
as previously described (27). Parallel to this, the induction of apoptosis was evaluated in 
these cells by DNA fragmentation analysis, using a commercially available ELISA kit (Cell 
Death Detection ELISAPlus, Roche Diagnostics GmbH, Almere, the Netherlands) according 
to the manufacturer’s protocol. Experiments were done in quadruplicates.
Membrane binding studies with [125I-Tyr11]-SS14 and [125I-Tyr3]-OCT
Membrane binding experiments were performed according to a previously published 
protocol (28). In brief, BON cells were grown to 40-50% confluency and subsequently 
treated with DEX 10 nM for 72 h. At 72 h cells were collected and homogenized with a 
Polytron Homogenizer (Kinematica). Membrane fractions were obtained by centrifuga-
tion at 14000 rpm for 30’ and protein content was determined by Bradford analysis. 50μl 
of membrane homogenates were incubated for 45 minutes at room temperature with 
25μl of increasing amounts of [125I-Tyr11]-SS14 (GE Healthcare, Brussels, Belgium) or [125I-
Tyr3]-OCT (Novartis, Basel, Switzerland) tracer, with or without excess (1 µM) of unlabeled 
SS-14 or OCT, respectively, in 25 µl HEPES buffer (10 mM HEPES, 5 mM MgCl2, and 0.02 
g/l bacitracin, pH 7.6) containing 0.2% BSA. Incubation was terminated by the addition 
of 1 ml of ice-cold HEPES-BSA buffer and membrane-bound radioactivity was separated 
from unbound by centrifugation for 2 min at 14,000 min-1. The remaining pellets were 
washed twice in HEPES buffer, air-dried and counted in a liquid scintillation γ-counter for 
1 minute. Specific binding was regarded as total binding minus the binding in the pres-
ence of excess (1μM) unlabeled SS-14 or OCT. Experimental conditions were in duplicate 
and experiments were performed at least twice.
Hormone release
After trypsinization, TT and DMS cells were pre-treated with DEX 10 nM or vehicle control 
for 72 h. Cells were then washed and subsequently treated with OCT 10 nM for 72 h. After 
that time, media were collected and stored at –20˚C. In DMS cells, aprotinin (4 x 105 IU/ml 
medium; Bayer, Mijdrecht, the Netherlands) was added to the media prior to storage to 
prevent ACTH degradation. ACTH and calcitonin levels were measured by commercially 
available, non-isotopic, automatic, chemiluminescence immunoassay systems (DPC Im-
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mulite, Los Angeles, CA, U.S.A.). Intra- and interassay coefficients of variation were 5.6 
and 7.8% for ACTH, and 2.0 and 3.5% for calcitonin, respectively. Sensitivity thresholds 
were 2.0 pg/ml (calcitonin) and 5.0 pg/ml (ACTH). 
Test substances
Dexamethasone and octreotide were obtained from the hospital pharmacy Erasmus 
Medical Center, aliquotted and stored at 4˚C. SS-14 and the glucocorticoid receptor 
antagonist RU-38486 (mifepristone) were obtained from Sigma Aldrich (Zwijndrecht, 
the Netherlands). 
Statistical analysis
Each experimental condition was run in quadruplicate and experiments were performed 
at least twice, independently of each other. Statistical analysis was done using Graph-
Pad Prism software Version 3.02 (San Diego, CA, U.S.A.). Average values per group were 
compared by ANOVA (Analysis of Variance). When significant differences were found, the 
Newman Keuls test was used to make comparisons between groups. IC50 values of dose-
response curves were calculated by non-linear curve fitting. Data of membrane binding 
studies were analyzed by the method of Scatchard. Values of p<0.05 were considered 
statistically significant. Data are reported as mean ± SEM. 
results
Baseline mRNA expression levels
The baseline expression levels of sst2, sst5 and D2 mRNA in the different cell lines are 
depicted in figure 1. All three cell lines expressed all receptors of interest, albeit in dif-
ferent ratios. BON cells expressed relatively high amounts of sst5 (0.43±0.09, mean±se), 
followed by D2 (0.22±0.05) and sst2 (0.08±0.01); TT cells predominantly expressed D2 
(1.26±0.13), followed by sst2 (0.40±0.06) and sst5 (0.34±0.03); DMS cells had overall lower 
expression levels: sst2 (0.15±0.03), D2 (0.12±0.01) and sst5 (0.04±0.01).
Cell proliferation and DNA fragmentation studies
We investigated whether DEX treatment (0.1-100 nM) caused significant changes at 24 
h, 72 h and 168 h in total DNA contents, hprt expression per nanogram RNA and the 
induction of apoptosis compared to untreated cells (data not shown). In the BON and 
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DMS cells we did not observe significant differences with different DEX doses at any time 
point. In TT cells, however, the highest DEX dose (100 nM) caused a significant decrease 
in DNA contents and an increase in apoptosis already after 72 h, which was not present 
at 24 h. For that reason we performed full dose-response experiments (0.1-100 nM) in TT 
cells at the 24 h time point instead of the 72 h time point, as for BON and DMS cells. 
Quantitative PCR 
In BON cells, sst2 was dose-dependently down-regulated by DEX (0.1-100 nM, 72 hr) with 
an ICmax of –85% at 100 nM (p<0.001 vs. control) and an IC50 just below 1 nM (0.84 nM), see 
figure 2. Sst5 was less sensitive to down-regulation with a 10-fold higher IC50 value (10.0 
nM) than sst2 and only showed significant down-regulation in the highest dose of DEX 
different ratios. BON cells expressed relatively high
amounts of sst5 (0.43G0.09, meanGS.E.M.), followed by
D2 (0.22G0.05) nd sst2 (0.08G0.01); TT cells
predominantly expressed D2 (1.26G0.13), followed by
sst2 (0.40G0.06) and sst5 (0.34G0.03); DMS cells had
overall lower expression levels: sst2 (0.15G0.03), D2
(0.12G0.01) and sst5 (0.04G0.01).
Cell proliferation and DNA fragmentation studies
We investigated whether DEX treatment (0.1–100 nM)
caused significant changes at 24, 72 and 168 h in total
DNA contents, HPRT expressi per nanogram RNA
and the induction of apoptosis compared with
untreated cells (data not shown). In the BON and
DMS cells, we did not observe significant differences
with different DEX doses at any time point. In TT cells,
however, the highest DEX dose (100 nM) caused a
significant decrease in DNA contents and an increase in
apoptosis already after 72 h, which was not present at
24 h. For that reason, we performed full dose–response
experiments (0.1–100 nM) in TT cells at the 24 h time
point instead of the 72 h time point, as for BON and
DMS cells.
Quantitative PCR
In BON cells, sst2 was dose-dependently down-regulated
by DEX (0.1–100 nM, 72 h) with an ICmax of K85% at
100 nM (P!0.001 vs control) and an IC50 just below
1 nM (0.84 nM; see Fig. 2). Sst5 was less sensitive to
down-regulation with a tenfold higher IC50 value
(10.0 nM) than sst2 and only showed significant down-
regulation in the highest dose of DEX 100 nM (K50%,
P!0.01). D2 did not show any down-regulation at any of
the tested concentrations; in fact, at the highest
concentration (100 nM) D2 was slightly up-regulated
(C33%, P!0.05). In TT cells (24 h), a similar dose-
dependent down-regulation for sst2 was observed with
n ICmax of K84% (P!0.001) and a subnanomolar
IC50 (0.16 nM). In TTcells sst5, nor D2 showed any signs
of down-regulation in any of the concentrations tested.
In DMS cells (72 h), no significant effects were observed
by DEX treatment.
Based on the presence of DEX-induced effects in
BON cells and the absence of growth inhibition or
apoptosis induction at any treatment duration or dose,
we investigated in these cells the effects of different
treatment periods (24 and 168 h) on DEX-induced
receptor down-regulation. We found that at 24 and
168 h, DEX treatment produced similar dose-depen-
dent decreases in sst2 mRNA expression as those
observed at 72 h. ICmax and IC50 values were respect-
ively K74% (P!0.001) and 0.60 nM at 24 h, and
K80% (P!0.001) and 0.84 nM at 168 h (see Fig. 3).
Also for sst5, comparable dose-dependent effects were
observed at these time points: ICmax K45% (P!0.01)
and IC50 4.0 nM at 24 h, and K52% (P!0.01) and
5.4 nM at 168 h. For D2, no down-regulation was
demonstrable at any DEX dose at these time points.
The observed D2 up-regulation after 72 h with DEX
100 nM was not demonstrable at 24 h or 168 h.
Figure 1 Sst2, sst5 and D2 mRNA expression in the three different
neuro-endocrine cell lines used in this study. Expression levels of
receptor subtypes were normalized against the housekeeping gene
HPRT. Values represent the meanGS.E.M. ofR3 independent
experiments per cell line. sst2&; sst5G; D2,.
Figure 2 Dose-dependent effect of DEX treatment on sst2, sst5 and D2mRNA expression in BON, TT andDMS cells. Cells were treated with
DEX (0.1–100 nM) for 72 h (BON and DMS) or 24 h (TT). Subsequently, cells were lysed and sst and D2 mRNA expression levels were
determined. Expression levels were normalized against the housekeeping gene HPRT. Values represent per cent change relative to control.
IC50 values were calculated for the dose–response effect of DEX on sst and D2 mRNA expression and are indicated in the results section.
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Figure 1: Sst2, sst5 and D2 mRNA expression in the three different neuro-endocrine cell lines used in this 
study. Expression levels of receptor subtypes were normalized against the housekeeping gene hprt. 
Values represent the mean ± SEM of ≥ 3 independent experiments per cell line.
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Figure 2: Dose-dependent effect of DEX treatment on sst2, sst5 and D2 mRNA expression in BON, TT and DMS 
cells. Cells were treated with DEX (0.1-100 nM) for 72 h (BON, DMS) or 24 h (TT). Subsequently cells were 
lysed and sst and D2 mRNA expression levels were determined. Expression levels were normalized against 
the housekeeping gene hprt. Values represent percent change relative to control. IC50 values were calculated 
for the dose-response effect of DEX on sst and D2 mRNA expression and are indicated in the results section.
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100 nM (-50%, p<0.01). D2 did not show any down-regulation at any of the tested con-
centrations; in fact, at the highest concentration (100 nM) D2 was slightly up-regulated 
(+33%, p<0.05). In TT cells (24 hr), a similar dose-dependent down-regulation for sst2 
was observed with an ICmax of –84% (p<0.001) and a subnanomolar IC50 (0.16 nM). In TT 
cells nor sst5, nor D2 showed any signs of down-regulation in any of the concentrations 
tested. In DMS cells (72 hr), no significant effects were observed by DEX treatment. 
Based on the presence of DEX-induced effects in BON cells and the absence of growth 
inhibition or apoptosis induction at any treatment duration or dose, we investigated in 
these cells the effects of different treatment periods (24h and 168 h) on DEX-induced 
receptor down-regulation. We found that at 24 and 168 h, DEX-treatment produced 
similar dose-dependent decreases in sst2 mRNA expression as those observed at 72h. 
ICmax and IC50 values were respectively: -74% (p<0.001) and 0.60 nM at 24 h, and -80% 
(p<0.001) and 0.84 nM at 168h, see figure 3. Also for sst5, comparable dose-dependent 
effects were observed at these time points: ICmax -45% (p<0.01) and IC50 4.0 nM at 24 h, 
and -52% (p<0.01) and 5.4 nM at 168 h. For D2, no down-regulation was demonstrable 
at any DEX dose at these time points. The observed D2 upregulation after 72 h with DEX 
100 nM was not demonstrable at 24 h or 168h. 
 To investigate whether DEX-induced down-regulation of sst2 and to a lesser extent sst5 
was a glucocorticoid receptor-specific effect, we also performed these experiments with 
the addition of the glucocorticoid receptor antagonist RU-38486 in all cell lines. The 
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Figure 3: Effect of treatment duration (DEX) on sst2, sst5 and D2 mRNA expression in BON cells. Cells were 
treated with DEX (0.1-100 nM) for either 24 or 168 hr. Subsequently cells were lysed and sst and D2 mRNA 
expression levels were determined. Expression levels were normalized against the housekeeping gene 
hprt. Values represent percent change relative to control (untreated cells). IC50 values were calculated for 
the dose-response effect of DEX on sst and D2 mRNA expression and are indicated in the results section.
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down-regulation after 72 hr by DEX 10 nM of sst2 (-71%, p<0.001) and sst5 (-22%, p<0.05) 
in BON cells, of sst2 (-69%, p<0.001) in TT cells, and sst5 (-24%, p<0.05) in DMS cells, was 
completely abrogated by co-incubation with RU-38486, see figure 4.
Reversibility of GC-mediated sst2 down-regulation was also investigated. BON and TT 
cells were pre-treated with DEX 10 nM for 24 h (t= Day 0). After changing the medium 
into DEX-free medium, the cells were subsequently cultured for another 2-4 days. After 
an initial sst2 down-regulation due to DEX treatment (BON –68%, p<0.001; TT –66%, 
p<0.001 at Day 0), a complete reappearance of sst2 expression was observed in both 
BON and TT cells after 2-4 days of culture in DEX-free medium (BON –2% after 4 days; TT 
+8% after 2 days, see figure 5).
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Figure 4: Antagonism of DEX-induced changes in sst2, sst5 and D2 mRNA expression by co-incubation with 
the glucocorticoid receptor antagonist RU-38486. Cells were treated for 72 h with DEX 10 nM, RU-38486 
100 nM or their combination. Subsequently, cells were lysed and sst and D2 mRNA expression levels were 
determined. Expression levels were normalized against the housekeeping gene hprt. CT = control; DEX = 
dexamethasone 10 nM; RU = glucocorticoid antagonist RU-38486 at 100 nM (BON, TT) or 1 μM (DMS), D+R 
= DEX 10 nM + RU-38486; Values represent percent change ± SEM relative to control and are the mean of 
≥ 2 independent experiments. *= p-value < 0.05, **= p-value < 0.001 vs. control.
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Membrane binding studies
To assess whether the observed sst2 mRNA down-regulation also occurred at the protein 
level, membrane-binding studies were performed on BON membrane homogenates 
with the radiolabelled SS-analogues [125I-Tyr11]-SS14 and [125I-Tyr3]-Octreotide. Treatment 
of BON cells with DEX 10 nM for 72 h led to a 42% decrease in total sst receptor binding 
sites, as measured by [125I-Tyr11]-SS14 binding: Bmax (DEX) 60 fmol/mg vs. Bmax (control) 
104 fmol/mg with unchanged binding affinity (Kd 1.2 nM), see figure 6a. The decrease in 
total sst binding sites included a marked decrease (-52%) in specific sst2-binding sites 
as shown by [125I-Tyr3]-Octreotide binding: Bmax (DEX): 40 fmol/mg vs. Bmax (Control): 84 
fmol/mg, with unchanged binding affinity (Kd 0.2 nM, see figure 6b).
Hormone release data
In TT cells, 72 h treatment with the sst2-preferring analogue octreotide 10 nM induced a 
significant decrease in calcitonin release compared to control (-32%, p<0.001, see figure 
7). However, when TT cells were pre-treated with DEX 10 nM for 72 h, the octreotide-
mediated inhibition of calcitonin release was completely abolished (-3%, p>0.05). In 
DMS cells, treatment with OCT 10 nM for 72 h did not significantly inhibit ACTH release 
in either control or DEX pre-treated cells. 
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Figure 5: Reappearance of sst2 expression after GC withdrawal in BON and TT cells. Cells were pre-treated 
for 24 h with DEX 10 nM. Part of the cells were lysed at that time (t= Day 0), whereas the remainder of the 
cells underwent prolonged culturing in normal, DEX-free medium. These cells were subsequently lysed 
either at Day 2 or at Day 4. Cell lysates were analyzed for sst2 mRNA expression at the different time points. 
Values are represented as percent change ± SEM relative to that in the control wells on the specific time 
points. * = p-value <0.001 vs. control. 
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DisCussion
In this study we have shown that somatostatin receptor subtypes (sst) and the dop-
amine D2 receptor, natively co-expressed by human neuro-endocrine cell lines, show a 
differential pattern of response to glucocorticoid exposure in vitro. 
In both BON and TT cells, sst2 is highly sensitive to GC-induced down-regulation in a 
dose-dependent manner, whereas the sst5 is significantly less sensitive. Moreover, D2 
is fully insensitive to this type of down-regulation. The phenomenon appears to be 
in vitro observations can model the clinical situation of a
CD patient in whom long-term GC overexposure is
relieved through cortisol-lowering therapy. Clinical
evidence in favour of a return of sst2 expression in vivo
does exist uponGC withdrawal, however. In patients with
Nelson’s syndrome, inoperable or recurrent corticotroph
adenomas (low sst2 expression) necessitate bilateral
adrenalectomy, leading to chronic hypo-/or normocorti-
solaemia. By r moving most of th excessive negative
feedback loop on the pituitary, the ACTH-producing
pituitary adenomas left in situmay expand with time and
can even show invasive growth in surrounding tissues.
Some of these Nelson adenomas, however, are visible on
111In-pentetreotide receptor scintigraphy (Octreoscan),
whereasmostprimary corticotrophadenomasarenot (de
Herder et al. 1994, de Herder & Lamberts 1996).
Moreover, octreotide has been effective in some of these
Nelson patients by lowering ACTH levels and stabilizing
tumour growth (Lamberts et al. 1989, Petrini et al. 1994,
Kelestimur et al. 1996). Most likely, this reappearance of
functional sst2 receptor expression is a direct effect of
removing chronic hypercortisolism in these patients.
In conclusion, we show that GCs selectively down-
regulate sst2, but not D2 and only to a minor degree sst5
in human neuro-end crine BON and TT cells. If this is
a common regulatory mechanism in human neuro-
endocrine cells, then these data would support the
hypothesis that chronically elevated GC levels in
Cushing’s disease may be directly responsible for the
low expression of sst2 in corticotroph adenomas. It also
suggests that sst5 and D2 are interesting candidate
receptors in the search for a medical treatment of CD,
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Figure 6 Membrane-binding studies. (A) Scatchard analysis of [125I-Tyr11]-SS-14 binding to cell membranes of BON cells, cultured in the
absence (Kd 1.2 nM, Bmax 104 fmol/mg) or the presence of 10 nM DEX (72 h; Kd 1.2 nM, Bmax 60 fmol/mg). (B) Scatchard analysis of
[125I-Tyr3]-OCT binding to cell membranes of BON cells cultured in the absence (Kd 0.2 nM, Bmax 84 fmol/mg) or the presence of 10 nM
DEX (72 h; Kd 0.2 nM, Bmax 40 fmol/mg).
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Figure 6: Membrane-binding studies. A: Scatchard analysis of [125I-Tyr11]-SS-14 binding to cell membranes 
of BON cells, cultured in the absence (Kd 1.2 nM, Bmax 104 fmol/mg) or presence of 10 nM DEX (72 h; Kd 
1.2 nM, Bmax 60 fmol/mg). B: Scatchard analysis of [
125I-Tyr3]-OCT binding to cell membranes of BON cells 
cultured in the absence (Kd 0.2 nM, Bmax 84 fmol/mg) or presence of 10 nM DEX (72 h; Kd 0.2 nM, Bmax 40 
fmol/mg). ■, Control; ▲10 nM DEX. 
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glucocorticoid receptor (GR)-specific, as addition of the GR antagonist RU-38486 can 
completely abrogate these effects and because sst2 down-regulation is fully reversible 
in time upon GC withdrawal. The functional relevance of this sst2 down-regulation could 
be demonstrated by the fact that the sst2-preferring analogue octreotide lost its efficacy 
in DEX pre-treated TT cells. In DMS cells, derived from a severely GC-resistant tumour 
type in vivo, these GC-mediated effects on sst2 expression were not demonstrable. 
The results in BON and TT cells could indirectly explain the low sst2 expression found 
specifically in human corticotroph adenomas (10, 11), whereas this receptor subtype 
is abundantly expressed in other pituitary adenomas, such as somatotroph and non-
functioning adenomas (29, 30). Based on our results, one can speculate that high endog-
enous GC levels in patients with Cushing’s disease (CD) are at least partially responsible 
for this observed difference in sst2 expression between adenoma types. It would also 
explain the low clinical efficacy of octreotide in the treatment of CD: most studies on the 
use of this sst2-preferring compound in CD report no to limited effect (31-33).
At the same time, these data do support the interest in the potential use of sst5 and D2 
selective agents in the medical treatment of CD. Apparently, these receptor subtypes 
are fully (D2) or partially (sst5) resistant to high GC pressure and thus may still be of 
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Figure 7: Effect of DEX pre-treatment on inhibition of hormone release by octreotide in TT cells. Cells 
were pre-treated for 72 h with DEX 10 nM (preDEX+) or not (preDEX-). At that time (t=0), cells were 
washed, media refreshed and incubations started for 72 h with octreotide 10 nM. After 72 h, media were 
aspirated and analyzed for calcitonin levels. All experiments were performed in quadruplicates. Values 
represent percent change relative to control (= no OCT treatment). * = p-value < 0.001 vs. control. CT= 
control; OCT = octreotide. 
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functional value in the regulation of ACTH release in corticotroph adenomatous cells. 
Several clinical studies have been performed already with these agents and have 
shown promising results in subsets of patients. Pivonello et al. showed that 3-month 
treatment with the D2-specific agonist cabergoline could significantly reduce urinary 
free cortisol (UFC) levels in 60% of patients and even induce complete normalization 
of UFC in 40% of patients with CD (5). An early report on the use of the multi-ligand 
SS analogue pasireotide (SOM230) which has subnanomolar affinity for sst2, sst3 and 
sst5, showed equally interesting results: 15-day treatment with pasireotide 600μg twice 
daily, led to a complete normalization of UFC in 19% (4/21) and a ≥ 50% decrease in 
UFC in another 24% (5/21) of CD patients, probably mediated through sst5 receptor 
activation (6). Considering the reported efficacy of both cabergoline and pasireotide 
in subsets of CD patients, combination treatment with these agents is an interesting 
future option. For that reason, studying the effects of GC on a single cell system from a 
neuro-endocrine origin that expresses sst2, sst5 and D2, could help us understand some 
more of the biological backgrounds of these clinical observations. 
This is the first study to describe a differential pattern of GC-responsiveness regarding 
both D2 and SS receptor subtypes co-expressed in human neuro-endocrine cell lines. 
The observed pattern closely resembles the one seen earlier in the murine corticotroph 
AtT-20 cells (19). In these cells, sst2 is sensitive whereas sst5 is largely insensitive to GC-
induced down-regulation. Unfortunately, D2 was not expressed at sufficiently high levels 
in these cells to allow for investigation of this receptor subtype (unpublished observa-
tions). Nevertheless, one could hypothesize that a similar pattern of GC-responsiveness 
exists in different human and murine neuro-endocrine cell lines. 
Our findings are in line with earlier studies that describe the presence of distinct GC-
responsive elements (GREs) in the murine sst2 gene, whereas the murine sst5 gene only 
contains multiple GRE-half sites (34-36). Moreover, in transfection experiments it was 
shown that the human sst2 gene promoter is under direct control of GC’s, whereas the 
sst5 promotor is not (37, 38). To our knowledge, comparable GC-responsive regulatory 
sequences have thus far not been identified within the D2 gene. 
Previously, Petersenn et al. found in GH4 cells (rat pituitary adenoma cell line) that 
hydrocortisone 100 nM did not influence sst5 promoter activity whereas we do find 
moderate but significant down-regulation of sst5 at higher DEX doses (100 nM) in BON 
cells (37). We believe that this difference can be ascribed to the difference in relative in 
vitro potency of hydrocortisone compared to dexamethasone. In previous studies on 
differential regulatory mechanisms by glucocorticoids it was found that DEX has a 14-
fold higher potency in vitro compared to hydrocortisone (GILZ EC50 of 4.1 and 56.7 nM, 
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respectively) (39). Therefore, the dose used by Petersenn et al. would be the equivalent 
of approximately 7 nM DEX in our study. At this dose we did not observe any significant 
effects on sst5 mRNA expression either. 
Even though corticotroph adenoma cells are GC-resistant to a certain degree, GC regula-
tion of SS receptors apparently remains intact in AtT-20 cells. Interestingly, BON and 
TT cells, derived from tumours which do not show GC-resistance in vivo, have indeed 
a higher degree of sst2 down-regulation when exposed to DEX 10 nM, compared with 
the partially GC-resistant corticotroph adenoma cell line AtT-20 (19). In the severely 
GC-resistant DMS cells, derived from an ectopic ACTH-producing small cell lung cancer, 
most of the GC-induced sst2 down-regulation is lost, as would be expected. The latter in 
vitro observation correlates with two interesting clinical observations. First of all, many 
ectopic ACTH-producing tumours are positive on 111In-pentreotide receptor scintigra-
phy (OctreoScan) (40-43), despite the hypercortisolistic environment they are exposed 
to. And secondly, octreotide has been shown to be effective in controlling tumour size 
and cortisol production in some of these patients as opposed to patients with pituitary-
derived CD (44, 45). 
Another aspect we have observed in this study is the reappearance of sst2 expression 
within 2-4 days after withdrawing GC-exposure. This observation could be of clinical in-
terest. When it is possible to lower GC levels in CD patients with the use of for instance sst5 
or D2 selective agents, then this state of normocortisolemia could lead to a re-expression 
of sst2 in the corticotroph adenomas of these patients. Return of sst2 expression in vivo 
would result in a strong increase in efficacy of traditional SS analogs such as octreotide 
(sst2) as well as pasireotide (sst2+sst5) and thus expand the pharmacological options to 
maximally inhibit ACTH production. Obviously, the question remains to which extent 
these in vitro observations can model the clinical situation of a CD patient in whom long-
term GC-overexposure is relieved through cortisol-lowering therapy. Clinical evidence 
in favour of a return of sst2 expression in vivo upon GC withdrawal does exist, however. 
In patients with Nelson’s Syndrome, inoperable or recurrent corticotroph adenomas 
(low sst2 expression) necessitate bilateral adrenalectomy, leading to chronic hypo-/ or 
normocortisolemia. By removing most of the excessive negative feedback loop on the 
pituitary, the ACTH-producing pituitary adenomas left in situ may expand with time and 
can even show invasive growth in surrounding tissues. Some of these Nelson adenomas, 
however, are visible on 111In-pentreotide receptor scintigraphy (OctreoScan), whereas 
most primary corticotroph adenomas are not (46, 47). Moreover, octreotide has been ef-
fective in some of these Nelson patients by lowering ACTH levels and stabilizing tumour 
growth (31, 48, 49). Most likely, this reappearance of functional sst2 receptor expression 
is a direct effect of removing chronic hypercortisolism in these patients. 
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In conclusion, we show that GCs selectively down-regulate sst2, but not D2 and only to 
a minor degree sst5 in human neuro-endocrine BON and TT cells. If this is a common 
regulatory mechanism in human neuro-endocrine cells, then these data would support 
the hypothesis that chronically elevated GC levels in Cushing’s disease may be directly 
responsible for the low expression of sst2 in corticotroph adenomas. It also suggests 
that sst5 and D2 are interesting candidate receptors in the search for a medical treat-
ment of CD, due to their (relative) resistance to GC-induced down-regulation. It needs 
to be emphasized, however, that these data require confirmation, preferably in primary 
cultures of human corticotroph adenomas. 
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ABstrACt:
Context: Previous studies have demonstrated the expression of somatostatin receptor 
subtypes (mainly sst5) and dopamine (DA) receptor subtypes (mainly D2) in smaller se-
ries of human corticotroph adenomas. In line with these findings, sst5 and D2-targeting 
agents have already been used clinically in patients with Cushing’s Disease (CD) and have 
shown promising results in subsets of patients. To what extent these receptor subtypes 
are co-expressed within individual adenomas, is not known however. 
objective: To investigate the (co-)expression of both sst and DA receptors in a large 
series of human corticotroph adenomas. 
Design: In vitro analysis of corticotroph adenoma tissue obtained via transsphenoidal 
adenomectomy
setting: Two university medical centers
Patients: 30 patients with Cushing’s disease 
results: Analyzed by quantitative RT-PCR, D2 and sst5 were significantly (co-)expressed 
in the majority (60%) of adenomas, whereas 23% of adenomas only expressed D2, but 
not sst5. The remaining 17% of adenomas did not significantly express either sst5 or D2. 
Overall, expression of sst1-4 and D4 was low to non-detectable. Corticotroph adenomas 
with invasive growth invariably showed loss of sst5 and D2 expression. Autoradiography 
revealed clear D2 and/or SS-14 binding in a subset of cases, which correlated well with 
their respective mRNA data. 
Conclusions: Sst5 and especially D2 are highly expressed in the majority of human cor-
ticotroph adenomas with co-expression of sst5 and D2 being a common phenomenon. 
These findings support the current studies with sst5 and D2-targeting agents in patients 
with CD and highlight the rationale behind sst5-D2 combination therapy.
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introDuCtion:
Cushing’s disease (CD) is a severe endocrine disorder, caused by an ACTH-producing 
pituitary adenoma. Patients suffer from the effects of chronic hypercortisolism, which 
can lead to hypertension, diabetes mellitus, osteoporosis and psychiatric disturbances 
among others (1). First line of treatment is transsphenoidal selective adenomectomy, 
but even in experienced hands long-term cure does not exceed 70% (2). In cases of per-
sistent or recurrent CD, re-operation, radiotherapy and/or bilateral adrenalectomy can 
be performed, but these treatment options all have significant disadvantages, includ-
ing the risk of permanent hypopituitarism and the lifelong dependence on hormonal 
replacement therapy. Until now, medical therapies with cortisol-lowering drugs such as 
ketoconazole or metyrapone, have not been shown to be both effective and safe for the 
long-term treatment of CD (3). 
In recent years, however, some interesting new advances have been made in the field 
of receptor physiology in CD. It was found that the dopamine receptor subtype 2 (D2) 
is expressed in approximately 80% of human corticotroph adenomas and that these 
adenomas can be responsive to the ACTH-inhibiting actions of D2-agonists in vitro (4). 
Moreover, treatment for three months with the D2-selective agonist cabergoline induced 
complete normalization of 24 hr urinary free cortisol (UFC) in approximately 40% of CD 
patients (4). This percentage of complete responders appears to be maintained after 
two years of therapy (5). At the same time, different groups demonstrated that most 
human corticotroph adenomas strongly express somatostatin (SS) receptor subtype 5 
(sst5) and that SS-analogues with high-binding affinity for sst5, such as the SS-multiligand 
pasireotide (SOM230), can inhibit ACTH-release and cellular proliferation in vitro (6, 7). 
The cortisol-lowering effects of pasireotide in vivo have recently been demonstrated in 
a phase II clinical trial in patients with CD (8). 
Based on these findings, medical therapy with D2-agonists and/or SS-analogues with 
sst5-affinity appears to be an interesting treatment option in cases of persistent or recur-
rent CD. To our knowledge, no study has investigated the expression of both SS and DA 
receptors within the same set of human corticotroph adenomas. A better understand-
ing of the (co-)expression patterns of these two receptor subtypes could be of clinical 
importance. First of all this could help predict the overall percentage of corticotroph 
adenomas that possess a molecular target for SS and/or DA directed medical therapy. 
At present it is not known whether the D2–positive and sst5-positive adenomas in the 
previously mentioned studies largely overlap or whether they constitute separate 
groups that require different therapies. Secondly, since Rocheville et al. (9) published 
their report on heterodimerization of SS and DA receptors and resulting synergism in 
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effect, combined treatment with DA agonists and SS analogues has been an important 
research topic in pituitary adenomas. It has also led to the pharmaceutical development 
of “dopastatin” chimeras: chemically engineered compounds that possess high binding 
affinity for both SS and DA receptor subtypes and which may display superagonistic 
properties compared with traditional SS analogues and DA agonists (10). 
For that reason, our main study aim was to characterize the co-expression of dopamine 
and somatostatin receptor subtypes in a large series of human corticotroph adenomas 
to gain a better understanding of the distribution of the primary molecular targets 
for DA/SS based medical therapy in CD. In addition, we aimed to correlate the DA/SS 
receptor expression patterns in these adenomas with the main biochemical and clinical 
parameters of HPA-axis over-activation in the corresponding CD patients. 
mAteriAls AnD metHoDs
Corticotroph adenoma tissue
Human corticotroph adenoma tissue was available from patients with CD who under-
went transsphenoidal selective adenomectomy in the period between 1991 and 2007 
in one of the two participating academic centers. Informed consent was obtained from 
all patients of whom we assessed receptor expression for investigational purposes. The 
diagnosis of CD was based on clinical signs, elevated 24 hr UFC excretion, incomplete 
suppression of serum cortisol by 1-mg dexamethasone and/or the absence of a diurnal 
cortisol rhythm. In all patients imaging (MRI with iv contrast) or inferior sinus petrosus 
sampling confirmed the pituitary source of ACTH overproduction. Normal anterior 
pituitary tissue was obtained at autopsy from two patients who had died from non-
endocrine diseases. 
Purity of corticotroph tissue
At the study start, the corticotroph adenoma specimens were transferred into Tissue 
Tek Compound (Sakura Finetek, Torrance, CA) at –80˚C for further handling. From these 
tissues, cryostat sections were cut at 5 μm. Sections from the center of the adenoma 
were used for an initial immunohistochemistry (IHC) step to check for ACTH expression 
(see below for protocol) and a sequential haematoxylin-and-eosin stain to demonstrate 
the histological presence of adenoma tissue. In samples where both of these criteria 
were sufficiently met, directly adjacent tissue sections were cut at 20μm, from which 
RNA was extracted for further quantitative PCR analysis of dopamine and somatostatin 
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receptor subtype expression (see below for qPCR methods). On average, 5-10 sequential 
sections (of 20μm each) per adenoma were needed to obtain sufficient amounts of RNA. 
Through this approach of sequential sections we aimed to obtain pure corticotroph 
adenoma RNA and limit the potential interference by normal anterior pituitary tissue 
surrounding the adenoma. As a secondary check for purity of corticotroph tissue, we 
assessed GH/POMC mRNA expression ratios in all corticotroph adenoma samples and 
compared these with the GH/POMC ratio in the normal human anterior pituitaries. 
GH/POMC ratios of less than 10% compared with normal pituitaries were regarded as 
pure corticotroph adenoma tissues; GH/POMC ratios of 10% or more were regarded as 
significantly contaminated with normal pituitary tissue and were excluded from further 
analysis in the pure corticotroph adenoma group (11).
Quantitative PCR
Expression analysis was performed by quantitative PCR, according to a previously 
described method (11, 12). The sequences and final concentrations of the hprt and 
sst1-5 primer-probe pairs have been described previously (6, 12). The sequence of the 
sst4 probe contains a single nucleotide polymorphism at one position. The other primer 
and probe sequences are depicted in Table 1. Samples were measured on an ABI Prism 
7900 Sequence Detection System (Perkin Elmer, Foster City, CA) and normalized against 
the expression of the housekeeping gene hprt. PCR efficiencies (E) were calculated for 
every primer-probe set and varied between 1.91 and 2.00 (13). Estimated copy numbers 
table 1 Primer-probe sequences for D2, D2L, D4, GH and POMC 
Primer sequence 5’-3’ efficiency
D2 forw GCCACTCAGATGCTCGCC 1.94
D2 rev ATGTGTGTGATGAAGAAGGGCA
D2 pr FAM-TTGTTCTCGGCGTGTTCATCATCTGC-TAMRA
D2,L forw CCCACCTGAGGGCTCCA 1.95
D2,L rev TGATAACGGTGCAGAGTTTCATG
D2,L pr FAM-TAAAGGGCAACTGTACTCACCCCGAGG-TAMRA
D4 forw TGCACCGCCTCCATCTTC 2.00
D4 rev CCACGAACCTGTCCACGC
D4 pr FAM-ACCTGTGCGCCATC-TAMRA
GH forw GCCCATCGTCTGCACCAG 1.96
GH rev GGGATATAGGCTTCTTCAAACTCCT
GH pr FAM-TGGCCTTTGACACCTAC-TAMRA
POMC forw GAGCAGCCAGTGTCAGGACC 1.92
POMC rev CGGATGCACTCCAGCAGG
POMC pr FAM-CACCACGGAAAGCA-TAMRA
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were calculated using the comparative threshold method with efficiency correction, as 
described previously (14). Expression of the D2 short isoform was calculated as D2 total 
minus D2 long isoform. 
Immunohistochemistry
The expression of ACTH in the corticotroph adenoma tissues was assessed by cutting 
cryostat sections (5μm) and performing immunohistochemistry according to a previ-
ously published method (15). The anti-ACTH primary antibody (Santa Cruz, mouse 
monoclonal) was used at a dilution of 1:100. 
Autoradiography
In a number of cases (n=9), sufficient adenoma tissue was available to perform addi-
tional receptor autoradiography, according to previously published protocols (4, 15). 
Slides were incubated with either the D2 receptor antagonist 
125I-sulpiride or the SS 
(sst1-5) analogue 
11Tyr-SS-14 (both from GE Healthcare, Brussels, Belgium) in the absence 
or presence of unlabeled cabergoline 10-6 M (Pharmacia, Milan, Italy) or somatostatin-14 
10-6 M (Sigma, Zwijndrecht, the Netherlands), respectively. The sections were exposed to 
phosphor imaging screens for 16 days in x-ray cassettes and analyzed using a Cyclone 
phosphor imager (Packard Instruments Co, Groningen, The Netherlands). The level of 
receptor binding was scored as: absent (-); weak or focal positivity (+); strong positivity 
(++). 
Clinical data
Patient charts were retrieved to collect data on various clinical, biochemical and 
radiological parameters, see Table 2. Adenoma size and growth characteristics were 
categorized according to the modified Wilson classification system (16). Baseline mean 
24 hr UFC values were documented at the time of initial diagnosis, before treatment 
with ketoconazole or metyrapone was initiated. For the determination of serum cortisol, 
plasma ACTH, serum prolactin and urinary free cortisol, different assays have been used 
in the two participating centers over the course of the study period (1991-2007). We 
expressed these parameters as a ratio of the upper limit of normal (ULN) of the specific 
assay. 
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table 2 Patient characteristics (n=30)
Parameters Value (% or mean±sd) Range
Clinical characteristics
Female sex (%) 83
Age (yrs) 42.1 14-68
BMI (kg/m2) 28.9 20.5-48.4
SBP (mm Hg) 154 120-240
DBP (mm Hg) 93 75-115
Pre-treatment received1 (%) 86
Duration pre-treatment (months) 3 1-7
Macroadenoma ≥10 mm (%) 50
Adenoma grade (modified Wilson):2
 - Grade 1 43 
 - Grade 2 33
 - Grade 3 7
 - Grade 4 17
Pre-operative3
UFC 24 hr (xULN): 4.6 ± 4.1 0.60-18.7
Cortisol serum (xULN):
 - mean diurnal4 1.04 ± 0.44 0.50-2.07
 - evening/morning 0.97 ± 0.34 0.57-2.10
 - 8 a.m. 1.15 ± 0.46 0.43-1.90
 - after DEX 1 mg5 0.99 ± 0.74 0.09-2.63
 - after CRH 100 μg.5 1.65 ± 0.77 0.68-3.80
 - after DEX 7 mg5 0.51 ± 0.48 0.05-1.75
ACTH plasma (xULN):
 - mean diurnal4 1.87 ± 2.06 0.33-9.13
 - 8 a.m. 1.31 ± 1.00 0.40-3.41
 - after CRH 100 μg5 2.11 ± 1.51 0.76-6.07
IGF-1 (nmol/l) 23.9 ± 10.5 5-46
PRL (xULN) 0.90 ± 1.27 0.18-5.77
Fasting blood glucose (mmol/l) 5.8 ± 2.3 3.7-14.4
Post-operative
% Remission 72
Cortisol serum 8 a.m. (xULN) 0.46 ± 0.39 0.02-1.32 
Fasting blood glucose (mmol/l) 5.3 ± 1.2 3.6-8.0
Serum PRL (xULN) 0.55 ± 1.11 0.00-5.97
Follow-up (months) 55.2 0-150
Hydrocortisone dependence (months) 14.6 0-62
1 Pre-operative treatment consisted of either ketoconazole or metyrapone monotherapy.
2 Modified Wilson classification: Grade 1 (noninvasive microadenoma), Grade 2 (noninvasive 
macroadenoma), Grade 3 (invasive microadenoma), Grade 4 (invasive macroadenoma)
3 Laboratory parameters are expressed relative to the upper limit of normal (ULN) of the individual assay 
(1.0 = value at the level of ULN), except for fasting blood glucose (ref 3.5-5.6 mmol/l) and IGF-1 (reference 
values age- and gender-specific). 
4 Mean diurnal serum cortisol and ACTH were calculated as the average of the 8 a.m, 5 p.m. and 10 p.m. 
values. 5 The resulting maximal (after CRH 100 μg iv) and minimal serum cortisol levels (after DEX 1 mg p.o. 
or 7 mg iv) are reported relative to the standard ULN of serum cortisol.
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Statistical analysis
SPSS for Windows 16.0 (SPSS Inc., Chicago, IL) was used for statistical analyses. Receptor 
expression levels are expressed as mean ± sd (or as median + range). Univariate analysis 
was performed between individual receptor expression levels and clinical parameters to 
calculate Spearman’s correlation coefficients, since the data were not normally distrib-
uted. For categorical variables the Chi-Square test was performed. 
results
Purity of corticotroph tissue and patient inclusion
Frozen corticotroph adenoma tissue was available from 48 different CD patients. Six of 
these 48 tissues did not display adequate ACTH+ staining on IHC or had an insufficient 
yield of mRNA and were therefore discarded. Twelve of the remaining 42 tissues had a 
GH/POMC mRNA expression ratio of >10% of the level found in normal human anterior 
pituitary (mean ± sd of GH/POMC mRNA copy number ratio in normal anterior pituitary: 
410 ± 17). We regarded these 12 tissues as corticotroph adenomas with a significant 
degree of contamination with normal surrounding anterior pituitary tissue and these 
were also excluded. Therefore, a final group of 30 pure corticotroph adenomas remained 
for further analysis in this study.
The clinical characteristics of the 30 CD patients from whom we received pure corti-
cotroph adenoma tissue, are depicted in Table 2. Mean age was 42 yrs (range 14-68) and 
83% were female. The majority of patients (86%) had received pre-operative treatment 
with cortisol-lowering drugs (ketoconazole or metyrapone) for an average duration of 
3 months. In our study population, 43% of cases were non-invasive microadenomas 
(Grade 1), whereas the remainder of the cases (57%) were adenomas with a Wilson clas-
sification Grade 2 or higher. Overall remission rate was 72% in this series with a mean 
follow-up of 55.2 months. 
Mean sst and DA expression levels
The mean mRNA expression levels of sst and DA receptor subtypes in the corticotroph 
adenomas are shown in Figure 1A and 1B. Among the different SS receptor subtypes, 
sst5 was most predominantly expressed with a mean of 0.136 ± 0.028 copy numbers 
relative to hprt (median 0.107), while sst2 was expressed at lower levels with a mean of 
0.043 ± 0.012 (median: 0.020). Sst1 (mean 0.024 ± 0.009; median 0.004), sst3 (mean 0.004 
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± 0.002; median 0.000) and sst4 expression (mean: 0.021 ± 0.007; median: 0.009) was very 
low (Fig 1A). 
With respect to DA (D2-like) receptors, total D2 expression was high with a mean of 1.30 
± 0.37 copy numbers relative to hprt (median: 0.22). The majority (78%) of D2 expression 
was of the D2 long subtype (mean 1.01 ± 0.27). The D4 subtype was not detectable in this 
series of corticotroph adenomas (Fig 1B). 
Co-expression of sst2, sst5 and D2 
The mRNA expression data of sst2, sst5 and D2 in the individual corticotroph adenomas 
C1-C30 is depicted in Figure 2. In 60% of cases (18/30) co-expression of sst5 and D2 mRNA 
was observed, with the use of 0.04 (sst/hprt) and 0.07 (D2/hprt) as a threshold value 
for significance (see below at autoradiography for the calculation of these threshold 
values). In 23% of cases (7/30) significant D2 expression was found, but not of sst5. In the 
remaining 17% of cases (5/30), no significant expression of either sst5 or D2 was found. 
Sst2 expression was generally much lower than that of sst5 or D2, but was present at 
significant levels in 30% (9/30) of adenomas. 
Adenoma grade and sst/D2 expression
In Figure 3 the mean sst and D2 mRNA expression levels are depicted, classified by 
adenoma grade (Wilson classification). This figure shows that in grade 1 noninvasive 
microadenomas (n=13), mean (±SEM) expression levels were relatively high: 1.83 ± 
0.55 (D2), 0.22 ± 0.05 (sst5) and 0.07 ± 0.02 (sst2). In grade 2 adenomas (n=10), which 
are noninvasive macroadenomas, similar expression levels were found, albeit somewhat 
lower: 1.49 ± 0.80 (D2), 0.12 ± 0.04 (sst5) and 0.02 ± 0.01 (sst2). However, in grade 3 (n=2) 
and grade 4 (n=5) adenomas, which exhibit invasive growth into surrounding structures, 
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Figure 1: Mean expression levels of somatostatin (fig 1A) and dopamine (Fig 1B) receptor subtypes in 
30 human corticotroph adenomas. Values represent the mean ± SEM per receptor subtype, assayed in 
duplicate. Expression levels are normalized against the housekeeping gene hprt. D2L and D2S are the long 
and short isoforms of the D2 receptor, respectively. N.d. = not detectable
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sst5 and D2 receptor expression was extremely low: 0.02 ± 0.02 (D2), 0.00 ± 0.00 (sst5) and 
0.01 ± 0.01 (sst2) for grade 3, and 0.06 ± 0.03 (D2), 0.00 ± 0.00 (sst5) and 0.03 ± 0.01 (sst2) 
for grade 4 adenomas.
Autoradiography
In 9 cases we had sufficient tissue to perform additional autoradiography. In the major-
ity of these tissues (7/9), there was a good correlation between the levels of sst and 
D2 mRNA expression and the degree of 
11Tyr-SS-14 (sst1-5 agonist) and 
125I-sulpiride (D2-
antagonist) binding at autoradiography, see Figure 4A. Receptor binding levels were 
scored as absent (-), weakly/focally positive (+) or strongly positive (++). The average 
mRNA expression levels per category of receptor binding were: 0.01 (-), 0.04 (+) and 
0.13 (++) for sst/hprt and 0.01 (-), 0.07 (+) and 3.07 (++) for D2/hprt. The resulting cut-off 
point between no binding (-) and demonstrable protein binding (+ or ++) was used 
to assess significance of mRNA expression (≥0.04 for sst/hprt, ≥0.07 for D2/hprt), as 
described earlier for the mRNA co-expression data. Two exemplary cases (C13 and C28) 
of autoradiography are shown in Figure 4B. C13 only had demonstrable D2 expression 
Fig 3
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Figure 3: Mean sst2, sst5 and D2 mRNA expression per adenoma grade. The modified Wilson classification 
was used. Grade 1: noninvasive microadenoma; Grade 2: noninvasive macroadenoma; Grade 3: invasive 
microadenoma; Grade 4: invasive macroadenoma. Expression levels are normalized against the 
housekeeping gene hprt. Values represent the mean expression levels ± SEM per receptor subtype per 
adenoma grade.
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at the mRNA level, which correlated with the observation that only 125I-sulpiride showed 
specific binding at autoradiography. Case C28 expressed significant levels of both sst5 
Fig 4A
Case 11Tyr-SS-14 125I-sulpiride
C1 ++ +
C2 - -
C9 + +
C11 - -
C13 - ++
C16 + +
C28 ++ ++
C29 ++-
C30 + +
 
Fig 4B
11Tyr-SS-14 11Tyr-SS-14125I-sulpiride 125I-sulpiride
H&E
Total binding
Non-specific
binding
Case C13 Case C28
Figure 4: Autoradiography on corticotroph adenomas for D2 (
125I-sulpiride) and SS-14 (11Tyr-SS-14) 
receptor binding. Fig 4A: Overview of autoradiography results in the 9 available cases. Receptor binding 
was classified as: absent (-); weak or focal positivity (+); strong positivity (++). Fig 4B: Two exemplary cases 
(C13 and C28): Case C13 shows high specific (i.e. total – aspecific) binding for D2, but not for SS-14. Case 
C28 shows specific binding for both D2 and SS-14.
Fig. 4A
Fig. 4B
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and D2 mRNA, which was in line with the specific binding of both 
11Tyr-SS-14 and 125I-
sulpiride. 
Correlation analyses 
First, we performed univariate correlation analyses between the expression levels of the 
individual receptors (sst2, sst5 and D2). This revealed a positive correlation between the 
expression of all three receptor subtypes; the correlation was especially high for sst5 and 
D2. Spearman (non-parametric) correlation coefficients were: r = 0.384 (p=0.036) for sst2 
and sst5; r = 0.377 (p=0.040) for sst2 and D2; r = 0.675 (p<0.001) for sst5 and D2. 
Subsequently, we analyzed the correlation between the expression levels of the indi-
vidual receptors and the principal biochemical parameters of hypercortisolism (i.e. 24 
hr UFC, mean diurnal serum cortisol and cortisol diurnal rhythm) and responses to the 
CRH-test and low-and high-dose dexamethasone suppression tests. None of these vari-
ables were significantly associated with the expression of any of the receptor subtypes. 
Moreover, after categorizing these nominal variables into tertiles to limit the effect of 
data heterogeneity, no significant associations could be identified. 
DisCussion
This study investigated the (co-)expression of somatostatin and dopamine receptor 
subtypes in a series of 30 pure human corticotroph adenomas. We found that D2 and 
sst5 receptors are expressed in the majority of these adenomas and that co-expression 
of these receptor subtypes is a common phenomenon. Our data indicate that approxi-
mately 80% of corticotroph adenomas obtained from CD patients express one or more 
of these molecular targets, which could make them suitable candidates for D2 and/or 
sst5-targeted medical therapy. 
In this series, we find that approximately 60% of CD patients have adenomas that sig-
nificantly express sst5 receptors. In a recent study, monotherapy with pasireotide (high 
sst5 affinity) decreased urinary free cortisol (UFC) levels in 76% (22/29) of patients after 
15 days of treatment (8). Complete normalization of UFC occurred in only 17% (5/29) of 
these patients (8). It needs to be emphasized, however, that this was a short trial and that 
the maximal cortisol lowering effects of pasireotide may require a longer duration of 
treatment in some patients. From this perspective, the percentage of complete respond-
ers found in this trial may still be an underestimation of the total number of responders 
with prolonged sst5-directed therapy. On the other hand, different mechanisms of tac-
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hyphylaxis have been described with the use of SS-analogues in the treatment of some, 
but not all neuro-endocrine tumours (17). Future studies will have to show whether this 
process of tachyphylaxis could affect the long-term efficacy of pasireotide therapy in hu-
man CD. An important safety concern with the use of this drug in CD is the deterioration 
of glucose tolerance, which is observed in approximately one third of patients (8). 
The vast majority of adenomas, more than 80% of cases, clearly expressed D2 recep-
tors, which is similar to what has been found previously in another study by different 
analytical methods (4). These percentages are comparable, albeit somewhat higher than 
the percentage of initial responders (both complete and partial) observed in vivo with 
cabergoline monotherapy, which varies between 51 and 75% (4, 5, 18). In these studies, 
patients were treated considerably longer (3-6 months) than in the abovementioned 
15-day pasireotide trial before response was assessed. Importantly, two of these studies 
also demonstrated that some patients on cabergoline monotherapy show a relapse after 
having been in full remission, which reduces long-term remission rates to 27-40% after 
approximately two years of treatment (5, 18). The mechanisms that cause these escapes 
from cabergoline monotherapy are not known. Receptor down-regulation or various 
post-receptor desensitization mechanisms may be involved in this process. Regardless 
of the cause, these treatment escapes pose a great challenge to physicians managing 
CD patients and limit the efficacy of cabergoline monotherapy as a long-term treatment 
option for human CD. 
The observation that the majority of corticotroph adenomas in our study expressed both 
D2 and sst5 receptors suggests the possibility of combined targeting of these receptor 
subtypes. It has been shown that different sst and DA receptor subtypes can heterodi-
merize at the plasma membrane when they are activated simultaneously, leading to 
enhanced cAMP inhibition and functional synergism (9, 19). Moreover, co-activation of 
sst and DA receptor subtypes by chimeric dopastatin molecules may further enhance 
inhibition of hormone release by pituitary adenomas in vitro (20, 21). These studies all 
suggest potentially beneficial effects of combined sst5 and D2 targeting therapy, but 
clinical studies are needed to show whether this concept also translates into increased 
normalization rates in patients with CD. 
An important issue from a clinical perspective is that we found a very low level of expres-
sion of sst5 and D2 in the corticotroph adenomas with invasive growth (Wilson grade III 
and IV). Whether this is due to loss of receptor expression in the course of dedifferentia-
tion of these adenomas or whether low expression levels are causally related to extensive 
corticotroph adenoma growth, remains to be elucidated. Nonetheless, this finding could 
have clinical consequences, as not all subgroups of CD patients have the same likelihood 
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of receiving medical therapy at some point. It is well known that neurosurgical cure 
rates in patients with large corticotroph macroadenomas or those with invasive growth 
into structures surrounding the pituitary fossa, are decreased due to incomplete tumor 
removal (22). Therefore, these patients often require effective secondary therapies to 
achieve biochemical remission. Unfortunately, in the light of our findings, sst5 and/or 
D2-targeting agents are unlikely to be effective in this subgroup of patients. 
 
It needs to be emphasized, however, that the group of corticotroph adenomas in-
cluded in the present study can not be regarded as a representative sample for the total 
group of corticotroph adenomas as they would occur in clinical practice. Due to the 
problem of limited tissue availability in the case of corticotroph microadenomas, our 
data set contains a relatively large number of macroadenomas for which adenomatous 
tissue was more readily available. Moreover, a significant number of microadenomas 
that were initially included in this study, turned out to be a mixture of adenoma and 
surrounding normal pituitary tissue, as expressed by a GH/POMC ratio similar to that in 
normal anterior pituitaries and had to be excluded from further analysis. For that reason, 
our data set contains an overrepresentation of corticotroph adenomas in the higher 
Wilson classification grades (≥2). In clinical practice, it is estimated that macroadenomas 
and/or invasive corticotroph adenomas represent less than 10-20% of the total num-
ber of CD cases, whereas in our study 57% of cases belonged to this category (23, 24). 
Consequently, the true percentage of CD patients with grade 3 or 4 invasive adenomas 
and overall low sst/D2 expression levels, will certainly be lower than the 23% identified 
in this study. In addition, it is important to note that microadenomas and noninvasive 
macroadenomas (grade 1 and 2 adenomas, respectively), which represent the vast 
majority of corticotroph adenomas, were found to have a very similar sst and DA recep-
tor expression pattern. Therefore, our main findings in this study could be regarded as 
representative for both grade 1 and grade 2 corticotroph adenomas alike. 
Previous in vitro studies have shown that glucocorticoids may directly down-regulate 
sst2 expression in human and murine neuro-endocrine cell lines, whereas sst5 is sig-
nificantly less sensitive and D2 is fully resistant to this type of glucocorticoid-induced 
down-regulation (25, 26). In this study we did not find a correlation between sst2, sst5 or 
D2 expression levels and the height of the main biochemical parameters of hypercorti-
solism at the time of initial diagnosis, including 24-hour UFC and mean diurnal serum 
cortisol. The interpretation of the absence of these correlations is difficult, however, as 
most patients in our study were treated pre-operatively with cortisol-lowering drugs. 
Therefore, we do not know the exact effects of therapy-induced reductions in cortisol 
levels on the documented receptor expression levels in the adenomas. One can only 
hypothesize on the basis of the previous in vitro studies that reductions in cortisol are 
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likely to have resulted in a relative increase in sst2 expression, rather than to have af-
fected sst5 or D2 expression levels in these adenomas. 
In conclusion, we demonstrate that the vast majority of human corticotroph adenomas 
express significant numbers of sst5 and/or D2 receptors, with co-expression of these 
receptor subtypes being a common phenomenon. These findings support the ongoing 
clinical studies with agents that target these receptor subtypes in patients with CD. Our 
results also suggest that combination therapy with both sst5 and D2 targeting agents 
could be a feasible next step, as this may increase the total number of CD patients that 
can be biochemically controlled by the use of these agents. 
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introDuCtion
Recent studies show that complete normalization of urinary free cortisol levels occurs 
in approximately 40% of CD patients after 3-24 months of cabergoline monotherapy 
and in 17% of CD patients after 15 days of high-dose (2x600μg) pasireotide (SOM230) 
therapy (1-4). Whether or not the responders in these separate studies show a high 
degree of overlap or whether they constitute two different groups is not known. Either 
way, medical combination therapy with dopamine (DA) agonists and novel somatostatin 
(SS) analogues with high sst5 affinity appears to be a feasible approach (5). In theory, 
SS-DA combination therapy could increase the total number of (complete) respond-
ers to this type of medical therapy. Hypothetically, it could also help in maintaining 
long-term remission rates by reducing the risk of tachyphylaxis, which can be observed 
under cabergoline monotherapy in human CD (2, 4). Moreover, in vitro studies using 
corticotroph tumour cells have shown that ketoconazole, which is used in many centers 
as monotherapy during the pre-operative phase to decrease cortisol levels, may display 
functional synergism with pasireotide in lowering ACTH secretion (Feelders et al., per-
sonal communication). Whether this also occurs in vivo has not been investigated until 
now. 
For the above reasons, we are currently conducting a phase II open-label multi-center 
clinical trial to assess the efficacy and safety of a novel stepwise medical treatment ap-
proach with the use of the multiligand somatostatin analogue pasireotide (SOM230) 
with high sst5 affinity in either a low-dose (3x100μg) or a higher dose (3x250μg), the 
dopamine D2 agonist cabergoline and low-dose ketoconazole in patients with de novo 
or recurrent CD. The primary aim of this ongoing trial is to identify which percentage of 
CD patients can be biochemically normalized within a period of three months by the use 
of this treatment regimen. In this chapter we briefly describe four different patients that 
were included in this trial, who differ clearly in terms of disease presentation, adenoma 
characteristics and ultimate treatment outcome. The responses in these patients are 
discussed here to illustrate patient heterogeneity and as an extension of our in vitro 
findings in CD that were described in previous chapters. The complete details of this 
study and its results will be presented elsewhere. 
CAse rePorts
Patient 1 
Patient 1 is a 42-year-old female with de novo CD due to a pituitary microadenoma (9 
mm). Main complaints consisted of severe obesity (135 kg, BMI 44.5 kg/m2), uncon-
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trolled hypertension and recently diagnosed type II diabetes mellitus. Urinary Free Cor-
tisol (UFC) excretion was 5.1 fold the upper limit of normal (ULN) (figure 1). Pasireotide 
monotherapy did not significantly decrease UFC levels after 28 days of treatment (-6%). 
However, when the D2 agonist cabergoline was added, her UFC values decreased sharply 
(-69%) to 1.6 fold the ULN at Day 56 of treatment. Finally, when low-dose ketoconazole 
(3 x 200μg) was added, UFC values normalized at Day 77. Over the study period, she 
reported a 5 kg weight loss, a spontaneous return of menses and diminished heat 
intolerance. In addition, her blood pressure had completely normalized and exercise 
capacity had increased. In this patient, however, we did observe an overt worsening of 
glucose tolerance, which required additional medical therapy. 
Patient 2
Patient 2 is a 67 year-old male with persistent CD after unsuccessful transsphenoidal 
adenomectomy one year prior to inclusion in this study. During that surgery, the 7 mm 
pituitary microadenoma had shown signs of invasive growth in the underlying sella; in 
fact, pathological examination of the biopsies from the surrounding sellar bone, showed 
intra-osseal (parasellar) remnant adenoma cells. Therefore, this adenoma was classified 
as Wilson Grade 3 (invasive microadenoma). At the study start, this patient complained 
of a mild centripetal weight gain (+5 kg), muscle weakness, easy bruising and fatigue. 
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Figure 1: Urinary Free Cortisol excretion levels (in nmol/24 hr) in patients 1-4 enrolled in this study. 
Patients started at baseline (Day 0) with pasireotide monotherapy (Pas or P). If UFC was not normalized at 
Day 28, cabergoline (CAB or C) was added. If at Day 56 UFC was not normalized, low-dose ketoconazole 
(keto or K) was added until the study end at Day 77. ULN = Upper limit of normal for UFC assay. LLN = 
Lower limit of normal for UFC assay.
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At baseline, he was already receiving treatment for hypertension, osteoporosis and hy-
percholesterolemia. On pasireotide low and high-dose monotherapy, his UFC excretion 
did not decrease, but rather increased over time (figure 1). Also after the addition of 
cabergoline, UFC levels continued to rise. Only when low-dose ketoconazole was added, 
UFC excretion decreased slightly, but did not normalize. At the study end, the patient 
did not report any symptomatic improvements; neither did his blood pressure or labora-
tory values ameliorate. 
Patient 3
Patient 3 is a 65-year old woman with de novo CD due to an invisible pituitary microad-
enoma, which was suggested by inferior sinus petrosus sampling (IPSS). Biochemical 
parameters of hypercortisolism were mildly elevated, but over the years had gradually 
resulted in increased abdominal size, 20 kg weight gain and progressive fatigue. On low-
dose pasireotide monotherapy her UFC levels decreased slightly but did not normalize. 
On high-dose pasireotide therapy, however, UFC levels completely normalized and 
remained below the ULN throughout the entire study period (figure 1). She lost 3 kg in 
weight and reported some minor symptom improvements. 
Patient 4
Patient 4 is a 43-year old woman with progressive symptoms of central obesity, easy 
bruising, hirsutism and amenorrhea. Her de novo CD was due to an invisible pituitary 
adenoma, which was proven by IPSS. Low- and high dose pasireotide monotherapy 
decreased her 24 hr UFC excretion slightly, but not sufficient (figure 1). After addition 
of cabergoline, however, UFC values completely normalized and remained in the mid-
normal range until the end of the study period. She reported a marked improvement 
of her emotional state and exercise capacity, a spontaneous return of menses and a 
decrease in symptoms of hirsutism.
DisCussion
We here describe four patients that were included in an ongoing phase II, open-label 
multi-center clinical study that investigates the feasibility of a stepwise medical treat-
ment regimen that combines the SS-analogue pasireotide with high sst5 affinity, the D2 
agonist cabergoline and/or low-dose ketoconazole in patients with de novo or recurrent 
CD. As this is an ongoing clinical trial, final results of this study will be presented in detail 
elsewhere. However, these four patients are illustrative for the wide spectrum of treat-
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ment responses, which can be observed with SS and/or DA-targeted medical therapy 
for this deleterious endocrine disease. Responses varied from partial or complete re-
sponsiveness to SS-analogue monotherapy or combined SS/DA analogue treatment, to 
a total lack of response to these analogues or their combination.
The reasons behind this large variability in treatment responses are multiple, but 
the most important factor appears to be tumor heterogeneity. As already described in 
chapter 4 of this thesis and also in previous publications, significant differences exist in 
somatostatin and dopamine receptor subtype expression levels in series of human cor-
ticotroph adenomas (1, 6, 7). Preferably, one would be able to correlate clinical outcome 
data with the corresponding in vitro data of adenomas of individual patients. In two out 
of four of the patients that we have described above, we were able to do so (patients 1 
and 2). 
Patient 1 had newly diagnosed CD when she entered the study and underwent trans-
sphenoidal surgery approximately five months after completion of the study. In the time 
period between the study end and transsphenoidal surgery, she opted to continue the 
study drug regimen (extension study), which kept the UFC levels well within the normal 
range and further ameliorated her symptoms and signs of CD. When she underwent 
transsphenoidal surgery, we freshly isolated a part of the operative specimen and 
performed quantitative PCR for sst and DA receptor expression. The results are shown 
in figure 2. It shows she has clearly demonstrable sst2, sst5 and D2 receptor expression, 
which is partially in line with her clinical response observed in the trial. The data are 
supportive of a D2 mediated cabergoline effect, but do no fully explain why she did 
not respond better to sst-targeted monotherapy (pasireotide) in the first 28 days of the 
study. 
Two issues need to be addressed in this respect. First of all, receptor status was assessed 
after 8 months of successful, glucocorticoid-lowering therapy in this patient. As has been 
described by many different studies and also in chapter 3 of this thesis, glucocorticoids 
can directly influence expression levels of sst in human neuro-endocrine cells, while for 
D2 such an effect can not be demonstrated to the same extent or may even be absent 
(8-12). Especially sst2 expression is sensitive for glucocorticoid-induced down-regulation 
and may be restored after correction of the hypercortisolism. Therefore, it is likely that 
the long-term normocortisolemia induced in this patient by the study drug regimen 
will have positively affected tumoral sst2 expression levels in this patient. Therefore, 
measured sst2 levels as shown in figure 1, may be an overestimation of tumoral sst2 levels 
when the patient first entered the study. This may explain the absence of a therapeutic 
effect after 28 days of treatment by SS-multiligand pasireotide in this patient, even 
though sst2 levels were well demonstrable after 8 months of therapy.
Another aspect could be the onset of rapid tachyphylaxis after the start of pasireotide 
monotherapy in patients with adenomas that are susceptible for such a phenomenon. 
Early clinical experiences with sst/DA therapy 103
Ch
ap
te
r 5
If adenomas display high levels of sst2 in the absence of sufficient levels of sst5, desen-
sitization to SS-analogues may occur. The in vitro susceptibility of sst2 receptors for 
internalization and subsequent desensitization has recently been demonstrated by Liu 
and Cescato et al., while this was not demonstrable for sst5 (13, 14). In fact, co-expression 
of sst5 is believed to prevent sst2 from rapid internalization and desensitization upon 
agonist exposure (15). When observed more in detail, our data show that in this patient 
after 10 days of low-dose pasireotide treatment, UFC levels dropped from 5.1 x ULN to 
3.0 x ULN (-42%), but then rose steadily again to 4.8 x ULN (-6%, compared to baseline) 
on high-dose pasireotide therapy. This suggests a rapid desensitization mechanism 
upon SS-analogue therapy in this specific patient and may be associated with its high 
tumoral sst2 expression levels. Whether this is a pattern of response that occurs more 
frequently in patients with CD, will have to be shown by final analyses on the total group 
of CD patients that participated in this study.
The other patient, for whom we had access to the surgically resected corticotroph 
adenoma tissue, was patient number 2. This patient had persistent CD after one, non-
curative transsphenoidal surgery approximately 6 months before study entrance. As de-
scribed before, UFC levels did not decrease in this patient with either pasireotide and/or 
cabergoline therapy. After the study end, when we retrospectively analyzed the archived 
adenoma tissue obtained during the first transsphenoidal surgery, it showed very low D2 
and sst2 expression and total absence of sst5 expression, which readily explains the com-
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Figure 2: Sst2, sst5 and D2 mRNA receptor expression levels in isolated corticotroph adenoma cells from 
patients 1 and 2, obtained at transsphenoidal adenomectomy. Values depict the mean (±SEM) of two 
measurements, assayed in duplicate. Expression levels are normalized against the housekeeping gene 
hprt.
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plete lack of response in this patient to either SS-analogue and/or DA-agonist therapy. 
This specific expression pattern is unusual for corticotroph adenomas in general, but 
may be observed more frequently in advanced corticotroph adenoma stages (stages III 
and IV, see chapter 4 of this thesis (16)). In fact, the adenoma of this patient had been 
classified as a stage III adenoma, due to its invasive growth in the underlying sella and 
the presence of intra-osseal adenoma cells in the parasellar bones. 
In summary, we have here described four patients in an ongoing clinical trial, which 
exhibit different responses to SS-analogue and/or dopamine agonist therapy, which 
could be correlated at least partially to their adenoma sst and D2 receptor status. Defini-
tive results of this ongoing study, including correlation between treatment responses 
and in vitro receptor expression data, will be presented elsewhere.
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Somatostatin receptor expression 
in a patient with Cushing’s 
syndrome due to ectopic 
adrenocorticotropin secretion after 
successful mifepristone therapy
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ABstrACt
Context: A 40-year old female patient presented in our clinic with Cushing’s syndrome 
due to ectopic ACTH secretion of unknown primary origin. Cortisol levels decreased 
upon high-dose dexamethasone suppression testing, indicating intact tumor glucocor-
ticoid responsiveness, while 111In-pentreotide scintigraphy (OctreoScan) was negative. 
The patient was treated with the glucocorticoid receptor antagonist mifepristone, 
which dramatically improved her clinical symptoms. A repeat OctreoScan after 6 months 
mifepristone therapy showed the unequivocal presence of a bronchial carcinoid. 
objective: To combine in vivo and in vitro findings in a patient with ectopic ACTH-
producing syndrome, in whom glucocorticoid suppression was still partially intact.
methods: We obtained the fresh carcinoid tissue at surgery and investigated the ex-
pression of somatostatin and dopamine receptor subtypes in vitro by quantitative PCR, 
immunohistochemistry (IHC) and in vitro culturing of tumor cells.
in vitro results: The tumor was strongly positive for sst2 and D2 both at quantitative 
PCR and at IHC. Octreotide (sst2 preferring analogue) and cabergoline (D2-agonist) both 
decreased ACTH levels in the cultured tumor cells.
Conclusion: We describe a patient with an ACTH-producing bronchial carcinoid, in 
whom a direct down-regulatory effect of glucocorticoid levels on tumoral sst2 receptor 
expression is suggested by a remarkable change in OctreoScan status after successful 
mifepristone therapy. Further studies will have to demonstrate whether glucocorticoid 
lowering or antagonizing therapy indeed improves the diagnostic yield of somatostatin 
receptor scintigraphy in patients with ectopic ACTH production of unknown primary 
origin in whom tumor glucocorticoid responsiveness is still (partially) intact. 
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introDuCtion
Ectopic adrenocorticotropin (ACTH) secretion (EAS) by a non-pituitary tumor is a rare 
cause of ACTH-dependent Cushing’s syndrome (1). It is most frequently caused by either 
a bronchial carcinoid or a small-cell lung carcinoma, which accounts for approximately 
50% of all cases, but also thymic carcinoids, gastro-entero-pancreatic neuro-endocrine 
tumors and medullary thyroid carcinoma are well-known causes of this syndrome (2, 3). 
The overall prognosis of the patient is largely determined by the nature of the underly-
ing malignancy and the tumor stage at the time of diagnosis (1). 
Primary therapy consists of surgical removal of the tumor, but in some EAS cases the pri-
mary tumor can not be identified by routine imaging procedures, including ultrasound, 
CT and MRI. The fact that a significant proportion of these tumors express somatostatin 
receptors (sst) allows the use of sst-scintigraphy with 111In-pentreotide (OctreoScan) in 
the diagnostic work-up of these patients. The expression of sst is not only useful from a 
diagnostic perspective, it can also be used for therapeutic purposes because a signifi-
cant number of EAS patients respond to traditional somatostatin (SS) analogues such 
as octreotide (1, 3-6). Apart from sst, dopamine receptors have also been proposed as 
potential targets in the medical treatment of these tumors (7).
However, a substantial number of tumors with EAS can not be detected with Octreo-
Scan, although the exact percentage remains difficult to establish (6, 8-11). In addition, 
an important subset of EAS patients does not show any clinical or biochemical response 
to traditional SS-analogues that mainly target somatostatin receptor subtype 2 (sst2) (1, 
3). The reason for this large variability in functional sst2 expression is not clear, but could 
be due to differences in glucocorticoid (GC) sensitivity of these tumors. It is well known 
that EAS tumors can differ strongly in their GC-responsiveness, which is reflected by 
the wide range of results obtained after high dose dexamethasone suppression testing 
in patients with EAS (12). At the same time, it also known that GCs can directly down-
regulate sst expression in human neuro-endocrine tumor cells and more specifically sst2 
(13-15). Therefore, in the subset of EAS patients, in whom regulatory feedback by GC is 
still partially intact, cortisol-lowering or antagonizing therapy could directly influence 
tumoral sst2 expression levels. If this occurs, one would expect to find evidence for such 
a mechanism both in vivo (serial OctreoScan imaging), as well as in vitro (analysis of 
the surgically resected tumor). We here present a case, for which we combined both 
investigations. 
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CliniCAl CAse
A female 40-year old patient was referred to us by her physician with a clinical suspicion 
of Cushing’s syndrome. She complained of severe fatigue, which was progressive over 
the past few months, combined with easy bruising, muscle weakness and some mild alo-
pecia. She had also noticed a weight gain of approximately 8 kg in the past months. She 
did not use any medication except for oral contraceptives. Previous medical history was 
unremarkable except for an extra-uterine pregnancy 15 years ago and a more recent epi-
sode of trigeminal neuralgia. At physical examination she had a Cushing-like appearance 
with marked facial and central obesity, combined with proximal muscle atrophy. Routine 
laboratory parameters were all within the normal range including serum potassium lev-
els. Endocrinological laboratory evaluation revealed mildly elevated serum cortisol levels 
without any diurnal rhythm, insufficient overnight suppression of serum cortisol after 
administration of 1-mg oral dexamethasone and elevated 24-h urinary free cortisol (UFC) 
levels, see table 1. Plasma ACTH levels were within the high-normal range. A gadolinium-
enhanced MRI of the pituitary did not reveal abnormalities. Bilateral inferior petrosal 
sinus sampling showed a basal central-to-peripheral ACTH gradient below 2.0 and after 
CRH administration below 3.0, indicating an ectopic cause of the ACTH-secretion. Results 
of an abdominal MRI were normal, but on a chest CT a small round nodule was seen in the 
right upper lung initially reported as an aspecific nodule (Figure 1A). Somatostatin recep-
table 1. Laboratory parameters at time of diagnosis
Value Ref range
Serum cortisol (nmol/l) 
 09.00 hr 792 200-800
 17.00 hr 924
 22.00 hr 979
 24.00 hr 866
Serum ACTH (pmol/l)
 09.00 hr 7.4 <11
 17.00 hr 11.0
 22.00 hr 9.9
 24.00 hr 9.9
1 mg dex. suppressiontest
cortisol 09.00 hr (nmol/l) 646 < 50 
high dose dex. suppression test
 (48 h 2mg/day)
 cortisol baseline (nmol/l) 530
 cortisol post-dex (nmol/l) 108 < 50
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tor scintigraphy with 111In-pentreotide (OctreoScan) did not show pathological uptake at 
that time (Figure 1B), nor did additional 18F-DOPA-PET and 11C-5-hydroxytryptamin-PET 
scans. The patient was treated with the glucocorticoid receptor antagonist mifepristone 
(RU-486, obtained from HRA Pharma, Paris, France) at a dose of 400 to 600 mg/day, which 
clearly improved the condition of the patient with 23 kg weight loss and disappearance 
of Cushingoid features. At follow-up, six months after initiating mifepristone treatment, 
a repeat chest CT showed the same nodule in the right upper lung without signs of ana-
tomic growth (Figure 1C). However, at this time a repeat OctreoScan showed a positive 
uptake at the site of this nodule (Figure 1D and 1E). Subsequently, the patient underwent 
resection of the right upper lobe of the lung, which revealed a small tumor of 5 mm in 
diameter. Immediately after resection, the fresh carcinoid tissue was obtained for further 
analysis in vitro (see methods section). Pathological examination showed a neuroendo-
crine tumor with a positive staining for ACTH, synaptophysin and chromogranin A. The 
patient recovered well post-operatively without any major complications. She received 
hydrocortisone replacement therapy, which was gradually tapered. At present, 10 months 
after surgery, she is doing well without any evidence of a recurrence of hypercortisolism. Fig 1
Figure 1: 111In-pentreotide scintigraphy (OctreoScan) and CT imaging results in this patient before (A-B) and 
after 6 months of therapy with mifepristone (C-E). Before therapy was initiated, CT scan (A) shows a small 
round nodule in the right upper lung (white arrow), which is not visible at OctreoScan (B). After 6 months of 
therapy, the CT scan shows the same lesion (white arrow) within the upper lobe of the right lung (C). At that 
time a repeat OctreoScan shows pathological uptake at the site of the lesion (D and E; black arrows).
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in vitro stuDies
Informed consent
These studies were performed according to the rules of the ethics committee of our 
hospital. Informed consent was obtained from the patient. 
Surgical tissue and cell isolation
After resection, the fresh carcinoid tissue was placed in 4˚C Minimal Essential Medium 
(MEM) with Earle’s salts, supplemented with 10% fetal calf serum (FCS), L-glutamine (2 
mmol/l), penicillin (105 U/l) and fungizone (0.25 mg/l). The tissue was dispersed with 
dispase 103 U/l (Roche, Almere, the Netherlands) + collagenase 2 mg/ml (Sigma Aldrich, 
Zwijndrecht, the Netherlands) at 37ºC for 1 h to obtain a single cell population. Viable 
carcinoid cells were counted in a standard haematocytometer. 3 x 105 of the cells were 
used for qPCR analysis. The remainder of the cells were cultured in 48 well plates (Corn-
ing, Cambridge, USA) at a density of 40,000 cells/well for 4-6 days at 37 ˚C in a humidi-
fied incubator in 5% CO2. At that time, culture media were refreshed and incubations 
were started with octreotide (Novartis, Basel, Switzerland), cabergoline (Pfizer, Capelle 
a/d Ijssel, the Netherlands) or their combination for 96 h. At the end of the incubation 
period, media were collected and stored at –20˚C for hormone analysis after addition 
of aprotinin (4 x 105 IU/ml medium; Bayer, Mijdrecht, the Netherlands) to prevent ACTH 
degradation. All experimental conditions were performed in quadruplicates. 
Quantitative PCR
Quantitative PCR for the different SS and DA receptor subtypes was performed accord-
ing to a protocol that has been described previously (13, 16). All samples were assayed 
in duplicate and values were normalized against the expression of the housekeeping 
gene hprt. Dilution curves were constructed to calculate PCR efficiencies (E) for every 
primer-probe set (17). Estimated copy numbers were calculated using the comparative 
threshold method with efficiency correction, as described previously (18). 
Immunohistochemistry
The expression of sst2 and D2 in the carcinoid tissue was assessed by cutting cryostat sec-
tions (5μm) and performing immunohistochemistry according to a previously published 
method (19). The polyclonal anti-sst2 antibody (Gramsch laboratories, Schwabshausen, 
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Germany) was used at a dilution of 1:2000 (overnight) and the monoclonal anti-D2 anti-
body (Santa Cruz Biotechnology Inc, Santa Cruz, CA) was used at a dilution of 1:400.
Statistics
All data were analyzed with GraphPad Prism software (San Diego, CA, USA). Data on hor-
mone release are expressed as mean ± SEM. All experiments were run in quadruplicate. 
Overall differences between treatment groups were determined by ANOVA. In case of 
significant differences found by ANOVA, a multiple comparison between groups was 
performed with a Newman-Keuls test. P-values less than 0.05 were considered statisti-
cally significant.
in vitro results
The somatostatin and dopamine receptor mRNA subtype expression pattern in the 
carcinoid tumor cells is depicted in Figure 2. Sst2 was highly expressed in this tumor 
(0.18 copies/hprt), while sst1, sst3 and sst5 expression was low to very low (0.03, 0.01 and 
0.03 copies/hprt, respectively). D2 mRNA was also highly expressed in this tumor (2.13 
copies/hprt). 
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Figure 2: Somatostatin and dopamine receptor mRNA subtype expression. Values represent the mean ± 
SEM of two duplicate measurements. Expression levels are normalized against the housekeeping gene 
hprt.
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In the cultured tumor cells of this patient, octreotide (OCT, -25%) and cabergoline (CAB, 
-25%) at 10 nM concentration both decreased ACTH release after 96 hr, although these 
inhibitions were not significant at the 0.05 significance level (Figure 3). The combination 
of OCT and CAB was less efficacious (-20%) than either agent alone. 
At immunohistochemistry the tumor tissue was clearly positive for sst2 with a mem-
branous staining pattern, which was not present when the primary sst2 antibody was 
pre-incubated with an immunizing sst2 receptor peptide or with omission of the primary 
sst2 antibody (Figure 4A-D). D2 was also strongly expressed by this tumor (Figure 4E). 
DisCussion
We here describe a patient with Cushing’s syndrome due to an ACTH secreting bronchial 
carcinoid, in whom 111In-pentreotide scintigraphy (OctreoScan) became positive after 6 
months of successful GC antagonizing therapy with mifepristone. During that period, 
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Figure 3: Inhibition of ACTH release by cultured carcinoid tumor cells of this patient after 96 hr. Cells 
were cultured in the absence (control, CT) or presence of octreotide 10-8 M (OCT), cabergoline 10-8 M 
(CAB) or their combination (OCT+CAB) in 10-8 M. At the end of the incubation time, media were collected 
and ACTH levels were determined. All experimental conditions were performed in quadruplicate. Values 
represent percent change ± SEM relative to control (= untreated cells).
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no anatomical growth of the lesion was observed on the accompanying CT scan, which 
could account for this change in OctreoScan status. 
A sufficient degree of sst2 expression is required to detect neuro-endocrine tumors via 
111In-pentreotide scintigraphy. Different studies have demonstrated that GC can directly 
down-regulate sst2 expression in neuro-endocrine tumor cells (13-15, 20) and this may 
also explain the low levels of sst2 in human corticotroph adenomas (21-23). In the hu-
man (pancreatic) neuroendocrine tumor cell line BON, we previously demonstrated 
that dexamethasone dose-dependently down-regulates sst2 expression, which could 
completely be abrogated by co-incubation with mifepristone (13 ). For down-regulation 
Fig 4 A B
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Figure 4, A-e: Immunohistochemistry for the sst2 and D2 receptor in the primary carcinoid tissue of 
this patient. All photographs were taken at a magnification of 100x. A: Hematoxylin and eosin stain. B: 
Negative control (omission of the primary sst2 antibody). C: sst2 polyclonal antibody. D: sst2 antibody after 
immunoneutralization with an immunizing sst2 receptor peptide. E: D2 monoclonal antibody.
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of sst2, however, an intact GC signaling pathway needs to be present within these cells, 
which is not the case in many of the neuro-endocrine tumors that cause ectopic Cush-
ing’s syndrome (24, 25). In our patient, however, the glucocorticoid feedback system 
was still partially intact, as demonstrated by an absent suppression of serum cortisol on 
low-dose 1 mg DST, but a strong suppression on high-dose dexamethasone suppression 
testing (HDDST). This likely explains why after alleviation of the functional hypercorti-
solism by mifepristone therapy, sst2 expression levels were restored. 
The reported sensitivity of diagnostic OctreoScan in ectopic Cushing’s syndrome is 50% 
at best in most series (1, 8, 11, 26, 27). It is important to note, however, that most of 
these data were obtained in patients with untreated ectopic Cushing’s syndrome. As 
demonstrated by the results in our patient, the diagnostic accuracy of the OctreoScan 
may be increased after resolution of hypercortisolism in those EAS tumors, in which the 
GC signaling system is still (partially) intact. This is clinically relevant because in 12 to 18 
% of patients the primary cause of EAS can not be localized initially (1), frequently neces-
sitating a bilateral adrenalectomy. Future studies should prospectively investigate the 
diagnostic value of repeated OctreoScan after GC lowering or GC receptor antagonizing 
therapy.
The appearance of clearly demonstrable levels of sst2 in our patient following mifepris-
tone treatment strongly suggests the presence of a dynamic and potentially reversible 
relationship between GC action and the expression of sst2 within neuro-endocrine 
tumors, including some cases of EAS. In this specific patient, we could not assess at 
what point of time the upregulation of sst2 occurred as we only had access to two serial 
OctreoScans in a 6-month interval. An interesting question would further be whether 
this visible return of sst2 expression also correlates with a response to treatment with SS 
analogues resulting in decreased ACTH production. If so, this could have implications 
for secondary treatment options in EAS patients that are not cured by surgery alone and 
in whom bilateral adrenalectomy is not feasible or desirable. Temporary pre-treatment 
with GC lowering (e.g. ketoconazole) or GC receptor antagonizing (mifepristone) therapy 
could result in a reappearance of sst2 expression and consequently increase the efficacy 
of sst2-preferring compounds such as Octreotide.
It is important to note that such a proposed mechanism of action only pertains to those 
cases of EAS, in which some form of GC regulation is still present. It is known that the 
majority of EAS cases will not suppress serum cortisol levels on HDDST (12). However, 
it is well conceivable that the minority of EAS cases, that do adequately suppress on 
HDDST, may constitute an important part of the group of EAS cases that are negative 
on OctreoScan. 
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In this tumor sst2 was highly expressed: 0.18 copies/hprt. For comparison, we have 
measured sst2 expression data recently in a large series of corticotroph adenomas with 
identical analytical methods. In these corticotroph adenomas the mean sst2 expression 
level was 0.04/hprt (22). EAS tumors can display substantial numbers of sst2 receptors, as 
demonstrated by the percentage of OctreoScan positive EAS tumors in several series (1, 
3, 8, 11). These receptors can also be functional, as some EAS patients display a favour-
able response to Octreotide therapy in contrast to patients with CD (4, 28). 
The fact that sst2 expression levels tend to be higher in patients with EAS than in 
patients with CD is not surprising by itself. If EAS tumors are fully insensitive to gluco-
corticoid feedback, as demonstrated by absent or insufficient suppression at HDDST, 
then GC-induced down-regulation of sst2 receptors is not likely to be present. We have 
investigated this phenomenon previously in vitro, in which the severely glucocorticoid-
resistant EAS cell line DMS-79 did not show any signs of sst2 down-regulation, even at 
the highest dexamethasone doses of 100 nM (13). As stated previously, the majority of 
EAS tumors will belong to this category, because in approximately 90% of EAS patients 
serum cortisol levels are not adequately (>50%) suppressed after HDDST (3). This does 
not pertain, however, to our patient, in whom HDDST did decrease serum cortisol levels 
(>50%) and in whom a negative OctreoScan was observed at the time of initial diagno-
sis. This indicates that some degree of intrinsic GC responsiveness was present in this 
tumor and that upon reversal of functional hypercortisolism by mifepristone therapy, 
sst2 expression was restored. It is therefore important to note that the tumoral sst2 levels 
we have measured in vitro in this individual patient after mifepristone therapy are not 
necessarily representative for the majority of fully GC resistant EAS tumors in clinical 
practice. 
D2 was also well expressed in this tumor (2.13 copies/hprt), which is in line with the re-
ports by Pivonello et al. that these tumors can respond to cabergoline therapy, depend-
ing on their D2 receptor status (7). The level of expression in this tumor was in the same 
order of magnitude as what we observed earlier for corticotroph adenomas (22). The fact 
that, in contrast to the sst2 receptor, the expression levels between CD and EAS do not 
differ significantly for D2, can be explained by the fact that the D2 receptor gene does not 
appear to be as sensitive for GC regulation as sst2 and to a much lesser degree sst5 (13). 
For both sst2 and D2, the mRNA expression levels were confirmed by the clear presence 
of sst2 and D2 at immunohistochemistry of sequential tumor tissue sections. Moreover, 
the expression data correlated with the inhibitory trend of Octreotide and Cabergoline 
in the primary cultured ACTH-producing carcinoid cells. The inhibition of ACTH release 
by cabergoline in vitro confirms earlier reports by Pivonello et al that these tumors can 
be responsive to D2 agonists. In a study of six patients with EAS, 5/6 of these primary tu-
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mors were D2 receptor positive (7). Of these six patients, three were not cured by surgery 
and were treated adjuvantly with the D2 agonist cabergoline, which induced a complete 
initial normalization of urinary free cortisol excretion in two of them. In another case 
report, combined treatment with the sst2 preferring SS analogue Lanreotide and the 
dopamine D2 receptor agonist Cabergoline induced complete remission in a patient 
with EAS due to a lung carcinoid (29). In our patient, we did not find signs of synergism 
between these receptors when they were co-activated in vitro. 
In conclusion, we have described a patient with an ACTH-producing bronchial carci-
noid tumor, in whom a direct regulatory effect of GC levels on tumoral sst2 receptor 
expression is suggested by a remarkable change in OctreoScan status after successful 
mifepristone therapy. Further studies will have to demonstrate whether this is a more 
general mechanism of response in the subset of EAS cases, in which GC responsiveness 
is still partially intact. 
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Functional characterization of 
the dopamine somatostatin 
chimeric molecule BIM-23A760
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ABstrACt
Somatostatin (sst) and dopamine (D2) receptor subtypes are co-expressed in various 
neuro-endocrine tumours and may show functional synergism. Novel dopamine-
somatostatin chimeric molecules that bind to both receptor subtypes, have displayed 
superagonistic properties in earlier studies. Whether this is due to heterodimerization 
of target receptors or to enhanced activation of individual receptors, remains unknown. 
In this study we investigated the functional role of the different components of the 
novel dopamine-somatostatin chimera BIM-23A760 (high sst2-D2 affinity). We transiently 
transfected HEK-293 cells with D2 and/or sst2 cDNA and measured inhibition of forskolin-
stimulated cAMP release by BIM-23A760 in comparison to its internal controls BIM-53097 
(D2) and BIM-23023 (sst2). In D2-monotransfected cells, BIM-23A760 was 15-fold more 
potent than BIM-53097 (EC50 0.02 vs. 0.3 nM, p<0.01), even though both compounds have 
a similar D2 receptor binding affinity (IC50 15.9 and 22.1 nM, respectively). In contrast, in 
sst2-monotransfected cells BIM-23A760 was 4-fold less potent than BIM-23023 (EC50 0.04 
vs. 0.01 nM, p<0.01), while BIM-23A760 sst2 receptor binding affinity is 14-fold higher 
(IC50 0.03 and 0.42 nM, respectively). In sst2-D2 co-transfected cells cAMP inhibition by 
BIM-23A760 was identical to that in D2-monotransfected cells (EC50 0.02 nM). Both the D2-
antagonist sulpiride and the sst2-antagonist BIM-23454 were required to fully abrogate 
the effects of BIM-23A760. We conclude that in this transfected cell system, BIM-23A760 
is a strong activator of sst2, but also a remarkably potent activator of D2 receptors, 
which cannot be explained by its binding affinity profile alone. Co-expression of sst2 
and D2 does not enhance cAMP-inhibition by BIM-23A760 via either of these receptors. 
This suggests that the superagonistic properties of this compound in vivo, may at least 
partially be due to superior activation at the level of the individual (D2) receptors.
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introDuCtion
Dopamine (DA) and somatostatin (SS) receptors are (co-)expressed in many different 
neuro-endocrine tumours, including pituitary adenomas, gastro-entero-pancreatic 
tumours and carcinoids (1-3). Agents that target these receptors have been shown to 
be effective in inhibiting hormone release and/or tumour growth (4). Several years ago 
it was shown that dopamine receptor subtype 2 (D2) and somatostatin receptor subtype 
5 (sst5), both members of the family of G-protein coupled receptors (GPCRs), could form 
heterodimers in a transfected cell system, leading to enhanced functionality of these 
receptors and synergism of action (5). Recently, similar phenomena have been described 
for the D2 and sst2 receptor (6). The discovery that these receptors can heterodimerize 
with a resulting increase in efficacy has opened up the way for potential combination 
therapy of both DA and SS-targeting agents in patients with neuro-endocrine tumours. 
Along with these developments, new compounds have been designed, which combine 
high-affinity binding to both DA and SS receptors within the same molecule, the so-
called dopastatin chimeric molecules. In addition to the activation of both receptors 
individually, these compounds could in theory also draw both receptors together in a 
spatial manner, and thereby increase the degree of synergism between these recep-
tors.
One of such chimeric compounds of interest is BIM-23A760. Saveanu and Jaquet have 
shown previously that this compound has superior efficacy in terms of GH-inhibition 
compared with traditional SS-analogues in some GH-secreting adenomas (7, 8). In a re-
cent multicenter study, it was found that this compound also inhibited the proliferation 
rate of non-functioning pituitary adenomas (Florio et al. 2008 End. Rel. Ca.). Due to its 
binding affinity profile, with superior affinity for sst2 and D2, combined with a good affin-
ity for sst5,, this compound could in theory also be of interest for the medical treatment 
of Cushing’s disease (9), as well as the Ectopic-ACTH producing Syndrome (10, 11). 
The mechanism behind the reported superpotency of these chimeric dopastatins has 
not been fully elucidated (1). In view of the clinical interest in this molecule and the on-
going debate on whether or not its superpotency can be attributed to heterodimeriza-
tion of its target receptors, we performed the present study. With the use of an in vitro 
reporter gene assay, we aimed to study some of the functional characteristics of this 
interesting new dopastatin compound BIM-23A760, with the main research question 
being: can we ascribe the observed superpotency of this compound to heterodimeriza-
tion or could it be due to superior activation of the individual receptors? 
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Transfection studies and reporter gene assay 
Since sst2 and D2 are both GPCR’s that signal through the activation of cAMP, we investi-
gated the functionality of BIM-23A760 in a reporter gene system, which indirectly mea-
sures intracellular cAMP levels. HEK293 cells (kind gift from Dr. A.P.N. Themmen, Erasmus 
MC) that natively do not express sst2 and D2, were transiently transfected with either 
human sst2 cDNA (kind gift from Dr. Bell, Howard Hughes Medical Institute, Chicago, IL) 
or human D2 cDNA (commercially available at UMR cDNA resource center; www.cDNA.
com). For transfection, the calcium chloride precipitation method was chosen as this 
method has been used previously for this particular assay (12, 13). HEK-293 cells seeded 
at 20% confluency were transiently transfected with 2 μg of the cAMP-reporter plasmid 
pCRE6Lux (14), 2 μg pRSVlacZ (15) as a control for transfection efficiency, 2μg of human 
sst2 cDNA and/or 0.1 μg of human D2 cDNA and 14 μg carrier DNA in 75 cm
2 culture 
flasks (Costar, Cambridge, MA). Two days after transfection the cells were trypsinized 
and plated in 48-well tissue culture plates (Costar, Cambridge, MA). On the third day, 
medium was changed to serum-free medium supplemented with 0.1% bovine serum 
albumin. Cells were then stimulated with forskolin (10-6 M) for 6 hr in the presence or 
absence of the different BIM-agonists and/or antagonists. After 6 hr stimulation, cells 
were lysed with 25 mM Tris phosphate, pH 7.8, 8 mM MgCl, 1 mM dithiothreitol, 15% 
glycerol, 1% Triton X-100 and analyzed for luciferase (cAMP-responsive element driven) 
and Renilla luciferase (transfection control) activities using the Dual-Luciferase Reporter 
Assay System according to the manufacturer’s instructions (Promega Corporation, Madi-
son, WI) (16).
Quantitative PCR
To check for adequate sst2 and D2 transfection efficiency, additional transfected cells 
were lysed for quantitative PCR (qPCR) in every experiment. This was performed via a 
previously described method (17). The sequences and final concentrations of the hprt, 
sst2 and D2 primer-probe pairs have been described previously (17, 18). The D2 primer-
probe set measures total D2 expression (D2 long + short isoform). All primers and probes 
were purchased from Sigma Aldrich (Zwijndrecht, the Netherlands). Samples were 
measured on an ABI Prism 7900 Sequence Detection System (Perkin Elmer, Foster City, 
CA) and normalized against the expression of the housekeeping gene hprt. All samples 
were assayed in duplicate. 
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Test substances
BIM-23A760, BIM-23023, BIM-23454 and BIM-53097 were provided by Biomeasure In-
corporated (Milford, MA). Sulpiride was obtained from Sigma Aldrich (Zwijndrecht, the 
Netherlands). The binding affinities of the compounds are depicted in Table 1.
Statistical analysis
All statistical analyses were performed with GraphPad Prism version 3.02 software (San 
Diego, CA). EC50 values of dose-dependent inhibition of cAMP-release were calculated 
with non-linear regression curve fitting. Differences in dose-effect curves (EC50) between 
the tested compounds were analyzed by the unpaired student t-test. Reported values 
are the mean of 2-4 different experiments. A significance level of 0.05 was set. 
results
Control experiments
To exclude the presence of natively expressed sst2 or D2 receptors in HEK-293 cells, 
lysates of mock transfected HEK cells were analyzed by quantitative PCR. No expression 
of sst2 or D2 was demonstrable. Moreover, neither the agonists BIM-23A760, BIM-23023 
and BIM-53097, nor the antagonists BIM-23454 and sulpiride had an effect on forskolin-
stimulated cAMP production in these mock-transfected HEK-293 cells (data not shown). 
Sst2 monotransfected state
In sst2 monotransfected cells, the BIM-23A760 chimera induced a dose-dependent 
decrease in forskolin-induced cAMP production with an EC50 of 0.04 nM (figure 1). BIM-
23A760 was 4-fold less potent, however, than its internal control BIM-23023 (EC50 0.01 
nM, p<0.01), even though BIM-23A760 has a 14-fold lower binding IC50 for the sst2 recep-
table 1 Binding affinities (IC50) in nM of compounds used in this study 
Compound Type sst1 sst2 sst3 sst4 sst5 D2
BIM-23A760 agonist 622 0.03 160 >1000 42 15.9
BIM-23023 agonist 6616 0.42 87 2700 4.2 >1000
BIM-53097 agonist n.d. n.d. n.d. n.d. n.d. 22.1
BIM-23454 antagonist n.d. 32 n.d. n.d. n.d. n.d.
Sulpiride antagonist n.d. n.d. n.d. n.d. n.d. 0.45
n.d. = not determined
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tor (0.03 nM vs. 0.42 nM, respectively, see Table 1). Maximum inhibitions were similar 
for both compounds (BIM-23A760: –86% vs. BIM-23023: –80%, p>0.05). The inhibitory 
actions of both BIM-23A760 and BIM-23023 could be antagonized by co-incubation 
with the sst2 antagonist BIM-23454. 
D2 monotransfected state
In D2 monotransfected cells, BIM-23A760 induced a dose-dependent decrease in 
forskolin-induced cAMP production with an EC50 of 0.02 nM (figure 2). In these cells, 
BIM-23A760 was 15-fold more potent than its internal control BIM-53097 (EC50 0.30 nM, 
p<0.01), even though both compounds have a relatively similar binding IC50 for the D2 
receptor (15.9 and 22.1 nM, respectively). Maximum inhibitions were similar for both 
compounds (BIM-23A760: –88% vs. BIM-53097: –82%, p>0.05). Co-incubation with the D2 
antagonist sulpiride completely antagonized the inhibitory effects of both compounds. 
Sst2-D2 cotransfected state
Sst2 and D2 cDNA were co-transfected in specific amounts, so that comparable mRNA 
copy numbers of these receptors were expressed: 0.66 (sst2) and 0.58 (D2) copies/hprt 
(figure 3). 
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Figure 1: Sst2 monotransfected cells. Forskolin-induced cAMP-inhibition by dopastatin BIM-23A760 (dashed 
line, solid squares), sst2 agonist BIM-23023 (solid line, open squares) and BIM-23A760 in the presence of 
sst2 antagonist BIM-23454 10
-7 M (solid line with open triangles). The EC50 value of BIM-23A760 is shifted 
4-fold to the right, compared to BIM-23023: 0.04 nM vs. 0.01 nM; * = p-value <0.01; CT = control. The values 
represent the mean ± SE from two different experiments, each performed in quadruplicates.
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In this sst2-D2 cotransfected state, the monotargeting compounds BIM-23023 (sst2) and 
BIM-53097 (D2) had the same EC50 values as compared to their efficacy in the monotrans-
Fig 2
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Figure 2: D2 monotransfected cells. Forskolin-induced cAMP-inhibition by dopastatin BIM-23A760 
(dashed line, solid squares), the D2 agonist BIM-53097 (solid line, open squares) and BIM-23A760 in the 
presence of D2 antagonist sulpiride 10
-4M (solid line with open triangles). The EC50 value of BIM-23A760 is 
shifted 15-fold to the left, compared to BIM-53097: 0.02 nM vs. 0.30 nM; * = p-value <0.01; CT = control. 
The values represent the mean ± SE from two different experiments, each performed in quadruplicates.
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Figure 3: Sst2-D2 cotransfected cells. Sst2 and D2 mRNA expression levels as determined by quantitative 
RT-PCR. Values represent the mean ± SE of two independent experiments, assayed in duplicate.
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fected states: BIM-23023 0.01 nM and BIM-53097 0.3 nM (figures 4A and 4B). The sst2 and 
D2 selective antagonists BIM-23454 and sulpiride were able to antagonize these effects. 
In the sst2-D2 co-transfected state, BIM-23A760 displayed the same EC50 as shown 
previously for the D2-monotransfected state: 0.02 nM (figure 4C). When only the sst2 
antagonist BIM-23454 was added, a strong dose-dependent decrease remained with an 
EC50 of 0.03 nM (p>0.05 for difference in EC50 values between BIM-23A760 and BIM-23-
A760+BIM-23454). When only the D2 antagonist sulpiride was added, a similarly strong 
dose-dependent decrease remained with an EC50 of 0.04 nM (p>0.05 for differences in 
EC50), which was identical to the EC50 of BIM-23A760 in the sst2 monotransfected state. 
However, when both antagonists were added, the inhibitory effects of BIM-23A760 were 
abrogated (EC50 4.3 nM, p<0.001). 
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Figure 4 A-C: Sst2-D2 cotransfected cells. A: Forskolin-induced cAMP-inhibition by sst2 agonist BIM-23023 
in the absence (solid line, open squares) and presence of sst2 antagonist BIM-23454 10
-7M (solid line, 
open triangles). B: Forskolin-induced cAMP-inhibition by D2 agonist BIM-53097 in the absence (solid line, 
open squares) and presence of D2 antagonist sulpiride 10
-4M (solid line with open triangles). C: Forskolin-
induced cAMP-inhibition by dopastatin BIM-23A760 alone (dashed line, solid squares), BIM-23A760 + 
sulpiride (solid line with solid triangles), BIM-23A760 + BIM-23454 (dashed line, open squares) and BIM-
23A760 + sulpiride + BIM-23454 (solid line, solid circles). CT = control. The values represent the mean ± SE 
from two different experiments, each performed in quadruplicates.
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DisCussion
In this study we have investigated the functional role of the different components of 
the sst2-D2 chimeric molecule BIM-23A760, which determine its overall cAMP-inhibitory 
effect in vitro. We found that the activity of this compound via the D2 receptor was higher 
than expected, whereas the activity via the sst2 receptor was lower than expected on the 
basis of its reported D2 and sst2 binding affinities. 
More in detail, we found that in D2 transfected cells BIM-23A760 was 15-fold more 
potent than its internal control BIM-53097, even though the reported binding affinities 
of these compounds for the D2 receptor are reported to be similar (15.9 and 22.1 nM, 
respectively). For the sst2 receptor the exact opposite pattern was observed: BIM-23A760 
was 4-fold less potent than its internal control BIM-23023, even though the binding IC50 
of BIM-23A760 for the sst2 is 14-fold higher than that of BIM-23023 (0.03 nM vs. 0.42 nM, 
respectively). It is important to emphasize that these observations were performed in 
sst2 and D2 monotransfected cell systems. In other words, the discrepancy between the 
observed efficacy in vitro and the reported binding affinity for both of these receptors, 
appears to be a direct feature of BIM-23A760 towards these individual sst2 and D2 recep-
tors. Alterations in ligand binding characteristics by the simultaneous co-expression of 
the other sst2 or D2 receptor can not explain these observations. 
The fact that dissociation is observed between binding affinities and in vitro efficacy, 
is not surprising by itself. It is well known that binding affinity (IC50) is only one of many 
factors that ultimately determine the signal transducing effects of any given compound, 
including DA and SS analogues. This issue has been elaborately described by Dr. Schon-
brunn in a recent review article and has been given the term “selective or biased agonism” 
(19). This refers to the phenomenon, by which different agonists that bind to the same 
receptor may trigger completely different post-receptor signalling pathways. Moreover, 
occupancy time of the receptor, internalization rates and recycling pathways may also 
vary considerably among different agonists of the same receptor (20). 
One reason for our observation that the efficacy of BIM-23A760 via sst2 is lower than 
expected, may be the susceptibility of sst2 for internalization and degradation. Previous 
studies in transfected HEK-293 cells have shown that sst2 rapidly internalizes upon agonist 
stimulation (20). Importantly, Cescato et al. have found that high-affinity binding to sst2 
is a prerequisite for an agonist to trigger the internalization process, also in HEK 293 cells 
(21). Moreover, they found that the agonist with the highest sst2 binding affinity in their 
study, BIM-23244, also had the highest sst2 internalization potency. Given the fact that 
the sst2 binding IC50 of BIM-23A760 (0.03 nM) is even 10-fold lower than that of BIM-23244 
(0.3 nM), it is to be expected that BIM-23A760 induced an even faster internalization of 
sst2 receptors in our experiments, which may account for a relative decrease in efficacy. To 
our knowledge, similar internalization processes that are induced by high-affinity ligands 
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have not been described for the D2 receptor. The question remains of course whether 
these processes, observed in (mono)transfected cell systems, occur in a similar fashion in 
vivo, where many different receptors are expressed in the close vicinity of these sst2 and 
D2 receptors. It has been shown for instance that sst5 may directly decrease the internal-
ization rate of sst2 (22). This may prove to be a favourable determinant of the efficacy of 
BIM-23A760 in human neuro-endocrine tumors, which often co-express sst2 and sst5. 
In the sst2-D2 co-transfected state, we had hypothesized that enhanced potency might 
occur because of synergism between the sst2 and D2 receptor. This has previously been 
shown to occur in a transfected cell system between the sst5 and D2 receptor (5). In 
this study by Rocheville et al. hetero-oligomerization of these receptor subtypes was 
proposed to lead to a sst5-D2 dimer with increased affinity for both sst5 and D2-targeting 
agonists and enhanced receptor activation. Recently, another group also showed that 
in co-transfected HEK-293 cells, sst2 and D2 receptors form heterodimers upon activation 
by selective ligands, leading to enhanced D2 signalling and also prolonged sst2 inter-
nalization (6). In our study, however, BIM-23A760 displayed the same EC50 in the sst2-D2 
co-transfected state as compared to the D2-monotransfected state (0.02 nM), without 
any increase or decrease in IC50 due to the presence of the extra sst2 receptors. 
As said, the mono-targeting compounds had the same EC50 and ECmax values in the 
monotransfected compared to the co-transfected states. In other words, the abundant 
presence of additional sst2 or D2 receptors did not stimulate nor decrease the signalling 
via these receptors. This is different from what has been reported previously by some but 
not all research groups in the same field of study. Both Ren et al. and Saveanu et al. found 
that the chimeric molecule BIM-23A387 (high sst2-high D2 affinity) showed enhanced 
inhibitory effects in human GH-producing adenomas compared to incubation with the 
individual targeting compounds (23, 24). Ren et al., however, found that by the use of 
the D2 antagonist sulpiride, all inhibitory properties of BIM-23A387 were lost, suggest-
ing a functional interaction between sst2 and D2, whereas Saveanu et al. showed only 
partial loss of inhibition by BIM-23A387 in this setting. Saveanu et al. therefore conclude 
that the potent effects of BIM-23A387 can not be explained by the process of receptor 
heterodimerization alone, but may also depend on specific interactions between the 
chimeric molecule and the individual sst2 and D2 receptors (24). 
In summary, we find that in this transfected cell system BIM-23A760 is a strong activator 
of sst2, but also a remarkably potent activator of D2 receptors, which can not be explained 
by its binding affinity profile alone. In our study, co-expression of sst2 and D2 does not 
enhance the cAMP-inhibiting capacities of BIM-23A760 via either of these receptors. This 
suggests that the reported superagonistic properties of this compound in vivo, may at 
least partially be due to superior activation at the level of the individual (D2) receptors.
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The principal aim of this thesis was to further explore the possibilities for a medical treat-
ment of human Cushing’s disease based on the use of somatostatin analogues and/or 
dopamine agonists. 
Despite all advancements in surgical technique, selective transsphenoidal adenomec-
tomy still fails to induce long-term cure in approximately 30% of patients with CD, even 
in most experienced hands (1). The group of patients with persistent or recurrent CD 
is known to suffer from increased morbidity and mortality and represents one of the 
most difficult clinical challenges for endocrinologists (2). Until now, medical therapy has 
only played a minor role in the treatment of these refractory patients (3-5). Antiserotin-
ergic drugs have been employed in the past without much success (5). Retinoic acid 
derivatives, despite promising results in vitro and in some animal models, have failed to 
make the transition to clinical studies in human subjects (6, 7). Moreover, peroxisome-
proliferator-activated-receptor-gamma agonists have not shown any significant efficacy 
in several recent clinical studies in humans with CD (8-10). The use of dopamine agonists 
including bromocriptine and cabergoline has been widely studied in CD, but its success 
is limited by the occurrence of treatment escapes in a subset of patients (3, 11). Therefore, 
the search for an effective and safe medical treatment for human CD continues. In this 
thesis we have focussed on the role of dopamine and somatostatin receptor subtypes as 
potential targets for such a medical therapy. 
AnimAl moDels For CD
One of the most important rate limiting factors in the advancements of research into the 
origins and treatment of human CD, has been the rarity of the disease. Interestingly, in 
dogs this disease is much more common, perhaps over 1000-fold more (12-14). The fact 
that at Utrecht University dogs with CD can be treated by a therapeutic hypophysectomy, 
provided a more than welcome opportunity to increase the availability of corticotroph 
adenoma tissue for in vitro functional studies. In chapter 2 we have described the char-
acterization of 13 of these adenomas for the presence of the receptor subtypes, in which 
we were primarily interested from a human point of view: sst2, sst5 and D2. We found 
that these adenomas do express all of these receptor subtypes, but in very different 
ratios than anticipated beforehand. Whereas in human CD sst2 only plays a minor role, it 
appears to be the dominant receptor subtype in canine CD, both in terms of expression 
levels, as well as functional responses in vitro. At the same time, sst5 only has a minor role 
in canine CD, while D2 also has lower expression levels than what is observed in humans. 
Inter-species differences in glucocorticoid regulation of the expression of these receptor 
subtypes are likely to contribute to these differences between human and canine CD: 
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whereas glucocorticoids decrease sst2 expression levels in humans, they remarkably 
increase the expression of sst2 in canine corticotroph adenomas. 
We do believe, however, that valuable research hypotheses can still be generated from 
the use of canine CD as a model for human CD. Due to the predominance of sst2 and D2 
in canine CD, the use of analogues that target these specific receptor subtypes could 
be of interest. This could be performed by co-administration of an sst2 (octreotide or 
lanreotide) and a D2 (cabergoline) targeting drug. The advantage of the use of these 
compounds is that both have been proven to be effective in dogs for the treatment of 
insulinomas and reproductive disorders, respectively (15, 16) . In other words, they are 
known to bind to canine sst2 and D2 receptors with sufficient affinity and can induce 
clinical effects. Their combined in vivo use in canine CD could provide firsthand evidence 
for the possible functional synergism between sst2 and D2 receptors, which has been 
suggested by recent in vitro studies (17). Moreover, the use of the novel dopamine-
somatostatin chimera BIM-23A760, which is also discussed in chapter 7, could be of great 
interest here. This compound has a very high sst2 and D2 binding affinity and is therefore 
likely to induce profound ACTH suppression in canine corticotroph adenomas, provid-
ing that the reported binding affinity profile of this compound is similar in humans and 
dogs. 
Finally, it is necessary to emphasize that canine corticotroph adenoma tissue can be 
valuable for various research questions that address the different etiological aspects of 
CD. For example, one study used canine corticotroph adenomas to investigate novel 
molecular aspects of glucocorticoid receptor function in CD (18). This study would have 
been much more difficult to perform if only human corticotroph tissue was available. 
HumAn CortiCotroPH ADenomAs
An important aim of this thesis was to increase our understanding of how many patients 
with CD have a reasonable chance of ultimately responding to somatostatin and/or 
dopamine targeted medical therapy. Data on this topic were still scarce at the start of 
this study, being derived from relatively small series of patients. Moreover, it was not 
known to which extent sst5 and D2 were co-expressed within the same corticotroph 
tumors. We aimed to reinvestigate the distribution of these target receptor subtypes in 
a larger population of CD patients, as the presence of demonstrable receptors is likely to 
be the first and foremost predictor of a successful response to this type of therapy. The 
importance of sufficient receptor numbers has been demonstrated by several studies, in 
which a direct relationship was found between the expression levels of sst and DA recep-
tor subtypes in GH and mixed GH/PRL-secreting pituitary adenomas and specific agonist 
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action, both in vitro and in vivo (19-22). The in vitro correlation has been demonstrated 
both at the mRNA level (21) as well as at the protein level by immunohistochemistry (19, 
20). 
The main results of our study in 30 human corticotroph adenomas are described in 
chapter 4. We found a large variation in expression levels of sst2, sst5 and D2 in our series 
of adenomas, similarly to what has been described before in GH-producing and non-
functioning pituitary adenomas (21, 23). Overall, we believe that the results from this 
study are encouraging, as we found that over 80% of patients express at least one of 
these target receptors at a level, where protein expression can be visualized by means 
of receptor autoradiography. Of course, demonstrable protein expression at recep-
tor autoradiography does not necessarily equal biological response, but at least the 
molecular substrate can be demonstrated on the cell membrane of the corticotroph 
adenoma cells. Various other factors, apart from the number of receptors, will ultimately 
determine how many patients will show a clinical response to sst2/sst5/D2 targeted 
therapy. In prolactinomas, for instance, loss of the Gi2 alpha protein can cause resistance 
to the dopamine agonist bromocriptine, even though sufficient D2 receptors are present 
on the cell membrane (24). In different neuro-endocrine tumors, especially carcinoids, 
various mechanisms of tachyphylaxis have been described (25). New studies will have 
to investigate whether similar phenomena also affect response rates in corticotroph 
adenomas.
tHe role oF gluCoCortiCoiDs
One aspect that could play a decisive role in the efficacy of sst/DA-targeting agents at 
any given time during therapy, is the level of circulating glucocorticoids. Before the start 
of this thesis it had already been clearly demonstrated that murine sst2 gene expression 
was under direct control by glucocorticoids, while sst5 appeared to be less sensitive for 
this type of regulation (26, 27). For D2, not much was known on glucocorticoid regulation 
in human neuro-endocrine tissues. 
In chapter 3 we have described the results of our study on glucocorticoid regulation of 
sst and DA receptors in three different human neuro-endocrine cell lines. Our results 
confirm the previous studies in murine corticotroph cells that sst2 is highly sensitive, 
while sst5 is far less sensitive for this type of down-regulation. We also found that the 
D2 gene is completely insensitive for down-regulation by high levels of glucocorticoids. 
This could be an interesting finding for future medical therapies of CD. It may well 
explain why D2 receptors are so highly expressed in the majority (80%) of corticotroph 
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adenomas, while expression levels of especially sst2 are much lower (chapter 4). We also 
found that glucocorticoid-induced down-regulation is a dynamic and also reversible 
process, when glucocorticoid levels fall. This could be an important observation from a 
clinical perspective, as this means that the induction of an initial biochemical remission 
in a patient with CD may aid to increase the total number of pharmaceutical targets in 
the adenoma tissue, including sst2 (see figure 1). 
In the same study we found that in the cell line derived from an ectopic-ACTH producing 
neuro-endocrine tumour (DMS-79), all receptors (including sst2 and sst5) were insensi-
tive to high levels of glucocorticoids. We found this an interesting observation, as this 
first of all confirms the clinical experience that many tumours that cause the ectopic 
ACTH-producing syndrome (EAS) are positive on a diagnostic OctreoScan, which primar-
ily identifies the presence of sst2 receptors (28). In other words, these neuro-endocrine 
tumours express high levels of sst2 receptors, despite the continuous hypercortisolemic 
environment they are exposed to. Gross mutations in the glucocorticoid receptor gene 
have been described in these tumours, which could explain the resistance of these 
tumours to glucocorticoid-mediated down-regulation of sst2 receptors (29). However, 
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Figure 1: Hypothetical scheme of the effect of glucocorticoids on sst2, sst5 and D2 expression 
in a corticotroph adenoma. In untreated CD (left panel), ACTH overproduction leads to chronic 
hypercortisolism, which down-regulates sst2, but not sst5 or D2 expression. In treated CD (right panel), 
e.g. by sst5 or D2-directed medical therapy, alone or in combination with ketoconazole, lowering of ACTH 
levels reduces endogenous hypercortisolism and relieves the hypercortisolistic pressure on the pituitary, 
which in turn could lead to an in vivo reappearance of sst2 expression. The latter would result in regained 
efficacy of sst2-preferring compounds and thus enhance the pharmacological options for medical therapy. 
Adapted from (41).
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not all EAS tumours are positive on Octreoscan (30, 31). Our hypothesis was that in this 
group of EAS tumours, apparently some degree of glucocorticoid regulation would be 
residually active. In these patients, reduction of circulating cortisol levels, could conse-
quently lead to a reappearance of sst2 expression, if this regulatory system is still intact. 
Recently, we identified a patient in our clinic that suffered from EAS due to a lung 
carcinoid. Her case history and additional in vitro studies are described in chapter 6. At 
the time of diagnosis, she had a negative OctreoScan, but a small pulmonary lesion 
on a regular chest-CT. We treated her for 6 months with the glucocorticoid receptor 
antagonist mifepristone, thereby inducing a pseudo-hypocortisolemic state. We refer 
to it as “pseudo”-hypocortisolemic, since measured glucocorticoid levels were high, but 
functionally inactive because of the glucocorticoid receptor blockade by mifepristone. 
When a chest-CT and OctreoScan were repeated after 6 months of therapy, the pul-
monary lesion had not increased in size but did show increased (pathological) uptake, 
indicating a strong upregulation of sst2 in this tumour, which provided important clinical 
evidence for a direct and dynamic relationship between sst receptor expression and in 
vivo glucocorticoid levels. When this pulmonary lesion was surgically resected in this 
patient, sst2 receptors were also clearly demonstrable by quantitative PCR and immuno-
histochemistry. Finally, the functionality of these receptors was proven by the inhibitory 
effects of octreotide in vitro on ACTH release. Interestingly, this carcinoid tumour also 
expressed high levels of D2 receptors, which is in agreement with findings from a previ-
ous study in EAS (32) . 
The results from this case study suggest that in a minority of EAS tumors, in which partial 
GC-responsiveness is present, glucocorticoid lowering or antagonizing therapy may be 
used for two purposes. First of all, in patients with EAS in whom no tumour can be visual-
ized, glucocorticoid lowering therapy may induce expression of sst2 in these tumours 
and allow for their proper localization, after which curative surgery may be performed. 
Secondly, if complete surgical removal of the tumour is not an option, cortisol-lowering 
therapy increases the level of sst expression and may therefore sensitize the tumour 
for subsequent SS-analogue therapy. The clinical utility of such an approach requires 
further investigation, however. 
CliniCAl AsPeCts oF novel sst/DA-tArgeting tHerAPy in CD
In chapter 4 we reported that the majority of patients with CD possess at least one mo-
lecular target (sst5 or/D2) in their corticotroph adenoma tissue for a possible therapeutic 
effect to occur. For that reason we designed a phase II open-label clinical trial in which a 
140 Chapter 8 
stepwise medical therapy, consisting of pasireotide ± cabergoline ± low-dose ketocon-
azole, was evaluated for its efficacy in patients with de novo or recurrent CD. At present, 
patient enrolment for this trial has just been completed and final data analyses are cur-
rently ongoing. As the definitive results of this trial will be published elsewhere, it is not 
possible to discuss the results of this trial in full detail within the context of this thesis. In 
chapter 5, however, we present and discuss four illustrative cases for the different types 
of clinical responses we have observed during this trial. On a general note, we can state 
that the study has produced firm clinical evidence for the efficacy of combined sst5 and/
or D2-targeted medical therapy in human CD. A few important issues, however, require 
further discussion as they could prove to be of substantial clinical importance.
Dose
In this trial we observed that already on low-dose pasireotide (3 x 100 μg), selected 
patients can respond with a dramatic reduction in serum and urinary cortisol levels. 
These reductions can be observed within days after the first administration of the study 
drug. This is an interesting observation, as we initiated treatment in these patients with 
only a quarter of the pasireotide dose that Boscaro et al. used in their study (total daily 
dose: 300 μg vs. 1200 μg)(33). The significant response on these low doses may be ex-
plained by the subnanomolar affinity of pasireotide for sst5 (0.38 nM). For comparison, 
octreotide can induce significant clinical responses in the 100μg dose in acromegalic 
patients, while its affinity for sst2 is around 1.0 nM. Therefore, from a pharmacological 
perspective, the 100 µg pasireotide dose should be able to induce similar biological ef-
fects in corticotroph cells, provided that the adenoma expresses relatively high levels of 
sst5 receptors, which some patients clearly do (chapter 4). The occurrence of these rapid 
reductions in serum cortisol after the initiation of pasireotide therapy also has clinical 
implications. The occurrence of acute glucocorticoid withdrawal symptoms or even an 
overt Addisonian crisis is a realistic possibility during this type of treatment. Therefore, 
close follow-up of these patients needs to be provided upon treatment initiation. 
Effects on glucose metabolism
Another important observation in this trial was that glucose homeostasis deteriorated 
significantly in two of the patients that we describe in chapter 5. This problem has also 
been clearly reported in the first study on pasireotide use in patients with CD by Boscaro 
et al., where over one third of patients had significant worsening of glycaemic control 
(33). Different biological mechanisms could be responsible for this phenomenon. First of 
all, it could be due to a direct effect of pasireotide on pancreatic insulin release. Sst1, sst2 
and sst5 receptors, which are all targeted by pasireotide, are well expressed in human 
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pancreatic islet cells and activation of these receptors, especially sst2, has been shown to 
strongly decrease pancreatic insulin secretion in vitro (34). One argument that strongly 
rules against such a direct effect via inhibition of insulin release, however, are the observa-
tions by Van der Hoek et al. in acromegalic patients, in whom pasireotide administration 
acutely increased blood glucose levels without a concomitant major decrease in insulin 
levels (35, 36). The latter would rather suggest that the observed hyperglycemia is due 
to acute peripheral insulin resistance, presumably at the level of the liver, skeletal muscle 
or adipose tissue. Another possible cause for the acute hyperglycemia after pasireotide 
exposure could be located at a more central level, for instance in the arcuate nucleus. 
It is known that this structure in the central nervous system is important for glucose 
homeostasis and that somatostatin receptors have been demonstrated here, including 
sst1 and sst2 (37, 38). Since pasireotide has nanomolar binding affinity for both of these 
receptor subtypes, this may be a potential mechanism of action, which has been un-
derinvestigated thus far. In conclusion, the mechanism of action of pasireotide-induced 
hyperglycemia remains poorly understood and strongly demands further investigation. 
Effects on GH/IGF-1 axis
Another potential problem might be any direct effects of pasireotide therapy on GH and 
IGF-1 levels in CD patients. It is well known that pasireotide, via sst2/sst5 receptor activa-
tion, directly decreases GH release and hence IGF-1 levels in patients with acromegaly. 
Whether this also occurs in normal subjects without GH/IGF-1 axis overactivation, has 
not been reported. Normal somatotrophs, however, express sst5 in significant numbers 
and in normal rats, primates and dogs pasireotide has been shown to significantly 
decrease GH and IGF-1 levels (39). In patients with CD, sustained hypercortisolism by 
itself causes a state of relative growth-hormone deficiency and therefore these patients 
may be at greater risk to become GH-deficient. Current and future clinical studies with 
pasireotide in CD patients should therefore include careful investigation of the effects 
on the GH/IGF-1 axis. 
Future DireCtions: novel DoPAstAtin CHimeriC moleCules
Finally, in chapter 7 we have investigated some functional aspects of the novel dopasta-
tin chimera BIM-23A760. This compound has been postulated as a promising new com-
pound for the future treatment of neuro-endocrine tumours, due to its unique binding 
affinity profile (IC50): high D2 (15.9 nM) and extremely high sst2 (0.03 nM) affinity. Given 
the abundant (co-)expression of both of these receptors in various neuro-endocrine 
tumours and the fact that these receptors can heterodimerize in vitro (40), which may 
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result in enhanced combined potency, this compound is of great interest from a clinical 
perspective. Some earlier studies have already shown superagonistic properties of this 
drug in selected cases (23). 
In our in vitro study, in which we transiently (co-)transfected sst2 and D2 cDNA into HEK293 
cells and used a luciferase reporter gene system to determine efficacy of the different 
SS/DA compounds, we found that BIM-23A760 is an unexpectedly strong activator of D2 
receptors in vitro, while sst2 activation is less pronounced than would be expected on 
the basis of its extremely high sst2 binding affinity. Both receptors are functionally active, 
however, in the low nanomolar range. We did not find direct evidence for an enhanced 
effect by combined targeting of both sst2 and D2 receptors by BIM-23A760. Moreover, 
in the presence of selective sst2 and D2 antagonists, BIM-23A760 potently inhibits cAMP 
formation by either one of the receptors.
In our view, these results indicate that the superior effects of BIM-23A760 are at least 
partially due to individual receptor-ligand interactions, as opposed to mere heterodi-
merization. This enhanced activation of individual receptors can be due to many differ-
ent factors that are involved in the process of ligand binding, receptor occupancy time, 
internalization rates and post-receptor processing of the ligand-receptor complex. At 
present, clinical studies in different phases (I-III) are ongoing with BIM-23A760 in hu-
man subjects and results of these studies are eagerly awaited. One crucial aspect for 
the future applicability of this drug will be whether BIM-23A760 will provide superior 
efficacy, compared to combined SS-analogue and DA-agonist therapy. 
In conclusion, we find in this thesis that the majority of patients with CD possess a 
molecular target for sst5 or D2 directed medical therapy, which makes them candidates 
for therapy with either one or both of these agents. Combination therapy by co-
administration of individual sst2/sst5 or D2-targeting compounds or by novel dopastatin 
chimeras, appears to be a feasible approach, which is supported by different in vitro 
studies. The decrease in circulating cortisol levels may induce a secondary beneficial 
effect of upregulation of sst2 expression in these adenomas, which further enhances 
pharmacotherapeutical options in these patients. Preliminary data from an ongoing 
clinical trial, which uses a stepwise approach of pasireotide (sst2/sst5), cabergoline (D2) 
and low-dose ketoconazole, are supportive for the efficacy of combining these partially 
independent medical therapies in the treatment of human Cushing’s disease. 
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summAry
Cushing’s disease (CD) is a rare endocrinological disorder due to an ACTH-producing 
adenoma in the pituitary gland. Although the clinical presentation is highly variable in 
terms of type and severity of symptoms, the disease invariably has grave consequences 
for the physical and emotional well being of patients. Despite the fact that neurosurgical 
removal of the adenoma is the first choice of treatment, only 70% of patients with CD 
can obtain long-term cure by surgery alone. Adjuvant radiotherapy and bilateral adrena-
lectomy are both effective secondary treatments, but have considerable disadvantages 
and side effects. Therefore, an effective and safe medical treatment for patients with 
persistent or recurrent CD could provide an important addition to the current manage-
ment of these patients. At present, the role of medical therapy for CD is limited, mainly 
due to a lack of treatment efficacy or unfavourable safety profiles, but new approaches 
have been sought. Dopamine and somatostatin receptors have been identified as novel 
targets for a medical therapy of CD, but data on their clinical applicability are still limited. 
The primary aim of the present thesis was to further investigate the future potential 
of medical therapies that target dopamine and/or somatostatin receptor subtypes in 
patients with CD. 
Chapter 1 provides an overview of the pathophysiology and current treatment of Cush-
ing’s disease. It also describes the current knowledge on somatostatin and dopamine 
receptors in the human neuro-endocrine system and especially in Cushing’s disease.
In Chapter 2 we investigate the possibility of using dogs with Cushing’s disease (canine 
Cushing) as a model to study human CD. In contrast to humans, CD is a very common 
disorder in dogs, but only a few veterinary centers worldwide can perform transsphenoi-
dal surgery for this indication. The abundance of pure corticotroph adenoma tissue that 
is surgically removed during this type of surgery could be of great benefit for the study 
of human CD. It could help in determining the efficacy of various novel compounds that 
are considered for use in human CD. In this study we investigated the functional expres-
sion of the somatostatin (sst2 and sst5) and dopamine (D2) receptor subtypes in 13 canine 
corticotroph adenomas. We found that canine and human corticotroph adenomas both 
express these receptor subtypes, but that distinct differences do exist, so that direct 
comparisons between humans and canine CD can not be made. In spite of these dif-
ferences, however, several future research questions in human CD could very well be 
addressed by the use of canine corticotroph adenoma tissue. 
Chapter 3 describes the studies we have performed to investigate the role of glucocorti-
coids on expression levels of sst2, sst5 and D2 in human neuro-endocrine tumor cell lines. 
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We found that glucocorticoids strongly down-regulate sst2, while sst5 and especially D2 
are relatively resistant to this type of down-regulation. These results may explain the 
observed sst and D2 expression levels in corticotroph adenomas of patients with CD 
who suffer from sustained hypercortisolism (e.g. low sst2, high sst5 and D2) and are also 
in line with earlier clinical studies that have shown marked inefficacy of sst2-preferring 
compounds such as octreotide in patients with CD, while sst5 and D2 targeting drugs 
are generally more effective. We also observed that this glucocorticoid-mediated down-
regulation of sst2 is a reversible phenomenon in vitro. This means that initial glucocorti-
coid lowering therapy in patients with CD may increase the expression of sst2 receptors 
within the adenoma and consequently increase the pharmacological options in these 
patients. 
Although some studies had already investigated the individual expression patterns of 
SS and DA receptor subtypes in patients with CD, these data were derived from relatively 
small patient series and co-expression data were not available. In chapter 4 we have 
investigated the expression of both receptor types in a relatively large number of hu-
man corticotroph adenomas (n=30). We found that more than 80% of these adenomas 
express sst5 and/or D2 at significant levels, which makes them potential candidates for 
sst5/D2-directed medical therapy. An important finding in this study was that large, 
invasively growing macroadenomas appear to be less suitable for this type of therapy, 
due to a general absence of sst5/D2 expression in these specific adenomas. Apart from 
adenoma stage, we were not able to identify pre-operative clinical correlates, which 
could predict sst5 or D2 status in patients diagnosed with de novo or recurrent CD.
In chapter 5 we show some early results from an ongoing multicenter clinical trial, 
which investigates the efficacy of combined sst2/sst5 and/or D2 targeted medical therapy 
in human patients with CD. This study uses a stepwise medical approach with the use 
of the novel multiligand SS receptor analogue pasireotide, the D2 agonist cabergoline 
and/or low-dose ketoconazole in de novo or recurrent CD patients. In this chapter we 
describe four patients who participated in this study and who showed a large variation 
in treatment responses. 
Apart from pituitary-derived hypercortisolism (CD), patients with ectopic ACTH-produc-
ing Cushing’s syndrome (EAS) could benefit from SS or DA receptor targeted therapies 
as well. In chapter 6, we describe our clinical and in vitro findings in a patient who 
presented in our clinic with EAS due to an ACTH-secreting bronchial carcinoid tumor. We 
found that six months of glucocorticoid receptor antagonizing therapy by mifepristone, 
caused a reappearance of sst2 receptors in this tumour, which was previously invisible 
on 111In-Pentreotide scintigraphy (Octreoscan). We hypothesize that the subset of EAS 
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tumors, which still display partial glucocorticoid responsiveness in vivo, could benefit 
from initial glucocorticoid lowering or antagonizing therapy to improve diagnostic ac-
curacy (111 In-Pentreotide scintigraphy) and to enhance potential treatment response to 
sst2 targeting therapies (Octreotide).
The interest in combined targeting of sst and DA receptors in the treatment of human 
neuro-endocrine tumours has led to the development of novel dopamine-somatostatin 
chimeric compounds, which combine high binding affinities for both receptors. In 
chapter 7 we have investigated the in vitro efficacy of one these chimeric compounds, 
BIM-23A760, which has displayed superagonistic properties in earlier preclinical studies. 
We found that in comparison to its reported binding affinities, this compound was a 
remarkably potent activator of D2, while its efficacy via sst2 was lower than expected. 
Combined targeting of both receptors in vitro did not result in enhanced potency, sug-
gesting that at least some of the superagonistic properties of BIM-23A760 are likely to 
be due to increased activation of individual receptors.
In chapter 8, the general discussion, the results of these studies are further discussed. 
Special emphasis is given to those issues, which will ultimately determine the clinical 
applicability of future medical therapies that target sst2, sst5 and D2 receptors in patients 
with human CD.
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sAmenvAtting
De ziekte van Cushing is een zeldzame endocrinologische aandoening, die veroorzaakt 
wordt door een ACTH-producerend adenoom in de hypofyse. Hoewel de klinische pre-
sentatie en de ernst van de symptomen sterk per patiënt kan variëren, heeft de ziekte 
doorgaans ernstige consequenties voor de lichamelijke en geestelijke gezondheid voor 
patiënten die lijden aan deze aandoening. Hoewel neurochirurgische verwijdering van het 
adenoom via de transsphenoidale route de behandeling van eerste keus is, kan slechts bij 
70% van de patienten blijvende genezing bereikt worden door middel van deze operatie 
alleen. Het geven van aanvullende radiotherapie en/of het chirurgisch verwijderen van 
de bijnieren, zijn beide effectieve secundaire behandelingsvormen, maar worden tevens 
gekenmerkt door aanzienlijke nadelen en bijwerkingen. Om die reden zou de ontwikkeling 
van een effectieve en veilige medische therapie een belangrijke aanvulling betekenen in het 
huidige arsenaal van behandelingsmogelijkheden, met name in de subgroep van Cushing 
patiënten, bij wie de ziekte persisteert of recidiveert na een eerste operatie. Op dit moment 
is de rol van medische behandeling voor de ziekte van Cushing nog zeer beperkt, met 
name door een gebrek aan behandelingseffect en ongunstige bijwerkingsprofielen, maar 
nieuwe invalshoeken zijn in ontwikkeling. Inmiddels kunnen dopamine en somatostatine 
receptoren gezien worden als mogelijke nieuwe aangrijpingspunten voor een medische 
behandeling voor de ziekte van Cushing, maar data over hun klinische toepasbaarheid is 
vooralsnog beperkt. Het hoofddoel van de huidige dissertatie was om verder te onderzoe-
ken wat het toekomstig potentieel is van medische therapieën die gericht zijn op dopamine 
en/of somatostatine receptor subtypen bij patiënten met de ziekte van Cushing. 
Hoofdstuk 1 geeft een overzicht van de pathofysiologie en de huidige behandeling 
van de ziekte van Cushing. Het beschrijft ook de reeds aanwezige kennis over de rol van 
somatostatine en dopamine receptoren in het humane neuro-endocriene systeem en 
met name bij de ziekte van Cushing.  
In Hoofdstuk 2 onderzoeken we of honden die aan de ziekte van Cushing lijden (“ca-
nine Cushing”), model kunnen staan voor humane patiënten met de ziekte van Cushing. 
In tegenstelling tot bij mensen is de ziekte van Cushing een frequent voorkomende 
aandoening bij honden. In een zeer beperkt aantal klinieken ter wereld, waaronder de 
Universiteit van Utrecht, kunnen honden door middel van transsphenoidale chirurgie 
behandeld worden voor deze aandoening. Het pure corticotrofe adenoomweefsel dat 
tijdens een dergelijke operatie in aanzienlijke hoeveelheden verwijderd wordt, zou van 
grote waarde kunnen zijn voor het onderzoek naar de humane ziekte van Cushing. Zo 
zou het verwijderde weefsel in vitro gebruikt kunnen worden om de effectiviteit te bepa-
len van diverse nieuwe medicamenten, die overwogen worden voor gebruik bij mensen 
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met de ziekte van Cushing. In deze studie hebben we de functionele expressie onder-
zocht van somatostatine receptor subtypen 2 en 5 (sst2 en sst5) en dopamine receptor 
subtype 2 (D2) in 13 gevallen van canine (=hond) Cushing. We vonden dat zowel canine 
als humane corticotrofe adenomen deze receptor subtypen tot expressie brengen, maar 
dat er specifieke verschillen bestaan, waardoor directe vergelijkingen tussen de humane 
en canine vorm van de ziekte van Cushing niet gemaakt kunnen worden. Ondanks deze 
distincte verschillen, zal het corticotrofe adenoom weefsel van honden zeer goed ge-
bruikt kunnen worden voor het beantwoorden van diverse andere onderzoeksvragen in 
het onderzoek naar de humane vorm van de ziekte van Cushing. 
Hoofdstuk 3 beschrijft de studies die we verricht hebben naar de effecten van glucocorti-
coiden (GC’s) op de expressie van sst2, sst5 en D2 in drie humane neuro-endocriene cellijnen. 
We hebben gevonden dat GC’s in sterke mate de expressie van sst2 down-reguleren, terwijl 
sst5 en met name D2 veel resistenter zijn tegen dit type down-regulatie. Deze resultaten 
zouden de sst en D2 expressie niveaus kunnen verklaren (laag sst2, hoog sst5 en D2), die in 
de corticotrofe adenomen gevonden worden van patienten met de ziekte van Cushing, 
aangezien deze blootgesteld worden aan langdurig hypercortisolisme. Daarnaast zijn 
deze resultaten in overeenstemming met eerdere klinische studies, die een opmerkelijk 
lage effectiviteit hebben aangetoond van sst2-gerichte medicamenten zoals Octreotide, 
terwijl sst5 en D2-gerichte therapieën doorgaans effectiever zijn. Verder vonden we dat 
deze glucocorticoid-gemedieerde down-regulatie een reversibel proces in vitro is. Dit 
betekent dat initiële glucocorticoid-verlagende therapie in patiënten met de ziekte van 
Cushing de expressie niveaus van sst2 in het adenoom zouden kunnen verhogen, waar-
mee de pharmacotherapeutische opties in deze patiënten aanzienlijk vergroot worden.   
Hoewel enkele andere studies reeds de individuele expressie patronen van somatostatine 
en dopamine receptor subtypen in patiënten met de ziekte van Cushing hadden onder-
zocht, waren deze data afkomstig van relatief kleine series patiënten en waren co-expressie 
data niet beschikbaar. In Hoofdstuk 4 hebben we de simultane expressie van beide typen 
receptoren onderzocht in een relatief grote serie humane corticotrofe adenomen (n=30). 
Hieruit bleek dat meer dan 80% van deze adenomen sst5 en/of D2 receptoren significant tot 
expressie brengt, waarmee dit potentiële kandidaten zijn voor sst5/D2 gerichte medische 
therapie. Een belangrijke waarneming in deze studie was dat grote, invasief groeiende 
macroadenomen minder geschikt lijken te zijn voor dergelijke therapie, als gevolg van 
een algehele afwezigheid van sst5/D2 receptor expressie in deze specifieke adenomen. 
Afgezien van het stadium van het adenoom, konden we geen andere pre-operatieve kli-
nische variabelen identificeren, die voorspellend zijn voor de sst5 of D2 status in patiënten 
die gediagnosticeerd worden met de novo of recidief ziekte van Cushing.   
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In Hoofdstuk 5 hebben we een aantal eerste resultaten laten zien van een lopende mul-
ticenter klinische studie, die de effectiviteit onderzoekt van gecombineerde sst2/sst5 en/
of D2 gerichte medische therapie in humane patiënten met de ziekte van Cushing. Deze 
studie gebruikt een stapsgewijze medische benadering met het nieuwe multiligand 
somatostatine receptor analogon pasireotide, de D2 agonist cabergoline en lage dosis 
ketoconazol in patiënten met de novo of recidief ziekte van Cushing. In dit hoofdstuk 
staan vier patiënten beschreven die deel hebben genomen aan deze studie en die een 
grote variatie in respons op deze therapie hebben laten zien. 
Naast de hypofyse-afhankelijke vorm van hypercortisolisme (de ziekte van Cushing), 
zouden patiënten met het ectopisch ACTH-producerend syndroom (EAS, ook wel 
Ectopisch Cushing syndroom genoemd) kunnen profiteren van somatostatine of do-
pamine receptor gerichte therapieën. In Hoofstuk 6 hebben we onze klinische en in 
vitro bevindingen beschreven in een patiënt die zich in onze kliniek presenteerde met 
EAS, welke veroorzaakt werd door een ACTH-secernerend bronchus carcinoid. Wij zagen 
dat 6 maanden behandeling met glucocorticoid receptor antagonerende therapie in 
de vorm van mifepristone, leidde tot een terugkeer van sst2 receptoren in deze tumor, 
die voordien onzichtbaar was op 111In-Pentreotide scintigraphie (OctreoScan). Wij den-
ken dat de subgroep van EAS tumoren, die in vivo nog enige mate van glucocorticoid 
responsiviteit toont, zou kunnen profiteren van initiële glucocorticoid verlagende of 
antagonerende therapie door enerzijds het vergroten van de diagnostische gevoelig-
heid van 111In-Pentreotide scintigraphie (OctreoScan) en anderzijds het versterken van 
de mogelijke respons op sst2 gerichte therapieën (Octreotide).  
De interesse in het gelijktijdig activeren van somatostatine en dopamine receptoren in 
de behandeling van humane neuro-endocriene tumoren heeft geleid tot de ontwikke-
ling van nieuwe dopamine-somatostatine chimere moleculen, die een hoge affiniteit 
voor beide receptoren bevatten. In Hoofdstuk 7 hebben we de in vitro effectiviteit van 
één van deze chimere moleculen onderzocht, BIM-23A760, welke in eerdere preklinische 
studies superagonistische eigenschappen heeft laten zien. We hebben gevonden dat in 
vergelijking met de opgegeven bindingsaffiniteiten van dit molecuul, BIM-23A760 een 
opmerkelijk krachtige activator van de D2 receptor is, terwijl dat voor sst2 juist minder 
is dan verwacht. De simultane activatie van beide receptoren in vitro resulteerde niet 
in toegenomen effectiviteit, hetgeen suggereert dat in ieder geval een deel van de 
superagonistische eigenschappen van BIM-23A760 verklaard kunnen worden door een 
verhoogde activatie van individuele receptoren. 
In Hoofdstuk 8, de algemene discussie, worden de resultaten van bovengenoemde stu-
dies verder besproken. Hierbij wordt de nadruk gelegd op die aspecten, die uiteindelijk 
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de klinische toepasbaarheid zullen gaan bepalen van toekomstige medische therapieën 
die gericht zijn op sst2, sst5 en D2 receptor activatie in patiënten met de ziekte van Cu-
shing.
Appendix 
Cushing’s disease in 
dogs and humans
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ABstrACt
Background: Cushing’s disease (CD) is a common endocrinological disorder in dogs 
with an estimated incidence of 1-2 cases/l000 dogs/year. This is in contrast to humans 
in whom CD is rare. The clinical presentation of CD, however, is highly similar between 
dogs and humans, with characteristic signs, such as abdominal obesity, weight gain, 
fatigue, muscle atrophy and skin changes. Canine CD may therefore serve as an animal 
model for human CD, especially since therapeutic canine hypophysectomy can generate 
substantial amounts of primary corticotroph adenoma tissue for in vitro research pur-
poses. In a recent study, we found that dopamine (DA) D2 and somatostatin (SS) recep-
tor subtypes are well expressed in canine corticotroph adenomas, but there are some 
distinct differences compared with the expression profile observed in human CD. These 
differences need to be considered when using canine CD as a model to evaluate the ef-
ficacy of novel DA/SS compounds for potential use in human CD. Case report: This case 
involves an 8-year-old female dog that developed signs of exercise intolerance, muscle 
weakness and polyuria/polydipsia due to an adrenocorticotropic hormone-secreting 
pituitary adenoma. The dog underwent curative transsphenoidal hypophysectomy and 
has remained in complete remission in the 3.5 years since surgery.
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introDuCtion
Cushing’s disease (CD) is a severe endocrinological disorder due to an adrenocorticotro-
pic hormone (ACTH)-secreting adenoma in the pituitary gland. Patients with CD suffer 
from the effects of sustained hypercortisolism, such as truncal obesity, diabetes mellitus, 
osteoporosis, hypertension and psychiatric disturbances [1]. In humans, CD is a rare 
disorder with an estimated incidence of 1.2 -2.4 new cases/million/year [2, 3]. 
CD is also known to occur in several animal species, including horses and dogs. In fact, 
canine CD is one of the most common endocrinological disorders encountered in gen-
eral veterinary practice. Exact incidence figures are lacking because there is no formal 
registration system, but some epidemiological studies have estimated its incidence to 
be 1-2 cases/1000 dogs/year [4]. Standard treatment of canine CD consists of medical 
therapy with drugs such as mitotane or trilostane. Another option is to perform transs-
phenoidal pituitary surgery. At present this option is only routinely available at a limited 
numbers of centers worldwide. We now present such a case.
CAse PresentAtion
The canine patient is an 8-year-old female Belgian shepherd dog. The owner had wit-
nessed a gradual decline in the dog’s condition over the course of the previous year, 
especially in terms of decreased physical activity. In addition, the owner had noticed 
a remarkable change in drinking pattern, which was estimated to be around 10 L/day 
(normal water intake corrected for breed, age and body weight: 2-4 L daily). On physi-
cal examination, the dog had mild abdominal obesity and pronounced atrophy of the 
leg and lumbar muscles. There was no alopecia or skin atrophy. Furthermore, the dog 
was panting while at rest, which is abnormal for dogs not participating in any physical 
activity.
Based on these clinical signs, a preliminary diagnosis of hypercortisolism (Cushing’s 
syndrome) was considered and further laboratory investigation was undertaken. 
Morning urine samples collected on 2 consecutive days showed elevated urinary 
corticoid:creatinine ratios (UCCRs) of 69 and 72 × 10-6, respectively (normal range: < 10 
× 10-6). To distinguish between a pituitary versus adrenal cause of the hypercortisolism, 
high doses of dexamethasone (DEX) were administered after collection of the second 
urine sample (three doses of 0.1 mg/kg at 8-h intervals). The next morning, a third urine 
sample showed DEX-induced suppression of the UCCR to 6.7 × l0-6 (> 50% suppression), 
which strongly suggested a functional corticotroph pituitary adenoma. Random blood 
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samples (average of two independent measurements drawn 15 min apart) confirmed 
the diagnosis of pituitary-dependent hypercortisolism. The mean plasma concentration 
of cortisol was 141 nmol/l (normal range: 11–136 nmol/l), ACTH was 17.9 pmol/l (normal 
range: 1.1–18.7 pmol/l) and α-melanocyte-stimulating hormone (α-MSH) was 23.4 
pmol/l (normal range: <  22 pmol/l). As a final diagnostic step, a computed tomography 
scan of the pituitary fossa was performed under general anaesthesia. This showed an 
adenoma within an enlarged pituitary of 7.3 mm (height) × 6.9 mm (width) × 8.0 mm 
(length) (see figure 1). 
The dog underwent transsphenoidal hypophysectomy with complete removal of the 
pituitary gland including the adenoma. The postoperative phase was unremarkable 
with rapid clinical improvement and discharge from the hospital on the second day after 
surgery. Post operative replacement therapy consisted of desmopressin for 4 weeks and 
lifelong treatment with cortisone acetate and levothyroxine. Histological examination 
of the resected pituitary tissue revealed a basophilic adenoma, which stained positive 
for ACTH and α-MSH on immunohistochemistry. Two weeks after surgery, UCCRs were 
measured after temporary withdrawal (24 h) of the cortisone acetate. These values were 
very low (0.8-1.0 × 10-6), which strongly suggested complete remission of the hypercor-
Pituitary adenoma
Figure 1
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tisolism. In the months thereafter, a gradual return of full physical activity and muscular 
strength occurred and the drinking pattern also normalized. At present, 42 months 
after surgery, the dog is in very good condition and UCCR values during follow-up have 
remained within the normal range.
DisCussion
As illustrated by this case, many similarities exist between the clinical presentation of 
CD in dogs and humans (see table 1). Fatigue, weight gain, truncal obesity and muscle 
atrophy are cardinal signs in both species [1, 5]. In both humans and dogs, approximately 
70% of CD cases are due to a pituitary adenoma, while the remaining cases are due to 
adrenal or ectopic causes. Subtle differences are present as well. Human CD patients 
often develop osteoporosis and hirsutism while dogs do not, and the main clinical sign 
of canine CD is polyuria/polydipsia, which is not observed in humans. The major dif-
ference, however, between dogs and humans is the large difference in incidence rates: 
1-2 cases/1000 dogs/year compared with 1.2-2.4 cases/million humans/year. The causes 
of the remarkable susceptibility of dogs to develop this endocrine disorder are still 
unknown.
The high natural incidence of canine CD and its many clinical similarities to human CD 
raises the question whether canine CD could serve as a spontaneous animal model for 
human CD. This question is particularly important because at present there is no accepted 
animal model for this deleterious disease and there are no human ACTH-producing cell 
lines to facilitate in vitro research into the pathogenetic mechanisms of CD. Moreover, 
table 1 Characteristics of human and canine Cushing’s disease
Clinical sign Human Canine
Fatigue + +
Weight gain + +
Truncal obesity + +
Muscle atrophy + +
Osteoporosis + -
Lordosis - +
Hypertension + +
Polyuria / polydipsia - +
Thinning of skin + +
Easy bruising + -
Hirsutism + -
Alopecia +/- +
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due to the low incidence of the disease, human primary corticotroph tissue obtained at 
transsphenoidal surgery is difficult to obtain, which can further slow advancements in 
research. From this perspective, the establishment of transsphenoidal hypophysectomy 
as an accepted treatment for canine CD may have opened up a new source of valuable 
primary corticotroph tissue, which could overcome some of the these obstacles [6, 7]. 
Van Wijk et al. have shown previously that canine corticotroph adenoma cells cultured 
in vitro retain important biological properties, such as the production of ACTH, and a 
variable responsiveness to both corticotropin-releasing hormone and glucocorticoids, 
just like human corticotroph adenoma cells in vitro [8]. Canine corticotroph adenomas 
also have been used to study fundamental aspects of the impaired feedback regulation 
of the glucocorticoid receptor in CD [9].
To fully evaluate the feasibility of using canine CD as a direct model for human CD, it is 
necessary to understand the molecular make-up of these canine corticotroph adenomas 
and to compare this with what is known about human corticotroph adenomas. To this 
end, we recently performed a study in which we investigated the expression of dop-
amine (DA) and somatostatin (SS) receptor subtypes in canine corticotroph adenomas 
[10]. We specifically investigated these receptor subtypes because compounds that tar-
get them have been shown to reduce ACTH and cortisol levels in subsets of human CD 
patients [11, 12]. Our study showed that DA and SS receptor subtypes were functionally 
expressed in these canine adenomas, but with some distinct differences compared with 
human adenomas. In particular, SS receptor subtype 2 (sst2) was highly expressed in 
canine adenomas, whereas its expression in human adenomas is very low, probably due 
to glucocorticoid-induced downregulation [13]. In the canine adenomas, D2 was also 
moderately well expressed, while sst5 expression was remarkably low, which is different 
from human adenomas [14, 15]. The expression pattern in canines was confirmed by 
quantitative polymerase chain reaction, immunohistochemistry and functional studies 
measuring ACTH release under the influence of specific DA/SS analogues.
imPliCAtions
These findings have implications for the use of canine corticotroph adenomas as a direct 
model for human CD. With respect to SS and DA receptors, direct extrapolations cannot 
be made regarding the efficacy of novel SS/DA compounds for future use in human 
CD patients. Based on our findings, it is likely that canine corticotroph adenomas will 
respond differently in vivo to specific SS/DA analogues compared with what we have ob-
served previously for humans. However, canine CD could provide a unique opportunity 
to directly test the in vitro and in vivo ACTH-inhibiting capacities of novel compounds 
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such as the DA-SS chimeric molecules, for which data from primary corticotroph cell sys-
tems are still limited. The canine corticotroph model also would enable more thorough 
investigation of secondary or auxiliary factors that determine the level of ACTH inhibi-
tion induced by treatment with SS/DA-targeting compounds in primary corticotroph 
cells. Furthermore, it would be interesting to characterize canine corticotroph adenomas 
for the functional expression of other receptors known to regulate ACTH release, such 
as retinoic acid receptor and peroxisome proliferator-activated receptor-γ [16]. In this 
way, we might gain a better understanding of the full spectrum of molecular differences 
and similarities between canine and human corticotroph adenomas and consequently 
increase our knowledge of the possibilities and limitations of using canine CD as a model 
for human CD.
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Aan de studies die in dit proefschrift beschreven worden hebben vele mensen bijgedra-
gen, die ik graag zou willen bedanken.   
Professor Lamberts, hartelijk dank voor de kans die u mij destijds geboden heeft om 
onderzoek te kunnen verrichten op uw afdeling. Uw enthousiasme, betrokkenheid en 
heldere visie op de grote lijnen alsmede de details van het onderzoek, zijn van zeer 
grote waarde geweest bij het tot stand komen van dit proefschrift.  
Dr. Hofland, beste Leo, vanaf het allereerste begin tot aan het einde aan toe heb jij je 
onmisbare input, kennis en morele steun aan alle hierboven beschreven studies ver-
leend. Je maakte altijd tijd vrij voor eventuele vragen en overleg, ook als je zeer druk 
was. Hartelijk dank voor je geweldige begeleiding gedurende het gehele traject. Heel 
veel succes met al het onderzoek dat jullie in de komende jaren gaan verrichten.    
Dr. Feelders, beste Richard, hartelijk dank voor de prima samenwerking bij de diverse 
studies en in het bijzonder bij onze gezamenlijke activiteiten voor de klinische studie.   
Professor van der Lely, Professor Visser en Professor Romijn, hartelijk dank dat u plaats 
wilt nemen in de kleine commissie van mijn promotie. 
Dr. Meij, beste Björn, het was een genoegen om zo nauw samen te werken bij onze ge-
zamenlijke studie op jouw aandachtsgebied, canine Cushing. Dr. Hanson en Dr. Kooistra, 
beste Jeanette en Hans, hartelijk dank ook voor jullie uitgebreide hulp bij deze studie. 
Dr. Pereira, beste Alberto, dank voor de altijd hartelijke en welkome ontvangst in het 
LUMC en je uitgebreide input bij onze gezamenlijke studies. 
Beste Michel en Rogier, allereerst dank dat jullie mijn paranimfen willen zijn. We doorlo-
pen alle drie een vergelijkbaar traject en hebben in de afgelopen jaren veel met elkaar 
gedeeld en meegemaakt. Het was en is me een zeer groot genoegen. Ik wens jullie veel 
succes met het afronden van jullie eigen proefschriften en we zien elkaar snel weer op 
een vergelijkbare gelegenheid. 
Beste Marlijn en Diane, jullie hulp op het lab is onmisbaar geweest. Ik wil jullie allebei 
heel hartelijk danken voor jullie grote bijdragen aan de diverse studies en de gezellig-
heid die jullie met je meebrengen op de werkvloer. 
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Beste Peter, in de afgelopen jaren ben je een geweldige kamergenoot geweest en had 
je altijd tijd voor vragen of advies, dank daarvoor. Dr. Koper, beste Jan-Willem, bedankt 
voor je uitleg en hulp waar nodig. Daarnaast wil ik graag de overige mensen van het 
neuro-endocrinologie lab bedanken voor de fijne tijd: Joost, Giovanni, Kati, Bedette, Fa-
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